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Abstract 
There is a clear need for a rapid, inexpensive point-of-care diagnostic test for tuberculosis (TB). 
The aim of this study was to analyze the performance of a novel rapid diagnostic test for TB, 
GeneXpert MTB/RIF, in symptomatic adults and to compare it to other commercially available 
nucleic acid amplification assays and to standard microbiological smear and culture. The 
GeneXpert system performs real time, nested PCR from sputum and provides a result within 
two hours of sampling. The result includes a semi-quantitative assessment of bacillary load in 
the sample and simultaneously detects rifampicin resistance.  
This study was part of a cross-sectional, multi-centre clinical trial. The Cape Town component of 
this study was conducted at three sites, one hospital based and other two community clinics, all 
with high TB/HIV coinfection rate.   
Among 43.2% of patients diagnosed with TB during the evaluation study, GeneXpert detected 
TB in 95.5% of all culture positive cases.  In smear positive patients, sensitivity was 99.0% and 
in smear-negative, culture positive patients, 86.1%.  Specificity in patients who were culture 
negative and clinically diagnosed as non-TB after follow up was 98.4%. Sensitivity and 
specificity of GeneXpert in detecting rifampicin resistance was 100% comparing to 
phenotypically detected drug resistance.  
GeneXpert is a highly promising novel tool for the rapid diagnosis of adult TB. Future studies 
are needed to establish the performance and impact of GeneXpert when performed at the level 
of the microscopy centre.  
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I Literature review  
This literature review will briefly review the epidemiology, pathology, clinical features and 
treatment of tuberculosis (TB), followed by a more detailed discussion of TB diagnostics with 
particular focus on the molecular diagnostic approach and commercial tests currently available.  
1 Epidemiology 
1.1 Global tuberculosis epidemiology 
Tuberculosis is the seventh leading cause of death worldwide, second only to human 
immunodeficiency virus (HIV) acquired immunodeficiency syndrome (AIDS) among infectious 
diseases (Keeler et al., 2006). There are 2 billion people today infected with Mycobacterium 
tuberculosis (MTB) and 1.7 million deaths worldwide are attributed to TB (WHO, Acute 
Respiratory Infections, 2009). In 1990 there were 6.6 million TB cases, while in 2007 there were 
an estimated 9.27 million cases per year (WHO report, 2009).  
Most of the estimated TB cases (92%) in 2007 were in developing countries (WHO report, 
2009). Also, 98% of TB-related deaths occur in the developing world (Charles et al., 2006). TB 
is generally referred to as a poverty-related disease. The TB epidemic has been contained in 
developed countries by introducing health measures such as screening, surveillance and follow-
up and a general improvement in living conditions (Modi et al., 2009). However, international 
travel and countries caught in war and conflict have contributed to a TB increase worldwide 
(Frothingham et al., 2005, Modi et al., 2009). 
It was estimated that 15% of TB cases were HIV-positive and 79% of these HIV-positive cases 
were in the WHO African region (WHO report, 2009).  The number of AIDS-related deaths has 
declined by over 10% over the past five years (WHO AIDS epidemic update, 2009) and about 
half a million deaths occurred among HIV-positive patients diagnosed with TB in 2007- which 
means that one in four TB deaths was HIV-related (WHO report, 2009). The paradoxal effect of 
antiretroviral therapy (ART) on HIV/TB coinfected patients provokes the immune system to act 
against TB antigens and further complicates the patient‟s condition (WHO, Acute Respiratory 
Infections, 2009). 
HIV has distorted demographic statistics in the TB epidemic. TB is no longer disease of older 
men; HIV has created a population of immune-depressed hosts, perfect for TB to thrive. So 
now, in a setting where HIV prevalence exceeds 1%, patients with TB/HIV coinfection are 
younger and tend to be more frequently female (Lawn et al., 2006, WHO report, 2009).   
Un
ive
rsi
ty 
Of
 C
a
e T
o
n 
15 
 
Children under the age of 14 contributed 10% to the total number of new cases in Africa and 2% 
in developed countries in 2004 (Dye, 2006), but this figure is influenced by difficulties in 
diagnosing TB in children. Unfortunately, children suffer from severe TB morbidity and mortality, 
especially in endemic areas (Marais et al., 2007). 
Even with rising awareness of TB presence worldwide and global projects aimed at reducing 
rates of TB incidence, Africa and Europe will still not be able to reach the WHO goal of halving 
the prevalence of TB disease from 300/100 000 to 150/100 000 and deaths from 30/100 000 to 
15/100 000 by 2015 (WHO report, 2009). 
1.2 Tuberculosis in South Africa 
South Africa‟s contribution to the worldwide incidence in 2007 was estimated to be 0.46 million 
total cases per year (WHO report, 2009). The incidence of all TB types in South Africa rose 
sharply from 169/100 000 in 1998 to 739.6/100 000 in 2007. In 2007 the incidence of all TB 
cases in the Western Cape Province was 1005.7/100 000 (Health Systems Trust, Tuberculosis). 
As in other developing countries with underdeveloped health care infrastructure, estimates were 
higher than reported cases and in South Africa there was a difference of 150 000 unreported 
cases of TB (WHO report, 2009). 
Antenatal HIV prevalence has risen in South Africa from 1.7% in 1991 to 28% in 2007 (Health 
Systems Trust, HIV). It is estimated that HIV positive incident TB cases represented 73% of all 
TB cases in 2007, which is by far the worse incidence among TB cases in the world (WHO 
report, 2009). 
1.3 Multidrug resistant tuberculosis 
MTB has affected humankind since 3000- 5000 BC. It reached its climax during the seventeenth 
and eighteenth century when 1 in 5 deaths were attributed to TB (Iseman, 1994). The first 
remedy for TB, streptomycin (SM), was discovered in 1943 and initial reports were highly 
promising (Feldman et al., 1948). However, it was soon discovered that different strains of the 
same species vary greatly in sensitivity and that some gain resistance (Waksman et al., 1945, 
Iseman, 1994). Changes were introduced into the drug regimen for TB, while MTB adaptation to 
administered drugs followed.  
In the 1960s rifampicin (RIF) was introduced as a drug used in combination therapy, and it lead 
to a decline in the number of TB cases worldwide (Johnson et al., 2006). Later outbreaks of TB 
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resistant to drugs used in combinational therapy occurred in the 1980s, in association with the 
HIV epidemic (Small et al., 1993). 
At present, combinational therapy of first-line drugs: isoniazid (INH), rifampicin (RIF), 
pyrazinamide (PZA) and ethambutol (EMB) or streptomycin (SM) for 6 months is recommended 
(Treatment of tuberculosis Guidelines, 2009). If TB is caused by an MTB strain resistant to the 
two first-line drugs INH and RIF, it is recognised as multidrug resistant-TB (MDR TB) (Zhang et 
al., 2009). 
Worldwide, 5% of all TB cases are MDR TB, based on data from more than 100 countries 
collected during the last decade (WHO, Tuberculosis facts, 2008). There were an estimated 0.5 
million cases of MDR TB in 2007 and more than half were among new TB cases (WHO, 
Tuberculosis facts, 2008).  
INH mono-resistance is common, with 6.7% of new TB cases INH resistant in surveyed 
countries (Wright et al., 2009). However, RIF mono-resistance is rare. Thus, RIF resistance is 
used as a surrogate marker for MDR-TB as nearly 90% of RIF resistant strains are also INH 
resistant (Johnson et al., 2006).  
South Africa, with almost 16 000 MDR cases annually, is ranked fourth among the leading 
countries representing 0.5 million MDR cases in 2007 (WHO report, 2009). In South Africa, 
1.8% of all new TB cases are MDR and 6.7% of previously treated TB cases are MDR (WHO 
report, 2009).  
Out of all MDR cases worldwide in 2007, 6.6% were found to be infected with strains resistant to 
first-line drugs (RIF and INH) and two classes of second-line drugs, a fluoroquinolone (such as 
ofloxacin) and an injectable drug (amikacin, kanamycin or capreomycin) and were therefore 
defined as extensively drug resistant or XDR TB (Schaaf et al., 2009, Wells et al., 2007). XDR 
TB had been identified in 57 countries in all regions of the world by 2009 (WHO report, 2009). 
Mortality in high HIV prevalence settings was 40% among patients with MDR TB and 51% 
among patients with XDR TB, within the first 30 days after sputum collection (Gandhi et al., 
2010). In a recent outbreak in a rural area of KwaZulu-Natal in South Africa, 52 out of 53 people 
infected with XDR strains died on average within three weeks from diagnosis (Gandhi et al., 
2006).  
The collision of two epidemics, TB and HIV, has created extraordinary rates of mortality, the 
majority occurring before a diagnosis is made (Gandhi et al., 2010). A rapid diagnostic test that 
Un
iv
rsi
ty 
Of
 C
ap
e T
ow
n 
17 
 
is sensitive in HIV infected patients and can be used at any rural health centre level is urgently 
needed.  
So far, attempts to challenge the MDR TB epidemic with available diagnostics, drugs, and 
vaccines have not had the desired success. Fortunately, rapid diagnostic tests are in late stages 
of clinical evaluation, drug candidates with new mechanisms of action have recently shown 
positive results in trials, and six vaccines are in human trials (Borgdorff et al., 2009). 
2 Mycobacterium tuberculosis 
2.1 M. tuberculosis structure and morphology 
Mycobacterium tuberculosis complex (MTBC) is a group of closely related species and 
subspecies that include MTB, namely Mycobacterium africanum, Mycobacterium bovis, 
Mycobacterium caprae, Mycobacterium microti, and Mycobacterium pinnipedii (Gordon et al., 
2009). MTBC is clustered with Gram-positive bacteria, since it has a peptidoglycan layer. 
However, MTB peptidoglycan has some distinctive characteristics as its outer layer consists of 
glycolipids – major cell wall component, lipoarabinomannan (LAM), polysaccharides and unique 
lipids with a hallmark molecule of Mycobacteria, mycolic acid (Cole et al., 1998, Chatterjee, 
1997). In addition, such membranes form dye complexes that are not decolourised following 
exposure to acidic ethanol or mineral acids. This property is recognised as acid fastness 
(Barksdale et al., 1977).  
Almost 60% of the bacteria‟s dry weight consists of lipids, which makes it highly hydrophobic 
and as a consequence, impermeable for drugs (Cole et al., 1998).  In vivo fatty acids are a 
major nutrient source and besides their role as nutrients, fatty acids, primarily in the form of 
mycolic acids, are a source of pathogenicity (Ehrt et al., 2007). Some differences in the host‟s 
immune response to different strains are related to the lipid composition in MTB‟s cell envelope 
(Ehrt et al., 2007). 
Mycobacteria are obligate aerobes, non-spore forming and non-motile (Dinnes et al., 2007, 
Barksdale et al., 1977). Microscopically, mycobacteria appear as spherical cells although, in 
cultures, mycobacteria show an inhibition of post-divisional cell separation forming short 
filaments, which can be branched (Barksdale et al., 1977). Tubercle bacilli from clinical 
specimens are usually rod-like cells. Individual bacilli are 0.5 to 1.0 µm in diameter and 1.5 and 
10 µm long (Figure 1) (Friedman, 2000). 
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Figure 1 Actively growing MTB H37Rv 102, (adapted from Barksdale et al., 1977) 
2.2 Nutritional factors and growth 
In vitro MTB can grow in simple synthetic media with glycerol and ammonium salts with 
nutritional preference for lipids like free fatty acids found in fresh eggs (Löwenstein-Jensen 
medium) or purified oleic acid in Middlebrook‟s medium (Bannister et al., 1996). MTB can 
persist in a medium with fatty acids as its sole carbon source; moreover it depends on fatty acid 
metabolism to resist being killed by the immune system (Ehrt et al., 2007). A high concentration 
of long chain fatty acids has an inhibitory effect on MTB growth so albumin is added to the 
medium to buffer the concentration of fatty acid (Bannister et al., 1996). Although MTB utilises 
oxygen metabolism it has low reproductive rates and long generation times.  
If MTB is grown on a solid culture it forms rough, dry, and cauliflower-like colonies (Gordon et 
al., 2009). In solution, MTB forms surface pellicles, (hence the name mycobacterium or mould-
like) and even if non-ionic detergents are used to grow it in a more dispersed form, it seldom 
grows as a single cell. Shaking is a preferred method of cultivation, at a carbon dioxide 
concentration of 6-8% (Barksdale et al., 1977). If other bacteria are presented in an inoculum 
they will rapidly overgrow MTB, so samples used to inoculate media require decontamination.  
In vivo, MTB is usually ingested by the lungs‟ macrophages, and within hours of infection 
bacteria are found in phagolysosomes, whereas some escape and are found in the cytoplasm 
(McDonough et al., 1993). Virulent MTB strains (see chapter 1, section 3.5), can persist and 
proliferate in a macrophage, by inhibiting fusion with lysosomes. Conversion into dormant form 
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is proposed to be influenced by oxygen limitation since it changes the metabolic state of 
bacteria (Rustad et al., 2009, Boshoff et al., 2005). While in dormant state, MTB cannot be 
detected using culture, but PCR has detected MTB in murine models (De Wit et al., 1995).  
2.3 M. tuberculosis genome and evolution 
MTB has a large genome. MTB strain H37Rv has 411 529 bp, and is remarkably guanine and 
cytosine (GC) rich; 65.6% of the whole genome comprises GC pairs (Cole et al., 1998). In 1998, 
when the first MTB genome was sequenced, it was the second largest bacterial genome 
available (the largest was Escherichia coli).  
Since the publication of the H37Rv genome there have been nearly 20 MTBC strains with 
complete or partially complete genomes sequenced (Gordon et al., 2009). Identifying the 
differences between genomes of virulent and non-virulent mycobacteria leads toward 
understanding phenotypic diversity and is a base for new vaccine, drug and diagnostic 
approaches.  
Differences in MTB strains‟ genomes are analysed within larger polymorphic regions, greater 
than 0.5 kb, named regions of difference (RD) loci. The most widely used vaccine containing 
viable attenuated BCG strain has portions of RD1 region missing, while the recombinant 
BCG:RD1 has at most partially restored it‟s virulence (Pym et al., 2002).  
From an evolutionary perspective it was believed that MTB emerged as a human disease 10 
000 -15 000 years ago as a consequence of a bovine to human transmission, at the time cattle 
were domesticated (Cole et al., 1998). However, recent discoveries imply co-evolution of bovine 
and human TB strains, since human bone samples dated from the Pleistocene era have TB-like 
lesions (Donoghue et al., 2004); while both cattle and humans have the same ancestral origin in 
environmental mycobacteria (Stinear et al., 2008). It appears that the direct ancestor of present-
day MTB emerged in East Africa, where co-evolution between the bacterium and man-shaped 
tuberculosis formed a lifelong asymptomatic symbiosis with this pulmonary disease (Gutierrez et 
al., 2005, Gordon et al., 2009). 
MTBC shows an extraordinary genetic homogeneity (with 0.01–0.03% variations between 
genomes within MTBC), and does not allow any lateral exchange of genetic material, leading to 
clonal evolution (Gordon et al., 2009). Even with exclusive homogeneity, several distinctive 
strains and strain lineages emerged from this clonal evolutional pattern, mostly by silent single 
nucleotide polymorphisms (SNP) as well as deletion, duplication and insertion deletions (Ernst 
et al., 2007). Based on the absence of a specific RD locus named TbD1, MTB strains can be 
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divided into ancestral and modern strains. Modern strains are characterised by the absence of 
the TbD1 region (Brosch et al., 2002). Lineages like W-Beijing, Haarlem, CAS and MTB H37Rv, 
belong to the modern families. Ancestral strains like the EAI family have an intact TbD1 region 
and are prevalent in India, Bangladesh, and South East Asia (Gordon et al., 2009, Brosch et al., 
2002). Since ancestral strains are mostly found in one part of the world, it may indicate that they 
have preference for a specific host and this fact is of critical when developing new vaccines, and 
new drugs. 
3 Pathology 
TB has been a disease of humans for thousands of years (Donoghue et al., 2004), but it was 
only in 1882 that MTB was found to be the cause of disease, when Robert Koch discovered that 
tubercle bacillus is the etiologic agent responsible for TB (Koch 1882, Gordon et al., 2009). 
As mentioned above, one third of the world‟s population is infected with MTB but only 5% to 
10% of this population has a lifetime risk of developing active tuberculosis (Van Crevel et al., 
2002).  MTB is either eradicated by the immune system or remains dormant for years.  Factors 
influencing the outcome of infection could be either pathogen or host related (McDonough et al., 
1993, Brosch et al., 2002, Caws et al., 2008). 
3.1 Infection on a cellular level 
MTB is an airborne pathogen and infection is caused by inhalation of droplet nuclei no bigger 
than 5 µm in diameter, from a cough or sneeze carrying MTB. Droplets remain in the air for 
several hours and if during that time enough droplets containing bacilli are inhaled MTB will 
cause infection in two thirds of immunocompetent individuals. (Beggs et al., 2003) 
Once inhaled by a human host and deposited in alveoli MTB initiates infection (Quast et al., 
2006). At the same time host immunologic defence starts. Alveolar macrophages or dendritic 
cells (DC) first encounter MTB in the lungs. Three types of receptors have been identified for 
phagocyosis of MTB by macrophages and DCs: complement receptors (responsible for uptake 
of opsonized MTB), and manose and scavenger receptors for uptake of nonopsonized MTB 
(Van Crevel et al., 2002). Phagocytosis initiates a cascade of events engaging innate immunity 
while initiating the intracellular life-stage of MTB in a phagosome (Korbel et al., 2008). At this 
point MTB can take the course of a disease or it can be cleared by the immune system. The 
outcome depends on the microbicidal capacity of host phagocytes and virulence factors of the 
ingested mycobacteria (Van Crevel et al., 2002). 
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MTB can survive phagocytosis, escape phagolysosomal fusion and proliferate within 
macrophages since it has a wide spectrum of survival strategies (Martino, 2008). MTB uses 
passive phagocytosis to enter macrophages, since it binds to: complement receptors (CR3) 
(opsonized phagocytosis), mannose-binding receptors, and scavenger receptors (non-
opsonized phagocytosis) (Korbel et al., 2008, Van Crevel et al., 2002). MTB uses its cell wall 
components, mannose-containing cell wall glycolipids, like LAM and phosphatidylinositol 
mannoside (PIM) to bind with phagocyte surface receptors (Korbel et al., 2008). This silent 
phagocytosis enables MTB to enter phagocytes without triggering a reactive oxygen respiratory 
burst or other cytocidal mechanisms (McDonough et al., 1993, Korbel et al., 2008). Thus, MTB 
can persist and proliferate within macrophages and to some extent within DC, and this will lead 
to disruption of the macrophage (Korbel et al., 2008, Van Crevel et al., 2002). When this 
happens, blood monocytes and other inflammatory cells are attracted to the lungs, beginning 
the second stage of the disease.  
Disruption of macrophages attracts blood monocytes into the lungs and they differentiate into 
macrophages that will also ingest MTB without being harmed, creating an event loop enabling 
MTB to proliferate and thrive within the macrophage (Van Crevel et al., 2002). This stage lasts 
for 2-4 weeks until T-cell acquired immunity develops (Quast 2006, Van Crevel et al., 2002).  
3.2 Immune response to M. tuberculosis 
The innate immune system, and subsequently acquired immune system, can clear MTB 
infection or sustain disease development. Once MTB gets into the lungs, factors at epithelial 
surfaces like collectins, defensins and natural antibodies may interfere with further MTB 
infection (Korbel et al., 2008). 
Then, MTB is recognised as a pathogen by a macrophage (Figure 2) using evolutionary 
conserved recognition patterns – MTB‟s LAM resembles Gram-negative bacterial 
lipopolysaccharide (LPS) engaging toll-like receptors (TLR) (Korbel et al., 2008, Martino, 2008). 
Sensory functions of TLRs promote signalling cascades of inflammation while engaging MyD88, 
responsible for releasing chemokines and pro-inflammatory cytokines (Reiling et al., 2008, Van 
Crevel et al., 2002). The downstream signalling cascade upon activation of TLRs and MyD88 
leads to the transcription of genes involved in the activation of the innate host defence, 
particularly cytokines such as tumour necrosis factor α (TNF-α), and interleukin 12 (IL-12) and 
chemokines (Jo, 2008).  
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Cytokine production is a vital step in response to MTB infection. TNF-α is a proinflammatory 
cytokine, produced by macrophages while initiating autoinduction of microbicidal activity. IL-12 
is produced by macrophages upon MTB phagocytosis, and is responsible for activation of 
Interferon γ (IFN- γ) production and initiation of adaptive immunity (Van Crevel et al., 2002, Jo, 
2008). IL-1 is also a proinflammatory cytokine, and IL-15 and IL-18 work in conjunction with IL-
12.  
 
Figure 2 M. tuberculosis (orange) binds to the TLR-2 receptor on the surface of a 
macrophage (green), (adapted from Kaufmann, 2008) 
Only after 9-14 days of extensive growth of the MTB population in alveoli, are the bacteria first 
detected in the draining lymph node. Upon IL-12 stimulation, DC migrates to the nearest lymph 
node and presents MTB antigens to naïve T-cells (Cooper et al., 2007). As the naïve T-cells 
become activated, they proliferate and begin to accumulate in the lungs. Migration of activated 
T-cells is also delayed and takes place 15-18 days post infection (Cooper, 2009). Activated 
CD4+ T-cells undergo clonal expansion and migrate to the lungs where they start producing 
cytokines of the Th1 milieu and represent the main source of IFN- γ. IFN- γ activates a 
bactericidal mechanism in macrophages, which in collaboration with TNF-α, activates synthesis 
of oxidative stress proteins. These enzymes are able to synthesize reactive nitric and oxygen 
intermediates, with microbicidal effect.  
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3.3 Tuberculosis disease 
Once acquired immunity is activated, 2-3 weeks after infection, T-cells have migrated to the site 
of infection and activated macrophages kill intracellular bacteria. By doing so, a necrotic centre 
is created, also known as a caseous centre (from the Latin caseus, meaning cheese), with 
necrotic tissue centrally and granulation tissue containing viable phagocytes and T-cells 
peripherally. Until this point MTB grows logarithmically with a 28h doubling time, while formation 
of the caseous centre inhibits growth of mycobacteria to some extent (Cooper, 2009, Van 
Crevel et al., 2002). Only at this point does the infected patient become tuberculin positive (see 
chapter 1, section 7.1), and this is usually 1-2 months after exposure to MTB (Quast et al., 
2006). 
MTB infection contained within the caseous lesion can heal; it may become latent or dormant; it 
may disseminate MTB into the bloodstream or lymph drains; it may liquefy and form a cavity 
(Quast et al., 2006, Van Crevel et al., 2002). Cavity formation provides the best conditions for 
extracellular growth of MTB. The cavity can enlarge and may cause rupture of bronchi, allowing 
MTB to enter airways and the outside environment, spreading the disease (Van Crevel et al., 
2002).  
Figure 3 shows possible outcomes following infection with MTB with number of cases 
worldwide.  
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Figure 3 Chronological events following MTB infection, adapted from Van Crevel et al., 
2002, ((1)-Rustad et al., 2009, (2)-Harries et al., 2004) 
Latent tuberculosis infection (LTBI) is characterised by MTB persistence within a cavity (Van 
Crevel et al., 2002, Rustad et al., 2009). A spectrum of MTB dormancy is characterised as a 
latent disease: cavitary lesions can be calcified with few viable bacteria; caseous lesions can 
contain low number of bacteria; or evolving lesions can contain replicating bacteria but they are 
actively destroyed by the immune system (Rustad et al., 2009). The risk of reactivation or 
progression from LTBI to active disease is greatest within the first 2 years after infection and 
subsequently declines over time but does not disappear (Keeler et al., 2006). 
Active TB can arise as a rapidly progressive primary disease or from reactivation of latent 
infection. Primary disease occurs in only 3% to 10% of those exposed, while most of the 
infected individuals are able to keep the disease latent or heal (Quast et al., 2006). The clinical 
outcome of primary disease can be tuberculous pneumonia, hyperinflation and 
collapse/consolidation or pleural effusion (Harries et al., 2004). 
Reactivating latent tuberculosis or exogenous reinfection is referred to as postprimary TB 
(Quast et al., 2006). Postprimary TB usually affects the lungs but can involve any other part of 
the body. The clinical picture of postprimary TB consists of upper lobe involvement with 
extensive lung destruction. Patients with these lesions are the main transmitters of infection in 
the community (Harries et al., 2004). 
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TB can affect any part of the body (nervous system, pleura, lymph nodes, bones and joints, 
pericardia, skin, larynx, gastrointestinal and genitourinary systems, eyes, endocrine system and 
ears) after MTB enters the blood stream and lymphatic system and this condition is generally 
referred to as extrapulmonary tuberculosis (EPTB) (Drobniewski 2005). Up to 25% of TB cases 
may present with EPTB (Harries et al., 2004). EPTB ranges from localised extrapulmonary 
infection to disseminated disease and most common forms of EPTB are: disseminated disease 
causing miliary TB or TB meningitis, pleural effusion, lymphadenopathy, pericardial disease.  
EPTB can also have coexistent pulmonary TB (Harries et al., 2004, Jacob et al., 2008). 
Vaccination against TB with Mycobacterium bovis BCG affects acquired T-cell immunity, but is 
more effective against disseminated infection than against pulmonary disease (Colditz et al., 
1994). 
3.4 Risk factors 
If the host immune system is uncompromised it typically clears TB infection and only 10% of 
infected immunocompetent individuals develop disease (Corbett et al., 2003). This number is 
much higher if the immune system is compromised. HIV infection is the most important factor in 
altering the course of a TB epidemic. In settings where TB and HIV infection overlap, TB is the 
main cause of morbidity and mortality in HIV infected population (Harries et al., 2004). TB/HIV 
coinfected patients have an estimated 10% risk of developing active TB each year (Corbett et 
al., 2003).   
In Africa the major consequence of TB/HIV coinfection is the high risk of reactivation of LTBI in 
HIV infected persons and the high risk of progressive TB by reinfection owing to the high TB 
transmission rate in the community (Lienhardt et al., 2005). HIV positive patients may be at 10 
times greater risk of developing MDR TB (Dinnes et al., 2007). TB in HIV positive patients has 
unusual clinical features: atypical pulmonary manifestations or false-negative microbiological 
results, which can cause diagnostic difficulties (Dinnes et al., 2007). 
Other factors affecting immune response include genetic defects in IFN-γ production, 
therapeutic interference in TNF-α activity (treating rheumatoid arthritis), nutritional factors 
(vitamin D deficiency), and ageing and alcohol or drug abuse, all of which may negatively alter 
the outcome of infection with MTB (Schwenk et al., 2000). 
Malnutrition and poverty were the most important TB risk factors before the HIV era. Low protein 
intake and a consequently depressed immune system were the main reason for TB epidemics 
through history (Schwenk et al., 2000). 
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Age is an important factor in disease progression, and in settings where transmission of MTB 
has been stable or increasing for many years, the incidence rate is highest among young adults, 
and most cases are recently infected. As transmission falls, patients are likely to be older adults, 
and a higher proportion of cases are due to the reactivation of latent infection (Dye et al., 2006). 
Environmental factors associated with TB are mainly products of poor living conditions: a high 
number of adults in the household, risk of TB is higher in singles than in married individuals, 
smoking (with a dose–effect relationship), a history of asthma, and a family history of previous 
TB (Lienhardt 2005). 
3.5 M. tuberculosis strains and virulence 
Virulence of the strain and tropism for specific tissues may determine the course of the disease 
(Diagnostic Standards, 2000). Also, MTB's tendency to acquire drug resistance as well as 
transmissibility between human hosts may be influenced by the genetics of MTB strain types 
(Wirth et al., 2008). 
The cell envelope is responsible for most immunological characteristics of MTB.  Members of 
the W-Beijing family of MTB strains have been associated with extensive morbidity and mortality 
worldwide (Bifani et al., 2002). Moreover, infection with W-Beijing accelerates time to death in 
mice, even though growth of these strains in murine models is not significantly different from 
several non-WBeijing isolates. The outcome of infections with different strains correlates with 
their ability to induce a strong Th1 response and those differences are likely to be attributable to 
the lipid composition of the cell envelope (Ehrt et al., 2007). 
In vivo generation time may be concurrent with strain virulence: virulent laboratory strain H37Rv 
has a generation time of 31h, while a strain isolated during a TB outbreak has shown to grow 
more rapidly with a cellular generation time of 25h (Valway et al., 1998). 
Using comparative genomics and molecular epidemiological tools it is demonstrated that the 
global population structure of MTB is defined by six phylogeographical lineages and that these 
are adapted to particular human populations. Those results agree with the observation that 
geographic subdivision exists for MTB and suggest that human migrations leading to human 
population bottlenecks might be responsible for this area-specific distribution of the pathogen 
(Arora et al., 2009). 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
27 
 
4 Clinical manifestations of tuberculosis 
Pulmonary TB can present with a wide variety of non-specific symptoms like cough, with or 
without mucus production. Symptoms like weight loss, malaise, fever, night sweats, as products 
of TNF-α activity, are also common. The patient usually presents to the health professional after 
≥2 weeks of persistent productive cough. Laboratory studies usually reflect a non-specific 
reaction to the infection: anaemia, leukocytosis, and an elevated sedimentation rate are 
common in TB (Quast et al., 2006).  
Children have different manifestations of the disease, highly dependent on their age and 
immunological status: newborns usually present with miliary TB and TB meningitis, and older 
children infected with TB can develop primary pulmonary tuberculosis (Cruz, et al., 2007). 
Childhood tuberculosis is manifested with strong inflammatory response to a relatively low 
burden of organisms, making it difficult to diagnose TB in culture (Cruz, et al., 2007). 
4.1 Chest X-ray 
Chest radiography is often used in the diagnosis of patients with active pulmonary TB.  
Pulmonary TB can present with any radiographic abnormality; or it can appear completely 
normal. In patients with reactivated pulmonary TB, lesions are found in upper lobes while in 
primary TB, the radiograph often shows abnormalities in lower or middle lobes predominantly 
with infiltrate without cavitation and associated hilar adenopathy. TB in the lower lobes takes a 
longer time to diagnose than upper lobe TB, and is associated with a high mortality rate (Quast 
et al., 2006).  
HIV positive patients often have an atypical chest X-ray for TB. The degree of 
immunosupression reflects on a radiograph such that in mild case of immunosupression, the 
appearance is typical for TB (with cavitation and upper lobe infiltrates). In severe 
immunocompromise, the appearance is often atypical (with no cavitations) (Harries et al., 2004). 
Some 36% of HIV infected patients have a primary pattern and 28% have a post-primary MTB 
pattern. In HIV infected patients with less than 200 CD4+ T-cells/µl a normal chest X-ray was 
seen in 21% of all cases (Tuberculosis. Clinical diagnosis and management, 2006). 
5 Treatment of tuberculosis 
The goal of TB treatment is to eliminate all TB bacilli from the infected individual and avoid 
emergence of TB resistance. The general approach is to administer multiple drugs to which the 
organism is susceptible, and to add at least two new drugs if treatment failure is suspected, to 
ensure the safest and most effective therapy in the shortest period (McPhee, 2008).  
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Treatment of TB requires combination therapy with isoniazid (INH), rifampicin (RIF), 
pyrazinamide (PZA) and ethambutol (EMB) or streptomycin (SM). Patients with previously 
untreated TB can be effectively treated with a six to nine month regimen. The initial phase 
consists of daily INH, RIF, PZA and EMB for two months. The second phase consists of RIF 
and INH for a minimum of four months or at least three months beyond conversion of sputum 
and culture to negative for MTB (Centers for Disease Control and Prevention (CDC), TB in 
persons not infected with HIV). Treatment of HIV positive patients can be longer, depending on 
the CD4+-T-cell count and rifabutin can be used instead of rifampin which can interact with 
certain antiretroviral agents (CDC, TB Treatment of Drug-Susceptible Tuberculosis Disease in 
HIV-infected persons, 2003). 
The treatment is long and can last up to nine months (CDC TB Treatment of Drug-Susceptible 
Tuberculosis Disease in Persons Not Infected with HIV, 2003) Patient adherence to treatment is 
problematic and rates of treatment completion are often low. Failure to adhere to the full 
treatment leads to the emergence of drug resistant strains due to inadequate dosing, making 
MTB growth conditions less bactericidal (Lipstich et al., 1998). The second reason for drug 
resistance is based on compartmentalisation of infection, since MTB grows inside and outside of 
macrophages, at different pH conditions within lung cavities. This may lead to suboptimal drug 
concentration, leading to resistance (Gillespie 2002, Lipstich et al., 1998). Also, the size of the 
initial bacterial population is associated with the possibility of resistance, based on mathematical 
models (Gillespie 2002). 
5.1 Isoniazid  
INH or isonicotinic acid hydrazide is a nicotinamide analog and has been used for TB treatment 
since 1951 (Johnson et al., 2006, Slayden et al., 2000). It enters the cell as a prodrug and gets 
activated by the catalase peroxidase encoded by katG. Activated INH affects mycolic acid 
biosynthesis while binding to ACP (enoyl-acyl carrier) reductase encoded by the inhA locus. The 
InhA-NADH complex becomes locked and aborts the reduction step in mycolic acid synthesis. 
This eventually results in loss of cell wall integrity and the bacteria die (Johnson et al., 2006). 
INH is used in the early stage of TB therapy. It is active mainly against MTB growing aerobically 
in pulmonary cavities and it rapidly reduces the number of MTB cells in sputum (Gillespie 2002). 
Mutation in the catalase gene katG results in resistance to INH. Also, several point mutations 
have been identified, associated with the structural inhA gene that result in decreased binding 
affinity to NADH. InhA promoter mutations are abundant and they result in overexpression of 
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InhA leading to low level INH resistance. Today 70% - 80% of INH resistance is due to katG and 
inhA mutations (Johnson et al., 2006). Another gene associated with INH resistance is the ahpC 
gene coding alkyl hydroperoxide reductase, responsible for a detoxifying effect on organic 
peroxides (Johnson et al., 2006). INH drug resistance based solely on katG mutation was 
detected in 63% of cases and on inhA mutation in only 2.5% of cases, while katG/inhA and 
katG/ahpC double mutations were detected in 21% and 13% respectively, of examined cases in 
a study performed in South Africa (Kiepiela et al., 2000). 
5.2 Rifampicin 
RIF has been used for TB treatment since 1972, and in combination with PZA allowed 
shortening the TB treatment from one year to six months (Johnson et al., 2006). RIF is a semi-
synthetic derivative originating from rifamycin B, produced by Streptomyces mediterranei (Floss 
et al., 2005). 
RIF binds to the RNA polymerase β subunit encoded by rpoB, preventing RNA chain elongation. 
RIF sterically blocks the extension of the nascent RNA chain in the initial stage, but once RNA 
synthesis has progressed beyond this point it is no longer sensitive to RIF (Floss et al., 2005). 
The inactivated RNA polymerase remains bound to the promoter, blocking initiation by 
uninhibited enzymes and eventually killing the organism (Floss et al., 2005, Johnson et al., 
2006). 
RIF is effective against semi-dormant MTB that are metabolizing slowly, killing persistent MTB 
and sterilising sputum (Gillespie 2002, Lipsitch, et al., 1998). 
There have been several nucleotide changes, insertions, deletions and multiple nucleotide 
changes detected in the rpoB all leading to RIF resistance. More than 95% of all mutations are 
located in the 81bp core region (also known as RIF-resistance determining region RRDR) 
(Somoskovi et al., 2001). 
5.3 Pyrazinamide 
PZA, a nicotinamide analogue, inactivates the enzyme involved in fatty-acid synthesis. PZA is a 
prodrug, and it is activated by MTB enzyme pyrazinamidase (Wade et al., 2005). PZA is 
activated at lower pH, as in caseous necrotic foci, where other drugs are inactivated (Johson et 
al., 2006, Gillespie 2002). PZA is specific for MTB and it is responsible for killing persistent, 
nonreplicating bacilli with low metabolic activity (Johnson et al., 2006, Wade et al., 2005). 
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Resistance to PZA emerges from mutation in the pyrazinamidase gene pncA accounting for 
97% of resistant strains. Mutations in the pncA gene are highly diverse and scattered along the 
gene (Wade et al., 2005). 
5.4 Ethambutol 
EMB inhibits synthesis of arabinogalactan, a cell wall component of mycobacteria and is only 
active against growing MTB. EMB inhibits the polymerization of arabinan by blocking arabinosyl 
transferase (embB) involved in cell wall biosynthesis (Wade et al., 2005, Johnson et al., 2006). 
Resistance mutations are found in the embABC operon, while routine phenotypic analysis fails 
to identify EMB resistance in most cases (Wade et al., 2005). 
5.5 Streptomycin 
Streptomycin was the first antibiotic used in the treatment of TB and today is an alternative first-
line drug. SM is aminocyclitol glycoside and it interacts with ribosomal 16S rRNA and ribosomal 
protein, causing an mRNA misfit and consecutive misreading and inhibition of protein synthesis 
(Johnson et al., 2006). SM kills actively growing MTB (Wade et al., 2005).  
Mutations in rrs, coding 16S rRNA and rpsL coding ribosomal protein 12S can lead to drug 
resistance in 20% and 50% of cases respectively (Wade et al., 2005).         
5.6 Second-Line drugs 
Patients with MDR TB can be cured with appropriate management based on second-line drugs. 
The following drugs can be classified as second-line drugs:  
- first-line oral agents: PZA, EMB, rifabutin  
- injectable agents: aminoglycosides (kanamycin and amikacin) polypeptides 
(capreomycin) 
- fluoroquinolones: ofloxacin, ciprofloxacin, levofloxacin, moxifloxacin 
- oral bacteriostatic second-line agents: cycloserine, terizidone, ethionamide, 
protionamide 
- agents with unclear role in treatment of drug resistant-TB: linezolid, 
amoxicillin/clavulanate, thioacetazone, imipenem/cilastatin, high-dose isoniazid, 
clarithromycin (WHO, Treatment of tuberculosis: guidelines, 2010). 
MDR TB treatment can be standardised or individualised, but in any case must be more closely 
supervised by the clinician. Since MDR MTB isolates are resistant to RIF and INH it is 
necessary to include at least four second-line drugs to which the organism is susceptible (WHO, 
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Treatment of tuberculosis: guidelines, 2010). Unfortunately, second-line drugs are more toxic 
and less effective than first-line drugs, while treatment is prolonged and significantly more 
expensive (Johnson et al., 2006). If a patient is INH mono-resistant, he can be successfully 
treated with a combination of RIF, PZA and EMB or SM for up to 12 months (McPhee, 2008). 
XDR TB is defined as MDR TB that is resistant to any one of the fluoroquinolones as well as to 
at least one of three injectable second-line drugs (amikacin, capreomycin or kanamycin). 
Among MDR and XDR TB cases, capreomycin resistance is associated with worst prognosis 
and death outcomes (Migliori et al., 2008). 
Agents with an unclear role in the treatment of drug resistant TB can be used in patients with 
XDR TB (WHO, Treatment of tuberculosis: guidelines, 2010).  
6 Traditional tests for diagnosis 
6.1 Clinical diagnosis  
The diagnosis of TB is based on a combination of symptoms, clinical signs and investigations. 
Clinical diagnosis of pulmonary TB is based on passive case-finding in patients presenting with 
a persistent cough (Keeler et al., 2006). Diagnosis cannot be made from a single piece of 
evidence and investigation including diagnostic tests should be interpreted according to the 
clinical scenario and sensitivity and specificity of each test (Knottnerus et al., 2002). A history of 
a recent TB contact, recent travel to, or residence in endemic areas, can influence the diagnosis 
(CDC Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis, 
2005). 
Common clinical signs of pulmonary TB are: loss of appetite, weight loss, fever, night sweats, 
chest pain, haemoptysis, and breathlessness (Siddiqi et al., 2003). TB has a gradual onset of 
symptoms over a period of time, which could be neglected by the patient, resulting in a delay of 
weeks or months before seeking medical attention (Schoch et al., 2007). 
6.2 Clinical specimens 
Mycobacterial disease may occur in almost any site in the body, so a variety of clinical materials 
may be submitted to the laboratory for examination: sputum (natural or induced), bronchial 
washings, gastric aspirate, blood, urine, cerebrospinal fluid, pleural fluid, material from 
abscesses, endometrial scrapings, bone marrow, and other biopsy specimens or resected 
tissue (Bannister et al., 1996). 
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The majority of clinical specimens sent to the mycobacterial laboratory are contaminated by 
rapidly growing normal physiological flora. To maximise the yield, contaminated specimens 
require treatment with a digestion and decontamination procedure. The most widely used agent 
for digestion is N-Acetyl-L-cysteine (NALC). Sodium citrate is added to NALC to bind heavy 
metal ions, which would otherwise inactivate NALC (Kubica et al, 1963). Sodium hydroxide 
(NaOH) is used for digestion and decontamination at a final concentration of 1% - 1.25%. In 
developing countries the final NaOH concentration is often increased from 1.25% to 1.5% to 
reduce contamination in cultures, but small reduction in contamination rates makes this method 
toxic to MTB, while reducing the culture positivity rate from 21% to 11% (Peres et al., 2009). 
The sample has to be subsequently vortexed to enhance mucolytic activity, centrifuged and 
concentrated (Kubica et al, 1963). Keeping in mind the infectious nature of the sample, these 
are hazardous steps and have to be performed in BSL 3 laboratory. 
There are decontamination kits on the market, with ready to use reagents (Mycoprosafe, 
Salubris, Inc., USA), but they still require vortexing and concentration. 
6.3 Traditional tests for detecting tuberculosis 
Traditional tests used for detecting TB are based on: 
- microscopy 
- culture 
- tuberculin skin test  
6.3.1 Microscopy 
Microscopy is a 100 year-old technique, used to examine clinical specimens or culture isolates 
for the presence of the acid-fast property of MTB. A variety of different stains is available, but 
most commonly used are carbolfuchsin-based methods (Ziehl–Neelsen, and Kinyoun) and 
fluorescence based auramine–rhodamine fluorochrome methods. 
Sputum must contain 5,000 – 10,000 bacilli/ml for AFB to be detectable by microscopy 
(Diagnostic Standards, 2000). The number of bacilli is determined by the type of tuberculosis 
lesion. Thus, a cavity of about 2cm in diameter opening into a bronchus may contain 100 million 
bacilli, whereas a non-cavitary lesion of the same size may contain only 100-1000 bacilli. Since 
the latter scenario is likely to be observed in early disease, moderately advanced non-cavitary 
disease as well as HIV-positive patients and children, the sensitivity of the test is greatly 
reduced in those groups (Toman et al., 2004). 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
33 
 
The AFB smear provides an index of the degree of infectiousness and provides valuable 
information for decision makers regarding infection control risk, although smear-negative 
patients have been shown to be infectious (Behr et al., 1999). Patients with smear negative, 
culture positive TB appear to be responsible for 17% of TB transmissions (Dinnes et al., 2007). 
Sensitivity of the microscopy ranges from 34% - 80% and is highest in patients with advanced 
cavitary disease, and lowest in those with a weak cough (Davies et al., 2008). In MDR and XDR 
TB patients, smear positivity was 60% (Gandhi et al., 2010). Rates of smear positivity in HIV-
infected patients vary from 30% to 80%, depending on immune status: when CD4+ T-cell count 
is higher than 200 cells/µl patients present with pulmonary cavities and sputum smear is positive 
in 70% of patients, and as the number of CD4+ T-cell decreases so does the sensitivity of the 
test (Charles et al., 2006). 
It has been recently recommended by the WHO to take two sputum specimens, on the day of 
the patient‟s visit, which is a reduction from the traditional three samples, but it is as effective 
and reduces laboratory work and cost and patient compliance (Harries et al., 2000, WHO, 
Reduction of number of smears for the diagnosis of pulmonary TB). 
Microscopy is inexpensive, quick and specific for high prevalence settings and detects the most 
infectious subset of patients. Downfalls of AFB are, unfortunately numerous: 
- sensitivity varies between laboratories and is only 40% - 60% under field conditions and 
in the HIV infected population sensitivity may be as low as 20% (FIND Diagnostics for 
tuberculosis, 2006) 
- it is difficult to maintain equipment in  field settings 
- it is highly operator dependent 
- even it is considered fast, in practise it often still takes one to seven days for the final 
result to be made available to the clinician 
- there is usually a need for sample duplicates (sensitivity increases from 22% - 43% to 
50% - 70% if more than one sample is inspected) (Toman et al., 2004) 
- sample volume influences the result and 5ml or more is desirable (sensitivity was 
increased from 72% to 92% when only samples of 5ml were processed) ( Royal College 
of Physicians of London, Tuberculosis, 2006) 
- bacillary load can vary and depends on time of the sampling (morning versus spot), 
method of sampling (with or without induction), severity of the disease and existence of 
cavitary lesions 
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- specificity is impaired if specimens are obtained from individuals who are heavily 
colonised with nontuberculous mycobacteria (NTM) or have chronic disease due to NTM 
(Cole et al., 2005) 
- drug resistance and viability of the organism cannot be established 
- some food particle precipitates, inorganic materials and artefacts may give false positive 
results (Toman et al., 2004) 
- only one third of microbiologists are senior microbiologists who can interpret a Gram 
stain the identify a pathogen at an early stage (Baron, 2006) 
Even with all the shortcomings, AFB direct smear remains “the gold standard” (since it 
demonstrates existence of mycobacteria in sputum) in developing countries, especially in 
peripheral health facilities, since there is no infrastructure for further testing. However, even 
peripheral health facilities often lack trained microscopists, properly functioning microscopes 
and adequate reagents (Keeler et al., 2006). 
Several attempts have been made in order to improve the performance of smear microscopy. 
Concentrating the sample by adding sodium-based reagent and centrifugation increases 
sensitivity, but this still requires BSL 2 capacities. At point-of-care, especially in rural settings, 
there is no infrastructure for introducing laboratory equipment like centrifuges or biosafety 
cabinets (Pai et al., 2008). Use of household bleach or ammonium sulphate and overnight or 
short-term sedimentation is more sensitive than direct smear, but still higher sensitivity is 
obtained if centrifugation follows bleach treatment (Steingart et al., 2006, Van Deun et al., 
2000). 
A great advantage in TB diagnosis would be to develop a new technique or improve the existing 
one in order to improve smear performance and at the same time have simple instruments easy 
to implement at the point-of-care level. The use of fluorescence method represents a significant 
advance in that context.  It has been shown that the auramine and auramine/rhodamine method 
has an advantage over ZN staining, because it is easier to detect a fluorescent rod against a 
darker background. The fluorescence method allows the technician to scan the slide at a lower 
magnification and thus observe a larger area than with ZN smears. These factors reduce the 
time spent per slide and lead to greater sensitivity (Somoskövi et al., 2001). 
However, the fluorescence method is more expensive and is not widely available in the 
developing world, considering the cost of the fluorescent microscope as well as reagents. More 
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recently much cheaper, light emitting diode (LED) microscopy is likely to make fluorescent 
microscopy more widely available (Pai et al., 2008). 
There is a clear need for a novel diagnostic test that can be introduced at the same level of 
health facility as smear microscopy, and with the same or higher specificity but with significantly 
improved sensitivity.  
6.3.2 Culture 
A definitive diagnosis of tuberculosis is still dependent on the isolation of MTB by cultivation. 
The goal is to detect viable mycobacteria in clinical samples. As few as 10 to 100 organisms are 
needed for a positive culture (Toman et al., 2004). A significant advantage of culture is that 
species identification as well as drug susceptibility testing is made possible. Culture is the most 
sensitive test available: sensitivity of culture ranges from 80% to 93% (sensitivity rates up to 
98% are reported) while specificity is 98% (Davies et al., 2008, Dinnes et al., 2007). Culture can 
be used to detect TB from biopsy material and needle aspirates, meaning it is also applicable 
for extrapulmonary TB. 
The biggest downfall of culture analysis is unfortunately that it time consuming. With a median 
time of more than four weeks for a conclusive result and four to six weeks more for DST it does 
not bring valuable information to the clinician at the moment of establishing the diagnosis and 
commencing treatment. Culture also requires more technical expertise and extensive laboratory 
infrastructure than microscopy and it is restricted to referral centres (Davies, et al., 2008, FIND 
Diagnostics for tuberculosis, 2006). 
Culture is considered the “gold standard” for TB detection. But in practise, there are still cases 
when bacillus is not successfully cultured. As a result a significant proportion of patients are 
started on empiric TB treatment if the clinical suspicion is strong enough (Davies, et al., 2008). 
6.3.2.1 Solid culture 
Traditional cultivation involves solid media, such as that of egg-based Löwenstein-Jensen (LJ), 
or agar-based Middlebrook 7H9, 7H10, 7H11. Both can be made into selective media by adding 
a cocktail of antibiotics allowing only MTB to grow. MTB is detected by the specific growth 
morphology: colonies are rough, dry, flat, and beige-coloured or granular and with time they 
grow into a cauliflower shape (Dinnes et al., 2007). The method is cost effective in comparison 
with liquid automated methods (FIND Diagnostics for tuberculosis, 2006). It is valuable to 
examine culture morphology and detect mixed cultures, and the solid medium allows this 
(Diagnostic Standards, 2000). 
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The biggest drawbacks of the method is that it is time-consuming, taking up to four weeks for a 
positive result, but incubation is necessary for six to eight weeks in order to be classified as 
negative (Davies et al., 2008). Each culture has to be examined weekly (Moore et al., 2005). 
MTB grows better on LJ medium, with higher sensitivity, but more rapidly on the agar medium 
(Diagnostic Standards, 2000). 
Several approaches have been made to improve time to result using solid culture. Blood agar 
slants, made from sheep blood, may be a good substitute for LJ as it saves about one third of 
the time for rapid detection of MTB, and it is suitable for resource-limited settings (Mathur et al., 
2009). The thin layered agar method is as sensitive as LJ and results are available within two 
weeks (Martin et al., 2009). 
A recent improvement is the commercially available solid culture-based colorimetric method, TK 
Medium (Salubris, Inc., USA). Metabolic activity of growing MTB changes the colour of the 
culture media, at the same time enabling positive identification of MTB. Time to detection is two 
weeks, and further advantages of the test are: low-cost, simplicity, and possibility for DST (Pai 
et al., 2006). However this method appears to have been abandoned by developer.  
6.3.2.2 Liquid culture 
The use of a liquid medium for cultivating MTB systems has led to a considerable shortening of 
the time (one to four weeks) required for the detection of mycobacteria (FIND Diagnostics for 
tuberculosis, 2006). Sensitivity of liquid culture methods is generally higher than of solid culture; 
specificity is also higher for liquid media, especially since contamination rates with non-AFB are 
higher in solid culture (Cruciani et al., 2004). Several automated and semi-automated methods 
and detection approaches are used: radiometric, oxygen quenching, and redox-reaction. 
Firstly, the radiometric approach was used as a semi-automated system. The BACTEC 460 
radiometric method uses 7H12 liquid medium containing 14C-lebeled palmitic acid and detects 
radioactive 14CO2 as a catabolic product (Ramachandran et al., 2003). The result is expressed 
as an arbitrary growth rate, enabling reproducibility. It has enhanced sensitivity and the time to 
positive result is shortened. The same culture can be used for DST, once it is reported positive 
for microbial growth and the result is obtained after 10 days. The radiometric system‟s main 
limitations are the high cost of disposal of the radioactive waste and the need for specific 
laboratory infrastructure and instrumentation (Ganeswrie et al, 2004). 
In order to resolve issues around radioactive waste and simplify the procedure, a fluorescence 
measuring system was developed. The principle is based on measuring the metabolic activity of 
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growing bacteria. The Mycobacteria Growth Indicator Tube (MGIT) contains modified 
Middlebrook 7H9 broth with an oxygen quenching-based fluorescent sensor. Oxygen is initially 
dissolved in the media and it quenches fluorescence. Consumption of the dissolved oxygen by 
the growing MTB results in a fluorescence from the sensor at the bottom of the MGIT, when 
illuminated with an ultraviolet lamp (Piersimoni et al., 1998, Palomino et al., 2008). The 
fluorescence system is usually preferable because of the increased convenience of the 
technology. 
The automatic BACTEC MGIT960 system (Becton, Dickinson and Company, USA) performs 
incubation of an MGIT tube at 370C and reads  the tubes continuously inside the machine, 
analysing the fluorescence signal for mycobacterial growth, and interpreting each MGIT as 
positive or negative for MTB (Palomino et al., 2008). 
MGIT is currently considered as the “gold standard” (FIND report, 2008) but the biggest 
drawback for this technology is that it is not available to the wide population; many problems 
have been encountered while implementing the system in laboratories, in developing countries, 
generally managing a medium load of samples, while the biggest issue is high cost (Palomino et 
al., 2008). 
A new pricing agreement between low income countries and BD for the BACTEC MGIT960 
system should make MGIT available to additional high burden countries (FIND press release, 
2007). 
There are several new liquid systems on the market having similar performance characteristics 
to the MGIT 960: 
- BacT/Alert 3D system (bioMerieux Inc., France), measures carbon dioxide production 
- Versa TREK system (Trek Diagnostic systems Inc., USA), measures changes in gas 
pressure 
- MB redox (Heipha diagnostika, Germany) detects colour change (red particles become 
visible) upon redox reaction between CO2 and tetrazolium salt-containing tube (Dinnes 
et al., 2007, Palomino et al., 2008, Grandjean et al., 2008, Cambau et al., 1999). 
6.4 Diagnosis of tuberculosis in smear negative cases 
In low resource/ high prevalence settings TB diagnosis is relying on sputum smear since it is 
highly specific (Keeler et al 2006). However, smear has impaired sensitivity in people living with 
HIV and in children.  
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People living with HIV are 20 to 30 times more likely to develop TB than HIV negative people. 
Moreover, as HIV increases the risk of developing active TB, so does TB accelerate the 
progression of HIV into AIDS. Without adequate TB treatment, approximately 90% of HIV 
positive people die of TB within months of infection (WHO, TB/HIV facts 2009). 
In a recent study two groups of HIV positive and HIV negative TB suspects were recruited and 
examined for TB culture and smear: direct smear was positive for 47% and 83.1% of all culture 
positive but HIV negative and HIV positive patients, respectively (Eyangoh et al., 2008). 
Over 250 000 children develop TB and 100 000 children will die each year from TB, since TB 
has been largely misdiagnosed in children under 10 years old. Diagnosis of TB in children is 
influenced by the children inability to cough up enough sputum to be analyzed for smear or 
culture and CXR of children are difficult to interpret as the typical shadow is rarely seen. Hence 
the diagnosis is based on the clinical features: cough, weight loss, history of contact with a TB 
patient (WHO TB and Children, 2006).  
In order to improve diagnosis in HIV positive patients and in children, existing methods of 
diagnosing TB should be evaluated in those groups and new approaches made. A number of 
studies aiming at those groups are ongoing and they should make an impact on changing 
clinical practice in those patients.   
7 Immunological diagnosis 
Demonstration of mycobacteria is often not possible, due to the paucibacillary nature of the 
illness in some cases, for example in children. Immunodiagnostic methods are used as an 
alternative option in order to increase detection rate in such cases, since they are considered 
cost effective and rapid (Palomino et al., 2007). 
Assays available today use various immunological approaches in response to TB antigens:  
they detect antibodies in blood (complement fixation, radioimmunoassay, enzyme-linked 
immunosorbent assay (ELISA)), or T-cell based assays (detect up-regulation of IFN-γ, and other 
Th1 cytokines, or delayed-type hypersensitivity (DTH) reaction). 
7.1 Tuberculin skin test 
Tuberculin skin test (TST) is a century-old test based on intradermal introduction of tuberculin, a 
concentrated protein mixture known as purified protein derivative (PPD) derived from MTB. The 
method was described by Mantoux who noticed that results of DTH reaction to tuberculin are 
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reproducible; if one measures the size of the induration produced after injection of a 
standardised dose (Palomino et al., 2007). 
The skin test is simple, inexpensive, and easy to administer and read. It can be done on site, 
but it requires two visits by the patient one for antigen administration and the second after 48h-
72h for interpretation of the result based on the skin reaction. There are several practical 
difficulties in performing the test: the return rate for the test reading can be very low, the 
injection sometimes causes painful skin inflammation and scarring (Dinnes et al., 2007). The 
test is used for surveillance for TB in a selected settings or, previously, to select subjects for 
BCG revaccination (Dinnes et al., 2007, Palomino et al., 2007). 
The dose of antigen, method of application and interpretation of results vary between settings. 
More than 10mm-15mm for the skin reaction is considered a positive result, depending on 
whether there is a history of BCG vaccination and more than 5mm for HIV infected patients.  
The test has 70% sensitivity in active TB patients, and in immuncompromised is as low as 30% 
(Palomino et al., 2007). The reason for the low sensitivity is a generally low immune response, 
especially in HIV-infected patients. In addition, antigen recognition in TB is very variable from 
individual to individual and may be specific to a stage of disease (Gennaro, 2000). TST can give 
a false positive result: PPD shares antigens with other environmental mycobacteria; a positive 
test may result from prior BCG vaccination; repeated TST may have a booster effect (Dinnes et 
al., 2007). It also cannot distinguish between active and latent infection. 
7.2 Serological tests 
Serological tests are based on detecting humoral immune response to TB antigens. Several 
serological tests for detecting active TB and LTBI have been developed over the years. They 
are simple, rapid and potentially useful in settings where culture is not routinely available.  
Serological tests available at present perform poorly for the diagnosis of active TB and in their 
ability to distinguish between active and latent TB infection. Their use cannot therefore be 
supported (Steingart et al., 2007). Responses to TB antigens vary individually however 
sensitivities are generally poor, ranging from 16% - 57% whilst specificities of 62% - 100% have 
been reported for commercial assays (Pottumarthy et al., 2000). Serological tests are not 
recommended for paediatric TB and development of new diagnostics is recommended by the 
WHO (WHO, A research agenda for childhood tuberculosis, 2007).  
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Serological test accuracy is influenced by the demographic and environmental determinants; 
exposure to atypical mycobacteria, BCG vaccination and HIV prevalence can influence the 
result (Dinnes et al., 2007, Lalvani et al., 2007). New approaches and new antigens are 
necessary for serological assays in order to improve their performance. They should be able to 
distinguish between active and latent infection, to increase specificity in order to discriminate 
between BCG vaccination and NTM infection, and monitor response to therapy. They should be 
simple, safe and rapid (less than 30 minutes) and cost-effective (Talbot et al., 2004). 
Performance should be evaluated in children and HIV-infected patients (Steingart et al., 2007).  
Commercial serology assays use single or compound TB antigens such as: antigen-60, LAM, 
38 kDa protein, or 16 kDa protein, while typically using ELISA as the detection technique. A 
recently developed ICT TB Test (ICT Diagnostics, Australia) is an immunochromatographic test, 
using strip technology, and is simple to use, especially at point-of-care, but with variable 
sensitivity, ranging from 20% - 73%, and specificity rates between 80% - 100% (Ongut et al., 
2006). Detection of active and latent TB and uninfected individuals should be improved by using 
multiantigen cocktails (Gennaro, 2000). 
7.3 Interferon-γ release assays 
Interferon-γ release assays (IGRA) have been designed to replace the TST. Mycobacterial 
antigens specific for MTB are used for in vitro stimulation of peripheral blood mononuclear cells 
(PBMC) or whole blood. IGRA has several advantages over TST: a single patient visit is 
required, there is reduced bias in interpretation of the result, a booster effect does not occur, 
and there is greater sensitivity in detecting LTBI and active TB in HIV-infected people (Dinnes et 
al., 2007) 
Antigens included in IGRA are RD1-specific antigens: early secretory antigen target 6 (ESAT-6) 
and culture filtrate protein 10 (CFP-10) and TB10.4 protein in QuantiFERON-TB. The RD1 
region is missing in BCG strains so RD1-antigens will not stimulate a BCG-related cellular 
response (Lavani et al., 2001). 
These tests need to be performed in an equipped tissue culture laboratory where blood cell 
separation and cultivation is followed by interferon-gamma ELISA or enzyme-linked immunospot 
ELISPOT assay. IGRA that are now commercially available are: the ELISPOT T SPOT-TB 
assay (Oxford Immunotec, UK), and ELISA based QuantiFERON-TB, and its enhanced version 
QuantiFERON-TB Gold In-Tube assay (Cellestis International, Australia). 
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Interpretation still depends on the clinical situation. As for TST, IGRAs cannot distinguish latent 
from active disease. Only if prevalence of TB is low and the clinical situation highly suggestive 
of TB, then a positive IGRA result can be used as an indication for active TB. In a high 
prevalence setting it can mean either latent or active disease. It is not uncommon to have false 
negative results in active TB (Dinnes et al., 2007). 
8 Molecular tests 
Molecular tests include a wide group of methods that utilise different nucleic acid moieties.  The 
unique sequences of nucleic acid specific to each species make it distinguishable from different 
species which provides a sounds basis for developing a microbial diagnostic test.  Hence, 
molecular tests have developed in the past few decades into essential tools in microbiology. In 
terms of sensitivity, specificity and most of all speed, molecular tests offer excellent 
performance.  
Molecular identification may be applied in three scenarios: identification of an organism isolated 
in pure culture, rapid identification of organisms in clinical specimens and identification of 
uncultivable organisms present in specimens (Speers, 2006). 
8.1 Molecular approaches to detecting tuberculosis 
Deciphering the MTB genome of strain H37Rv in 1998 was a benchmark in MTB research (Cole 
et al, 1998). This achievement made a breakthrough in functional and comparative genomics for 
this organism. Those events initiated development of the more sophisticated molecular 
diagnostic tools. New molecular tools for detecting TB emerged from the demand for rapid and 
reliable diagnosis, as well as a means for differentiation of MTB from NTM and for rapid DST. 
8.2 Nucleic acid amplification tests  
Nucleic acid amplification-based pathogen diagnostic tests are able to detect small amounts of 
genetic material, by amplifying a DNA or RNA sequence, from micro-organisms. The most 
important feature of molecular testing is that the result can be obtained within hours. 
There are several amplification methods and the most common NAAT is based on polymerase 
chain reaction (PCR). PCR has evolved from end-point reaction to real-time PCR detection 
where detection is done while the reaction is ongoing. NAAT uses different enzymes and 
strategies, such as amplification of different targets within DNA or RNA. Most NAAT-based tests 
involve three steps: DNA/RNA isolation, amplification and detection.  
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8.2.1 Polymerase chain reaction  
Since the first publication of the polymerase chain reaction (PCR) amplification technique in 
1985 (Saiki, et al., 1985) considerable progress has been made in pathogen detection and 
identification. The first semi-automated amplification system for pathogen detection, Cobas 
Amplicor was on the market in 1995 (DiDomenico et al., 1996, Thon et al., 2001).  Since then, 
nucleic acid amplification techniques have been refined and different approaches have been 
deployed in order to make it simple, cost effective and applicable for clinical use. 
PCR is the most widely used amplification technique for detection and characterisation of 
pathogens. It can give a simple answer whether a pathogen is present in the sample or not. 
PCR amplifies DNA, but in conjunction with reverse transcriptase it can amplify a sequence 
originating from the RNA. Reverse transcription polymerase chain reaction (RT-PCR) can 
assess viability of an organism in question if short-lived RNA is targeted.   
The reaction is performed by consecutive temperature alterations. High temperature melts the 
double stranded DNA (dsDNA), then the temperature is reduced to allow primers to anneal to 
the template and finally the temperature is set at an optimal temperature for polymerase 
enzymatic activity of incorporating deoxyribonucleotide triphosphates (dNTPs) into a new strand 
(Kubista et al., 2006). PCR targeted at a specific sequence within a genome requires optimal 
conditions for amplification: 
- template DNA 
- dNTPs, the four nucleotide triphosphates 
- primers, flanking the sequence to be amplified 
- heat-stable DNA polymerase 
- Mg2+ ions, stabilising double stranded dsDNA  
- buffer 
- temperature cycling 
At the beginning of PCR, the temperature should be high enough to separate the DNA template 
strands, since if dsDNA is not fully separated when temperature is lowered, strands will 
reanneal before primers have the same opportunity (Kubista et al., 2006).  
Primers should have a 40% - 60% GC content, be relatively short and similar in size (18-25 
bases), be free of repetitive motifs, and long stretches of polypurines or polypyrimidines (Roux, 
1995). Annealing temperature should be few degrees below primer melting temperature. 
Mg2+ ions stabilise dsDNA and raise the temperature of DNA annealing or (melting temperature) 
Tm; thereby a shift in Mg2+ ion concentration determines the reaction specificity: low Mg2+ 
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concentration requires more stringent base pairing in the annealing step, but it can also result in 
a low yield of PCR product, whereas high Mg2+ concentration enables primer binding to a non-
specific template and may result in amplification of unwanted product (Roux, 1995).  
Hot-start polymerases require a heat activation step prior to PCR, which is a practical 
advantage, since it can be added to the master mix prior to template without a possibility of 
elongation before the fist melting-annealing step.  Elongating temperature is usually set to be 
the optimal temperature for polymerase, and it is 720C for polymerase isolated from Thermus 
aquaticus or Taq polymerase (Kubista et al., 2006). 
PCR specificity is enhanced by nested PCR, involving a second round of PCR with an internal 
set of primers. This procedure involves more manipulation and extra cost, but more importantly 
it increases the chance of sample contamination, since it involves handling already amplified 
DNA product. One solution is to have PCR and nested PCR done in the same tube (Wilson et 
al., 1993). By doing this, both sensitivity and specificity rises and the possibility of cross-
contamination at this stage is less likely. 
PCR in microbial detection has been used in diagnostic laboratories in most of the cases as an 
“in-house” method. Assays are referred to as „„in-house‟‟, if they are based on a protocol 
developed in a non-commercial laboratory. In addition many of the PCR based technologies 
have already been developed into commercially available diagnostic kits and assays for use in 
clinical microbiology.  
PCR is a widely used method for MTB detection, and in 80% of all “in-house” NAAT protocols 
PCR is the amplification method of choice (Flores et al., 2005). Time to diagnosis is usually two 
days and it is cost effective in comparison with culture (Muhumuza et al., 2006). 
8.2.2 Real-time PCR 
A major advance in amplification has been the development of systems that allow monitoring 
amplification in real-time. The first application of real-time PCR used ethidium bromide and a 
CCD camera to monitor amplification of PCR (Muhumuza et al., 2006). The accumulation of 
fluorescence during thermocycling is directly related to the starting number of DNA copies 
(Higuchi et al., 1993). The fewer cycles necessary to produce a detectable fluorescence, the 
greater the number of target sequences. In this way DNA can be amplified and quantitated at 
the same time. Besides quantitation there are several practical advantages of real-time PCR 
over conventional PCR: the reaction is performed in a closed tube and there is no need for 
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subsequent post-PCR detection and amplicon handling, thereby reducing the possibility of 
amplicon contamination (Higuchi et al., 1992). 
There are two general approaches to quantifying real-time PCR product: standard curve or 
absolute quantitation and relative quantitation (Arya et al., 2005). The standard curve is made 
up using known concentrations of the gene in question and determining a threshold cycle (Ct) 
for each sample. Ct is the number of PCR cycles at which the detecting signal is greater than 
the threshold. The Ct number is lower if the concentration of sample is higher. Ct is specific for 
each experiment and it should not be used as the nominal value; rather internal control (IC) 
should be included in each run. The threshold is an arbitrary value of fluorescence, usually 
selected by the instrument or thermal cycler, but it can be adjusted for each experiment (Arya et 
al., 2005). Relative quantitation requires IC amplified at the same time as the template sample.  
IC has a defined numbers of copies and it is usually very similar to the target gene.  According 
to the proportional relationship between the IC‟s Ct and sample‟s Ct it is possible to estimate the 
number of gene copies in the original sample. Ct is defined as number of cycles necessary to 
reach the signal threshold line, so that signal can be distinguished from the background (Heid et 
al., 1996). 
Real time PCR detection is made possible by complex reactions of emitting or quenching 
fluorescence. The first attempt at emitting fluorescence was done using fluorescence dyes 
intercalating into DNA. As mentioned above, the first real-time PCR detection used ethidium 
bromide, which becomes fluorescent upon intercalating into DNA. Asymmetric cyanine 
intercalator dyes with two aromatic rings are used nowadays; they have no fluorescence in 
solution, but when they bind to a DNA minor groove, they become brightly fluorescent when 
exposed to the appropriate wavelength. Intercalating dyes widely used today are: SYBR Green 
I, BEBO, LC Green, and SYTO9. This is the simplest and most cost-effective detection system. 
The downside is that some dyes can inhibit PCR at certain concentrations (Monis et al., 2005) 
The second approach is to use labelled primers and probes. Probes can be covalently bound to 
one or two dyes. Probes based on a single dye are actually fluorophores that change their 
fluorescence properties upon binding to the nucleic acid. In case of two dyes, fluorophores are 
covalently bound to the probe or primer which is structurally designed to bring one fluorophore 
in contact with another fluorophore or a quencher (Monis et al., 2005). Summarised 
mechanisms or reporters used in real-time PCR are as follows: 
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Taqman probe or hydrolysis probe: The probe has a fluorophore on the 5‟ end and a quencher 
on the 3‟ end. Once the probe is bound to the ssDNA, Taq polymerase hydrolyses the probe 
near the 5‟ end with its exonuclease activity and releases fluorophore into the solution, thereby 
separating it from the quencher. 
Molecular beacon probe: Molecular beacons are self-complementary single-stranded 
nucleotides that form a hairpin loop. On one side of the loop structure there is a fluorophore and 
on the other a quencher. When a probe binds to the target sequence fluorescence is emitted 
since the fluorophore and quencher are further apart.  
FRET probe: Fluorescence resonance energy transfer probes are two separate fluorescently 
labelled oligonucleotides designed to bind to a DNA sequence bringing them in close proximity, 
thereby enabling energy transfer from one fluorophore to another and emitting fluorescence of a 
different wavelength.  
Scorpion primers: Scorpion primers perform a dual function of probe and a primer. In structure it 
is a molecular beacon. The link between the beacon and the primer has a PCR blocker to 
prevent replication of the beacon sequence. The loop is complementary to the sequence 
synthesised immediately after the primer. Once the sequence after the primer has been 
synthesised, the loop unwinds exposing the fluorophore and emitting fluorescence (Coleman et 
al., 2006, Monis et al., 2005, Kubista et al., 2006). 
Instruments used for real-time PCR are commercially available and the main differences 
between them are the excitation and emission wavelengths, single or multiple wavelengths, 
speed, and the number of reactions that can be run in parallel. Instruments may hold microtiter 
plates from 96 to 384 wells. Instruments with independent sample tubes, such as the Cepheid 
SmartCycler (Cepheid, USA), recently appeared on the market (Kubista et al., 2006). Such 
instruments have independent modules and each can perform operator instructed real-time 
PCR under individual heating and optical protocols, so that different tests can be done at the 
same time. This is, most probably, the way forward for non-commercial, “in-house” diagnostic 
assays (see chapter 1, section 8.5) 
Real-time PCR is the greatest advance since PCR found its place among diagnostic tests. Real-
time PCR is automated, is adjustable to any protocol when primers are designed, and minimises 
the risk of contamination. Specificity is enhanced if nested set of primers are used (Wilson et al., 
1993)  
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8.2.3 Ligase chain reaction 
Ligase chain reaction (LCx) uses thermostable DNA ligase and four primers: two pairs of 
forward primers and their complements. Forward primers are made in a way that once they 
attach to ssDNA a gap of 1-3 bases between them is formed. The next step takes place at the 
temperature optimal for DNA polymerase which fills the gap between primers. Thermostable 
DNA ligase acts to covalently connect extended primers. Product is detected using a capture 
system (see in detail below) (Coleman et al., 2006, Ausina et al., 1997, Monis et al., 2005). 
8.2.4 Strand displacement amplification 
Strand displacement amplification (SDA) is an isothermal reaction that uses a combination of 
exonuclease deficient DNA polymerase (Klenow fragment is omitted), restriction endonuclease 
and two sets of primers. The reaction mixture contains also dTTP, dCTP, dGTP and modified 
hemi-phosphorothioate dATPs. The reaction course is performed at 370C. The amplification 
process can be divided in two phases: target generation and amplification.  
Target generation uses a first set of primers with a specific restriction site. These primers anneal 
to the ssDNA, after short heating, close to the target sequence. This initiates DNA polymerase 
binding to the primers and their elongation toward the target sequence. Since DNA polymerase 
lacks endonuclease activity, the primer is not degraded. A second set of primers, bumper 
primers, bind within the target sequence and their extension displaces the newly synthesised 
strand containing the restriction enzyme site. This strand now becomes a template for further 
amplification since it is a target for reverse first primer as well as bumper primer.  
The restriction enzyme makes a nick only in the original double stranded molecule including the 
first set of primers.  If the first set of primer is abundant, then each time they anneal to the 
template end elongate, endonuclease will recognise the restriction site and make a nick, and 
this is a starting point for DNA polymerase to start synthesising new strands and displacing the 
downstream strand (Walker et al., 1992, Walker, 1993).  
8.2.5 Transcription-mediated amplification 
Transcription-mediated amplification (TMA) targets RNA molecules, abundantly present in each 
cell, and transforms them into cDNA, thereby starting with an about 10 000 transcriptional active 
DNA template instead of 1-2 copies of genomic DNA template.  
Amplification is an isothermal, two step process: rRNA is copied into cDNA using reverse 
trancriptase and then RNA polymerase is used to make amplicons of the target RNA using 
cDNA as a template.  
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To begin the reaction, a primer that is complementary to target rRNA is added to initiate the 
synthesis of cDNA using reverse transcriptase. RNase H degrades the primer upon cDNA 
synthesis, leaving single stranded cDNA. Then, a DNA-specific primer initiates DNA polymerase 
binding and dsDNA is produced. The final product is dsDNA matching the target RNA region 
with an RNA polymerase binding region. RNA polymerase binds to the dsDNA and generates 
RNA via transcription. Finally, the labelled probe complementary to the DNA amplicon is used to 
detect the amplified sequence (Coleman et al., 2006). 
8.2.6 Loop-Mediated Isothermal Amplification  
Loop-Mediated Isothermal Amplification (LAMP) is isothermal amplification based on strand 
displacement reaction, carried out at a higher incubation temperature at 650 C. Reaction mixture 
includes Bst DNA polymerase, with strand displacement activity, and a set of four primers, that 
together recognise six distinct sequences on the target DNA. LAMP reaction is based on a 
combination of cDNA synthesis, strand displacement DNA synthesis and formation of stem-loop 
DNA, by self-primed DNA synthesis. The product is a mixture of stem-loop DNAs with various 
lengths and cauliflower-like structures with multiple loops. Detection of DNA amplification is 
measured as turbidity or precipitate forming. Pyrophosphate, which is produced as a by-product, 
yields a white precipitate of magnesium pyrophosphate that can be detected visually. 
Furthermore, the increase in the turbidity of the reaction mixture correlates with the amount of 
DNA synthesised, allowing real-time monitoring of the LAMP reaction by real-time measurement 
of the turbidity (Palomino, 2009, Boehme et al., 2007, Notomi et al., 2000). 
8.3 Clinical use of nucleic acid amplification tests 
Performance analysis of both “in-house” and commercial NAAT for the diagnosis of TB 
demonstrates a wide range of performance. Overall, performance of commercial NAAT  for both 
smear positive and negative samples 85% (ranging from 36% -100%) and 97% (ranging from 
54% -100%) for sensitivity and specificity, respectively (Ling et al., 2008).  
Most studies report NAAT detection of MTB being 5 to 100 cells, when using dilutions of broth-
grown organisms. However, sensitivity is much lower when used on actual samples due to the 
inhibitory substances in a specimen which interfere with PCR or other amplification methods; 
also it could be that MTB isolated from humans is more rigid and resistant to lysis or difficult to 
concentrate by centrifugation (Cole et al., 2005). Further performance of molecular tests is likely 
to be affected by the low concentration of bacilli present in smear negative sputum (Ling et al., 
2008).  
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
48 
 
Real-time PCR systems developed previously for MTB diagnosis showed good levels of 
sensitivity, 90% - 100% only on AFB smear-positive samples (Dalovisio et al., 1996). The use of 
more specific primers and multi primers led to increase in sensitivity in smear negative samples 
(Broccolo et al., 2003). So far real-time PCR has not been applicable in the field at point-of-care, 
and that would be a significant break-through in diagnostic.  
Current NAAT are typically utilised in conjunction with, not instead of culture. The implication is 
that if the calculated sensitivity of a NAAT is 80% this does not mean that two out of every 10 
specimens containing MTB would be missed, but rather that 8 out of 10 people are actually 
diagnosed the same day (Meltzer, 1998). 
The prevalence of disease in the setting should be included when analysing the performance of 
NAAT. The actual clinical utility of the NAAT depends on how common TB is in the affected 
population (see chapter 3, section 12.2). Low prevalence of disease gives rise to high false 
positive rates and whilst the probability of having disease while having a positive test result rises 
with increasing prevalence. In high burden countries a test with a high negative predictive value, 
would be of particular value, since this could be used to rule out TB in patients presenting with 
related conditions causing symptoms indistinguishable from those associated with TB (Cole et 
al., 2005). 
One potential drawback of NAAT is the possibility of false positive results from culture negative 
patients, who were on TB treatment at the time of testing. Nucleic acid can be detected in 
respiratory specimens that yield no organisms on culture since dead cells might be detected 
and give a false positive result.  
The Food and Drug Administration (FDA) initially approved two commercial tests for use only 
with AFB positive respiratory specimens:  
- Amplified Mycobacterium Tuberculosis Direct Test (MTD) (Gen-Probe®, US) approved 
in 1995 
- Amplicor® Mycobacterium Tuberculosis Test (Amplicor MTB) (Roche® Diagnostic 
Systems, Inc., US), approved in 1996 
AMTD was improved recently and as AMTD2 it is cleared by the FDA for testing both smear 
positive and negative samples, as well as non-respiratory specimens. 
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8.4 When to use nucleic acid amplification testing 
CDC guidelines regarding NAAT for TB diagnosis were first established in 1996, and updated in 
2000 and 2009 (CDC Guidelines, 1996; CDC Guidelines, 2000; CDC Guidelines, 2009). CDC 
recommendations regarding NAAT for TB diagnosis are that NAAT should be performed on at 
least one respiratory specimen from each patient with signs and symptoms of pulmonary TB. 
Also, culture should remain the gold standard for laboratory confirmation of TB and it is still 
required for isolating bacteria for drug-susceptibility testing and genotyping. Nonetheless, NAAT 
should become standard practice for patients suspected to have TB, and all clinicians and 
public health TB programmes should have access to NAAT for TB diagnosis to shorten the time 
needed to detect TB from one to two weeks to one to two days. However, currently available 
NAATs should not be ordered routinely when the clinical suspicion of TB is low, because the 
positive predictive value of the NAAT is <50% for such cases (CDC Guidelines, 2009). 
The CDC states that rapid laboratory confirmation of TB also can help reduce inappropriate use 
of fluoroquinolones as empiric monotherapy for pneumonias. That practise is suspected to lead 
to development of fluoroquinolone-resistant MTB and it delays the initiation of appropriate anti-
TB therapy.  
The costs of adding NAAT to the routine testing of respiratory specimens from patients 
suspected to have TB might be considerable (operating costs exceed $100 per AMTD test); 
however, NAAT has the potential to provide overall cost savings to the treatment centre and TB 
control programme through reduced costs for isolation, reduced costs of contact investigations 
of persons who do not have TB, and increased opportunities to prevent transmission. For 
procedural and economic reasons, NAAT might be impractical in laboratories with a small 
volume of testing. Referral of samples to high-volume laboratories might be preferable to 
improve cost-efficiency, proficiency, and turnaround times. 
Overall, clinicians should interpret all laboratory results on the basis of the clinical situation. A 
single negative NAAT result should not be used as a definitive result to exclude TB, especially 
when the clinical suspicion of TB is moderate to high; rather, to expedite testing for an 
alternative diagnosis, or to prevent unnecessary TB treatment (CDC Guidelines, 2009). 
8.5 “In-house” nucleic acid amplification test 
Investigators design their own protocols for “in-house” assays. They are commonly used in 
developing countries where commercial kits may not be affordable. The accuracy of NAAT for 
TB has been extensively studied since the early 1990s (Flores et al., 2005). A major conclusion 
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in evaluating such assays is great variation in sensitivity and specificity. Sensitivity estimates 
have been lower in smear negative pulmonary TB and extra-pulmonary TB and higher in smear 
positive pulmonary TB. The most common cause of impaired sensitivity, besides low bacillary 
load, is the presence of inhibitors of enzymatic amplification and the lack of specificity is mainly 
due to sample handling and carryover of target DNA from samples containing heavy MTB load 
(Flores et al., 2005). 
Assay characteristics vary among laboratories as do laboratory techniques, but some general 
characterisation of all assays used can be made; all assays include sample preparation, PCR 
and analysis of the product.  
8.5.1 Sample preparation 
Samples used are mainly sputum samples, digested and decontaminated. Samples other than 
sputa used in different studies were: cerebrospinal fluid (CSF), joint fluid, abdominal fluid, 
pleural fluid and urine, and these are usually concentrated prior to DNA extraction (Almeda et 
al., 2000). 
Sample preparation involves: 
- disrupting the thick MTB cell wall 
- removing PCR inhibitors 
- DNA precipitation and extraction 
The sample is usually decontaminated and concentration is performed prior to DNA isolation. 
Typically, the first step in DNA extraction and preparation for PCR involves protease digestion 
(proteinase K), extraction of the solvent and nucleic acid precipitation. This is a time-consuming 
and complicated protocol. Another approach is to use a chaotropic agent (guanidinium 
thiocyanate) for cell lysis and capturing DNA onto silica. This is generally referred to as the 
chemical approach (Almeda et al., 2000).  
Samples may contain inhibitors of PCR. Examples of common PCR inhibitors are heme, 
heparin, IgG, and lipids (Akane et al., 1994, Kubista et al., 2006). Some detergents like sodium 
dodecil sulphate (SDS) and cationic detergent cetyltrimethylammoniumbromide (CTAB) are 
known to form complexes with polysaccharides and proteins, thereby enhancing purity of the 
extract (Rafi et al., 2007). 
Cells can be disrupted mechanically (using sonicator, vortex); or mechanical and chemical 
methods can be combined (Wilson et al., 1993). The easiest way is to use the sample as a 
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heat-killed suspension, concentrated by centrifugation. This crude mixture contains a significant 
proportion of PCR inhibitors as well as debris that also disables amplification. 
Examples of older isolation procedures involve:  
- washing bacteria in a buffer, incubating with lysozyme with vigorous shaking, then 
increasing temperature (up to 650C) to break the MTB membrane and adding 
SDS/proteinase K/CTAB and isolating DNA by extracting with chloroform/isoamyl 
alcohol, precipitating with isopropanol and washing with ethanol 
- lysis by boiling with Triton and glass beads followed by phenol/chloroform extraction and 
ethanol precipitation 
- consecutive cycles of boiling and freezing in Triton (Hermans et al., 1990, Portillo et al., 
1991, Suffys et al., 2000) 
Those protocols illustrate a decade-old approach to DNA isolation: time-consuming, 
cumbersome, and not practical. About 20 samples would keep a laboratory technician occupied 
the whole day, just for the DNA isolation. So far, approaches to DNA isolation have been 
impractical, since each requires BSL 3 or BSL 2 facilities and they are difficult for scaling up and 
automation. 
8.5.2 Amplification 
PCR is performed using a defined set of primers and DNA polymerase. Cycling conditions are 
adjusted according to the enzyme and sequence.  
8.5.3 Choice of sequence 
The majority of tests target DNA, since it is more stable and always present; not dependent on 
environmental or metabolic conditions. On the other hand, mRNA is a marker for organism 
viability and it is present in more copies; but generally molecular diagnosis is less concerned 
with the viability status but rather presence in a patient‟s specimens (e.g. detection of MTB DNA 
in CSF of a patient with suspected meningitis).  
Most “in-house” PCR assays amplify a 250 - 520bp long fragment of IS6110. However, the 
number of IS6110 elements differs between different MTB strains, varying between 1-25 copies 
(Arora et al., 2009). M. tuberculosis strains with low copy numbers of IS6110 have been more 
frequently isolated from Asian patients than from patients of European origin, and some 
previous studies reported strains with no IS6110 segments (Ali et al., 2007). In addition, there is 
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recent evidence that the IS6110 RFLP banding pattern changes during transmission, especially 
in high incidence settings (Hanekom et al., 2008). 
Other amplification targets are: 16S rRNA, 23S rRNA, genes coding 32-kDa and 38-kDa 
proteins, dnaJ, hsp65, IS986, internal transcribed spacer region between 16S rRNA and 23S 
rRNA, region 650-900, rpoB and phospholipase C gene fragments (plcA and mpt40) (Greco, et 
al., 2009; Suffys et al., 2000, Portillo et al.,1991). 
Some genes are predominantly used for nested PCR. The gene coding for Mpb-64, secreted 
immunogenic protein, has been used as a marker for MTB, using a nested PCR with an inner 
segment 200bp long (Rafi et al., 2007). A gene coding for 65-kDa protein was also used as a 
MTB marker for nested PCR with the inner sequence 220bp long.  
Some protocols targeted two genes: IS6110 plus either genes coding 38-kDa protein, or 
MPB624 (Greco et al., 2009). 
8.5.4 Detection 
Agarose gel electrophoresis is a simple technique, but it is not suitable for a large number of 
samples or automation. Still it is the most frequently used detection technique for “in-house” 
assays.  
Hybridization on microplates can be used if oligonucleotide capture probes are synthesised and 
immobilised to the wells on the microtiter plate.  Amplified DNA and labelled DNA is bound to the 
immobilised probes and detected using any colorimetric method. However, it makes no 
significant impact on the accuracy of the test if the hybridization method is used instead of 
agarose gel electrophoresis. Colorimetric detection has been described using DNA-binding 
proteins, biotin and the digoxigenin technique (Wilson et al., 1993).  
Since real-time PCR enables PCR and detection at the same time, there is no need for an 
additional instrument and separated post-PCR area. Turnaround time is shorter and the time 
after sample preparation is basically hands-off time. 
8.5.5 “In-house” nucleic acid amplification tests performance review 
Performance of in-house NAATs is highly variable. In a meta-analysis sensitivity estimates 
ranged from 9.4% to 100% and specificity ranged from 5.6% to 100% (Flores et al., 2005). 
Pooled sensitivity in a different meta-analysis was 96% and pooled specificity was lower and 
variable 81% ranging from 78% to 84%. Only one study had substantially low sensitivity, 20% 
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and this may be due to the amplification region in question being IS6110, appearing in a low 
copy number in MTB isolates from India (Greco et al., 2009). 
The general conclusion is that “in-house” NAATs are a broad group of diagnostic tests with 
significant heterogeneity in performance and diagnostic accuracy. Some variables within the 
different tests seem to increase the accuracy: use of specific amplification targets and the use of 
nested PCR (Flores et al., 2005). 
8.6 Commercial nucleic acid amplification tests 
An industry survey undertaken in the late 1990s identified more than 50 companies engaged in 
TB diagnostic research and development. Also recent technical advances in diagnostics and 
mycobacteriology lead to the development of a number of commercial TB diagnostic tests 
(Perkins et al., 2006). Each NAAT uses a different method to amplify specific nucleic acid 
regions in the Mycobacterium tuberculosis complex. Some of the commercially available tests 
for TB are:  
- Roche Amplicor MTB test 
- Cobas Amplicor  
- GenProbe Amplified M. tuberculosis Direct test (AMTD) 
- Abbott LCx test, discontinued 
- BD-ProbeTec (SDA) 
8.6.1 Amplicor MTB test 
The AMPLICOR M. tuberculosis assay is produced by Roche Molecular System, USA 
8.6.1.1 Description of the test 
Amplicor MTB assay is a PCR-based qualitative test based on detecting the 584-bp segment of 
the 16S rRNA MTB gene. The test consists of three steps: specimen preparation, amplification 
of target sequence by PCR in presence of biotinylated primers; hybridization of the amplified 
products to oligonucleotide probes specific to MTB and detection of probe-bound amplification 
product by colour formation (Piersimoni et al., 2003). 
- DNA isolation 
The procedure starts with 100µl concentrated sputum sample. Aliquot of the sediment sample is 
mixed with wash solution and centrifuged. After this step supernatant is removed and lysis 
reagent is added to the pellet. This, rather simple step, is of most importance for TB detection: 
since the pellet contains DNA, disturbance of the pellet can affect the yield of DNA and 
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performance of the test. The suspension is heated to complete lysis of the mycobacteria. The 
lysed material is then neutralised.  
- Amplification 
For amplification, a neutralised specimen is added to the master mix reagent. The latter is 
prepared by the addition of uracil N-glycosylase enzyme (AmpErase; Roche Molecular 
Systems, Inc.) to an amplification mixture containing excess nucleotides (dATP, dGTP, dCTP 
and dUTP in place of dTTP), biotinylated primers, and thermostable Taq polymerase just prior to 
the amplification process. The primers KY18 and KY75 are used to amplify a 584-bp sequence 
located in a highly conserved region of the 16S rRNA gene of Mycobacterium spp. The PCR 
procedure is carried out by using a thermocycler (Meltzer, 1998). 
Carry-over contamination from previous PCR can be a significant problem, due to the 
abundance of PCR products. Carry-over contamination can be controlled by incorporating dUTP 
in all PCR products (by substituting dUTP for dTTP, or by incorporating uracil during synthesis of 
the oligodeoxyribonucleotide primers) and treating all subsequent, fully preassembled starting 
reactions with uracil DNA glycosylase (UDG), followed by thermal inactivation of UDG. UDG 
cleaves the uracil base from the phosphodiester backbone of uracil-containing DNA, from 
previous amplification but has no effect on natural (thymine-containing) DNA ready to be 
amplified. The resulting apyrimidinic sites block replication by DNA polymerases, and are very 
labile to acid/base hydrolysis. Because UDG does not react with dUTP, and is also inactivated 
by heat denaturation at 55o C, prior to the actual PCR, carry-over contamination of PCR 
amplicons can be controlled effectively if the contaminants contain uracils in place of thymines 
(Longo et al., 1990). 
Each PCR reaction is comprised of three steps: denaturation, annealing, where biotinylated 
primers hybridize to the denaturated target, and extension, where dNTPs are added to the 
biotinylated primers and incorporated into the new DNA strand by Taq polymerase.  
A profile is made up by 37 cycles of PCR resulting in a theoretical billion-fold amplification within 
the 2h (Meltzer, 1998). 
- Detection 
After amplification, double strand products are denaturated by adding denaturation solution, 
followed by room temperature incubation.  
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Denatured nucleotide sequences are added to a microwell plate coated with a DNA probe 
specific for the MTB complex. If the product hybridizes to the probe it is subsequently detected 
by an avidin-horseradish peroxidase conjugate-tetramethylbenzidine substrate system. The 
reaction is stopped by the addition of hydrosulfuric acid, and the absorbance is read at a 
wavelength of 450nm. Specimens giving an absorbance value of 0.350 are considered positive 
(Schrim et al., 1995). Positive and negative amplification controls are included in each run. The 
result is ready after 6.5 h.  
8.6.1.2 Test performance review 
The biggest strength of the Amplicor MTB assay is good accuracy 96% in smear positive cases 
(Table 2). This is why it is an FDA approved NAAT for TB detection in smear positive samples 
only. 
Sensitivities in respiratory specimens (compared with culture and clinical diagnosis) are 
considerably lower in smear negative specimens, 61%. Also there is a correlation between test 
sensitivity and the number of tested specimens for each patient (the performance of NAAT is 
affected by the mycobacterial burden and its distribution in the sample) (Piersimoni et al., 2003). 
The test performs poorly in extrapulmonary specimens especially pleural fluids, gastric 
aspirates, lymph nodes and CSF with sensitivity ranging form 27.3% - 85%. There are no 
significant differences in performance between manual Amplicor MTB and Cobas Amplicor 
(Table 2).  
Manual Amplicor MTB does not have internal control, so the presence of PCR inhibitors cannot 
be detected. Most PCR inhibitors are found in extrapulmonary specimens (Piersimoni et al., 
2003). 
Sample preparation requires a BSL3 laboratory, since the sample has to be decontaminated 
and concentrated and DNA is isolated in the BSL3 cabinet, also designated pre-PCR. Separate 
PCR and post-PCR areas are required. Analysis of 20 samples takes 1.5 days. 
8.6.2 Cobas Amplicor 
The trend in molecular diagnostics is to put all processes on one platform and avoid operator 
involvement as much as possible. Roche and Cobas (Hoffmann-La Roche Ltd, Germany) made 
a system in order to perform PCR and detection of products in a way that minimises the 
operator‟s hands-on time and the risk of cross-contamination during sample manipulation.  
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8.6.2.1 Description of the test 
The COBAS® AMPLICOR Analyzer (automated test Cobas Amplicor will be referred to as 
Amplicor for the reminder of the thesis) is a benchtop system designed to fully automate the 
amplification and detection steps, as it combines five instruments into one: thermal cycler, 
automatic pipettor, incubator, washer and reader. This was the first automated system for 
diagnosing infectious disease using PCR (DiDomenico et al., 1995). 
The Cobas Amplicor Analyzer instrument is used for amplification of the MTB gene target and 
uses the same PCR strategy as the Roche Amplicor MTB manual system. The same 584bp 
sequence within a highly conserved region of the 16S rRNA gene of MTB is targeted. 
Important features introduced in Amplicor detection system are: 
- A species-specific oligonucleotide capture probe is coated with magnetic particles to 
capture an amplicon specific for the MTB complex (not hybridized in a plate with probes 
as in Roche Amplicor MTB) 
- An internal control is used; the primer pair allows simultaneous amplification of the MTB 
target and an internal control (IC) (Piersimoni et al., 2003) 
The internal control is a DNA plasmid with a length and base composition similar to that of MTB 
and a primer binding region sequence identical to the target sequence of MTB. The internal 
control (IC) is present in each reaction mixture (20 copies of IC plasmid per 50uL) and is co-
amplified with the clinical sample and detected separately with an oligonucleotide probe specific 
for the resulting IC amplicon. Only 20 copies of IC are introduced in each test sample to 
generate a positive result at the limit of test sensitivity (Reischl, et al., 1998) 
8.6.2.2 Test performance review 
Test has similar performance as manual test with sensitivity in smear positive samples 96% and 
smear negative 64%. Specificity is 99% in smear positive samples.  
The instrument is reliable and does not need high maintenance. A run takes about 6 hours and 
maximises the operator‟s walk-away time. It can accommodate 20 samples plus two positive 
and two negative controls. After amplification, new sets of samples can be loaded while 
amplified samples are moved on the detection rack. The system is barcode enabled. It can be 
used for tests other than MTB: HIV-1, hepatitis C, hepatitis B, Cytomegalovirus, Chlamydia 
trachomatis, Neisseria gonorrhoea, Mycobacterium avium, and Mycobacterium intercellulare. 
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The instrument has simple software in charge of the process. The system is robust and can only 
be deployed in a laboratory environment. It cannot detect drug resistance. Samples could be 
prepared in advance, except for the positive and negative control, which should be prepared just 
before the run. Some reagents are protein-based and thermo sensitive. The substrate is light 
sensitive and is also prepared just before the run. Proper handling of reagents is of the utmost 
importance.  
8.6.3 Gen-Probe AMPLIFIED M. tuberculosis direct test 
The AMTD assay is produced by Gen-Probe, Inc., USA 
8.6.3.1 Description of the test 
The AMTD test utilises Transcription-Mediated Amplification (TMA) and hybridization to 
qualitatively detect MTB rRNA. Theoretically the assay should have enhanced sensitivity in a 
sample with a small bacterial load, since it detects rRNA which is presented at approximately 
2000 copies per cell. A result is obtained within 2.5 to 3.5 hours. The AMTD test cannot 
ascertain drug susceptibility. The AMTD test consists of two parts: isolation of DNA and an 
amplification-detection step, which takes place in a single tube (Palomino et al., 2007). 
- RNA isolation 
The sputum sample is pre-treated with NaOH/NALC. 450µl of the sample is treated with 
detergent and afterward nucleic acids are released from mycobacterial cells by sonication. Heat 
is used to denature the nucleic acids and disrupt the secondary structure of the rRNA.  
- Amplification 
The Gen-Probe TMA method, using a constant 42°C temperature, then amplifies a specific 
mycobacterial rRNA target by transcription of DNA intermediates, resulting in multiple copies of 
mycobacterial RNA amplicon. MTB sequences are then detected in the RNA amplicon using the 
hybridization method. The MTB hybridization reagent contains a single-stranded DNA probe 
with a chemiluminescent label. This probe is complementary to MTB complex-specific 
sequences.  
- Detection 
When stable RNA:DNA hybrids are formed between the probe and the specific sequences, the 
hybridized probe is selected and measured in a luminometer (El-Sayed Zaki et al., 2008, 
Piersimoni et al., 1998). 
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8.6.3.2 Test performance review 
The first version of the test (AMTD1) as well as the second one (AMTD2) are approved by the 
FDA. The new version incorporates three main changes: 
- an increase in the initial amount of pre-treated specimen from 45 to 450μl 
- a reduction in the incubation time of the amplification reaction (60 to 30 minutes) 
- elimination of the termination reaction (Gamboa et al., 1998) 
AMTD's performance is similar to Amplicor in smear positive samples with sensitivity 97% and 
95% - 97% for AMTD and Amplicor respectively (Table 2), but AMTD is better in smear negative 
samples, with sensitivities of 73% - 83% and 43% - 74% for AMTD and Amplicor respectively 
(Forbes et al., 1997). Sensitivities in smear negative samples from 65% - 92% have been 
reported in per patient analysis (Bergmann et al., 1999). Hence, it has been approved by the 
FDA for use in smear negative samples as well as extrapulmonary samples. The FDA excluded 
patients on TB treatment for more than seven days within the previous 12 months from testing 
on any NAAT, since it may give false-positive results. 
On the other hand AMTD does not have an internal control, and that is one of the test‟s biggest 
drawbacks. So, a negative result could actually be the result of PCR inhibition. If a sample is 
suspected to be inhibited (AFB smear positive), a second reaction should be run, with the same 
sample spiked with the known target nucleic acid and then amplified. This increases the cost of 
the test, and decreased its usefulness.  
8.6.4 Abbott LCx Assay 
The LCx MTB assay, ABBOTT LCx probe system was produced by Abbott Laboratories, Abbott 
Park, USA, but production is discontinued.  
8.6.4.1 Description of the test 
LCx Mycobacterium Tuberculosis Assay (LCx) is based on the ligase chain reaction. The assay 
uses a semi-automated system and allows direct detection in clinical specimens. The amplified 
sequence is specific for all MTB complex strains (Ausina et al., 1997, Garrino, et al., 1999).  
The target sequence is the gene-encoding a 38kDa protein, Antigen b. Four primers in pairs 
recognise and hybridize to the complementary single-strand MTB target sequence. The target 
sequence is annealed and exposed using high temperature. Primers are designed so that once 
they hybridize to a target DNA a gap of few nucleotides remains between them. Polymerase fills 
the gap between them and, once the gap is filled, ligase covalently joins the pair of probes, 
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hence an amplification product is formed which is complementary to the original target gene. In 
that way product is amplified and analysed on the Abbott LCx Analyzer.  
- DNA isolation 
A volume of 500µl concentrated sample, treated for potential inhibitors using SDS/NaOH, is 
placed in an LCx specimen tube. After two washings and concentration steps the sample is 
exposed to heat at 950 for 20 minutes and subsequently to mechanical lysis in the LCx Lysor for 
10 min. 
- Amplification  
After DNA isolation, the sample is added to the master mix, containing thermostable DNA ligase, 
DNA polymerase, dTTP and four oligonucleotide probes labelled with haptens. Amplification is 
completed after 37 cycles on the LCx Thermal Cycler. 
- Detection 
The amplified product is transferred to the LCx Analyzer for detection. Detection is enabled by 
capture and detection hapten on each paired probes, thus the amplification product has capture 
hapten on one end and detection hapten on the other. The reaction mixture is incubated with 
microparticles coated with anti-capture hapten, after which the mixture is exposed to the glass 
fiber matrix to which microparticle complexes bind irreversibly. Following the washing step, 
bound microparticles are incubated with antihapten-alkaline phosphatase conjugate which binds 
to the detection hapten. After adding the substrate, product is detected by fluorescence 
measurement (Ausina et al., 1997). 
8.6.4.2 Test performance review  
Lack of sensitivity is its main shortcoming: 78% and 37% in smear positive and smear negative 
groups respectively (Garrino et al., 1999). It has been modified in the field in terms of increasing 
the concentration of target DNA, numbers of amplification cycles, lowering cut-off values, and 
increasing the number of washing steps to remove inhibitors. Since, even with all those 
improvements sensitivity was still unsatisfying; the test was removed from the market in 2002.  
The price varied between $30 per sample, if test is run at full capacities (20 samples and 4 
controls), and $200 if only one sample is analysed. The test is therefore affordable if performed 
on a batch basis, which counteracts its usefulness, since the main benefit from the test lies in 
obtaining results the same day (Garrino et al., 1999). 
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8.6.5 BDProbeTec ET system 
The BD ProbeTec ET Direct TB System (DTB) is produced by Becton Dickinson Biosciences 
Microbiology Products, USA. 
8.6.5.1 Description of the test 
The BDProbeTec system uses a strand displacement amplification (SDA) technique for rapid 
detection of MTB. The assay uses a thermophilic version of SDA to enzymatically replicate 
target sequence. Recently a new system was developed, called BDProbeTec ET, which couples 
SDA to fluorescent energy transfer (ET) detection (Berrett et al., 2002, Bergmann et al., 2000). 
- DNA isolation 
Specimens are decontaminated using NaOH-NALC and 500µl aliquots are used for further 
analysis. DNA isolation involves one washing step, concentrating, and pellet heat lysis at 1050 
for 30 minutes. The next step is resuspending of the pellet in the lysis buffer, neutralisation and 
sonication for 45 minutes. 
- Amplification 
The amplified region is a 95bp long fragment from IS6110. Nucleic acid amplification is 
isothermal and based on homogenous strand displacement amplification. An internal 
amplification control is run with each sample to confirm validity of amplification and detect 
potential inhibitory factors. 
The prepared sample is transferred into a priming plate and incubated for 20 minutes at room 
temperature and then heated for 10 minutes. After that, samples are transferred to an 
amplification plate containing 96 wells and placed in the amplification/reader instrument.  
- Detection 
Fluorescence detection is simultaneous with amplification.  
8.6.5.2 Test performance review 
BDProbeTec ET system‟s biggest strength is high sensitivity and specificity 98% and 97% 
respectively (Table 2); higher than other currently available commercial tests. It has internal 
control in the same PCR reaction mix, so the presence of inhibitors can be detected. Cross-over 
post-PCR contamination is minimised since amplification and detection happen in the same 
sealed well and there is no need for a post- PCR designated area. All reagents are stable at 
room temperature, which is another advantage.  
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DNA isolation is similar to the Amplicor, and needs additional instruments like: centrifuge, water 
bath, and sonicator. DNA isolation is labour-intensive, and a crucial step is removing the 
supernatant from the pelleted sample.  
8.6.6 Commercial nucleic acid amplification test performance review 
Two methods (Amplicor and BDProbe ET) are fully automated, but they still require 
cumbersome sample preparation and DNA extraction in BSL 3 facilities. This step extends time 
to result, usually for one more day. None of the methods gives any quantitative value regarding 
the microbial load. Only two methods (Amplicor and BDProbe ET) include an internal control, to 
detect inhibitors in the sample. Amplicor has a method for carry-over prevention. Cost per 
sample depends on the number of samples processed at the time, since the price is lower if the 
test is run at full capacities. Price per sample also depends on where the test is performed. Only 
two tests (Amplicor and AMTD) have FDA approval.  
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Commercial nucleic acid amplification tests characteristics 
Characteristic Amplicor MTB Amplicor AMTD LCx BDProbe ET 
 
Automated 
 
No Yes No Semi Yes 
Sequence 16S rRNA 16S rRNA rRNA gene coding 
38kDa protein 
IS6110 
NAAT method 
 
PCR PCR TMA LCR SDA 
Detection 
method 
Hybridization/ 
colorimetric 
Hybridization/ 
colorimetric 
Chemiluminiscen
ce 
Fluorescence Fluorescence 
DNA quantitation 
 
No No No No No 
Number of 
samples per run 
Depends on 
thermocycler‟s 
capacity 
24 Depends on 
luminometer 
capacity  
24 96 
Internal control 
 
No Yes No No Yes 
Positive and 
negative controls 
per run 
2 4 2 4 4 
Carryover 
prevention 
dUTP-UDG dUTP-UDG No No No 
PCR inhibitors 
 
Not detected Detected Not detected Removed Detected 
Time 
 
8h  8h 2.5 – 3.5h 6h 3h  
Hands-off time 
 
2h 6.5h 2h 2.5h 2h 
Sample 
preparation time 
1h 30 min 1h 30 min 30min 2h 1h 
Sample volume 
µl 
100 100 450 500 500 
Cell lysis and 
DNA isolation  
Reagent/heat Reagent/heat Sonication/heat Reagent/heat/ 
mechanical 
Reagent 
Sample 
decontamination 
Yes Yes Yes Yes Yes 
Labour cost 
($20/hour) 
$160 $160 $50 $120 $60 
FDA approval 
 
Yes Yes Yes No No 
Table 1 Technical characteristics of NAAT, TMA (transcription mediated amplification), 
LCR (ligase chain reaction), SDA (strand displacement amplification) (Piersimoni et al., 
2003, Neonakis et al., 2008, Palomino 2005) 
In general, performance of commercial NAATs is similar, however, AMTD appears to perform 
best in smear negative samples, and BDProbe has the highest sensitivity in smear positive 
sample. The diagnostic odds ratio (DOR) is the ratio of the odds of positivity in patients with 
disease to the odds of positivity in disease-free patients; it may be used as a useful summary of 
test performance. A DOR value of less than one indicates that a test more frequently positive on 
control subjects, whilst increasing values above one are associated with improved performance. 
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Table 2 summarizes the performance data of commercial NAATs. AMTD and BDProbe have the 
highest DOR values. 
Commercial nucleic acid amplification tests performance 
Performance Amplicor MTB Amplicor AMTD LCx BDprobe 
 
Sensitivity S+ % 
(range) 
96 (94-97) 96 (95-97) 97 (95-98) 96 (94-98) 98 (96-99) 
Sensitivity S- % 
(range) 
61 (57-65) 64 (59-69) 76 (70-80) 57 (50-64) 71 (66-76) 
Specificity S+ % 
(range) 
97 (96.8-97.4) 99.3 (99.2-99.4)  97 (96.6-97.4) 98 (97.8-98.5) 97 (96.4-97.4) 
Specificity S- % 
(range) 
83 (80-86)  74 (68-80) 96 (93-97) 71 (64-78) 89 (84-93) 
DOR S+ 
 
117 (56-246) 99 (56-173) 314 (99-995) 42 (12-142) 181 (39-834) 
DOR S- 77 (51-115) 220 (144-335) 157 (48-510) 71 (38-132) 96 (53-175) 
Table 2 Performance of NAATs S+ (smear positive sample), S- (smear negative sample), 
DOR (diagnostic odds ratio), (Greco, et al., 2006) 
Performance of Amplicor 
Type of specimen Sensitivity  Specificity Study 
 
Culture positive 91% 100% Kim et al., 2008 
Culture positive smear negative 59% 100% Takakura et al., 2005 
Culture positive smear positive 95% 100% Takakura et al., 2005 
Culture positive 81% 100% Takakura et al., 2005 
Culture positive 73% 100% Ozkutuk et al., 2006 
Culture positive smear negative 50% NA Goessens et al., 2005 
Culture positive smear positive 95% NA Goessens et al., 2005 
Culture positive 78% 98% Goessens et al., 2005 
Culture positive 73% 100% Alfaresi et al., 2006 
Culture positive 92% 100% Abu-Amero et al., 2004 
Table 3 Performance of Amplicor for diagnosis of TB in adult patients 
Amplicor is widely used automated NAAT for detection of MTB. It has been used since 1997 for 
diagnosis of TB in smear negative and smear positive sputum samples. It was chosen as a 
comparison test in this study, since it has high sensitivity and specificity in pulmonary samples 
and it is very well described and evaluated automated MTB detection system (Table 3). 
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9 Phenotypic Drug Susceptibility Testing 
A recent WHO recommendation is to perform DST for INH and RIF on initial isolates from all 
patients in order to identify drug resistance. Furthermore, DST should be repeated if the patient 
continues to produce culture positive sputum after three months of treatment or develops 
positive cultures after a period of negative cultures (WHO, Use of Liquid TB Culture and Drug 
Susceptibility Testing, 2007). 
Phenotypic determination of MDR TB using first-line drugs in inoculated culture is the 
benchmark for DST, but it can only be applied in a well equipped laboratory and may take many 
weeks for the final result. The WHO and Stop TB Partnership have called for the development of 
a more rapid and feasible DST method that could be deployed in low resource settings. It 
appears that the molecular approach is the way forward and the candidate test is based on the 
ability to detect mutated MTB genes that are responsible for drug resistance, particularly to INH 
and RIF. 
9.1 Traditional phenotypic methods 
The traditionally accepted methods include: 
- proportion method 
- absolute concentration method 
- resistance ratio method 
The most commonly used is the proportion method on LJ medium or Middlebrook agar and it 
compares the number of colonies on two plates with and without the drug and requires a 
minimum of three to four weeks to produce results (Palomino et al, 2008). The absolute 
concentration method involves inoculating a commercially available plate with serial 
concentrations of the drug, allowing determination of the minimal inhibitory concentration (MIC). 
The resistance ratio method compares the MIC of the isolate to the MIC of a strain with a drug 
susceptible phenotype. 
These provide valuable information for deciding on treatment, but the result is usually available 
only after six to eight weeks after diagnosis (Palomino et al, 2008). 
9.2 Newer phenotypic methods 
9.2 1 Liquid culture 
The radiometric Bactec 460 system greatly decreased the turnaround time for DST. The test can 
be performed in the same tube as culture, just by adding one antibiotic. Still a major 
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inconvenience is the use of radioactive materials especially for low-resource countries 
(Palomino et al., 2008). 
Bactec MGIT (MGIT) has been successfully used for DST. It has been evaluated for use for a 
range of antibiotics namely: RIF, INH, EMB, SM, PZA, amikacin, capreomycin and ethionamid; 
and it shows high accuracy, especially for RIF and INH. Antibiotic is added to one MGIT tube 
which is then inoculated with the culture. A second tube is inoculated with the same culture but 
without antibiotic. Comparing growth in tube with antibiotic and control tube allows determination 
of susceptibility or resistance. MGIT has also been evaluated for direct DST from patient 
samples (rather than from cultures). This considerably shortens the time to result to about six 
days whilst maintaining a high degree of result accuracy. It may, however, be associated with 
increased cost, since if it were routinely performed on all samples for TB testing, a high 
proportion would typically be culture-negative (El-Sayed Zaki et al., 2007).  
Bactec MGIT has a manual version as well as an automated format, and each has its 
advantages: manual for laboratory in a low-resource and low sample turnover and automated 
for laboratories testing larger number of samples. In the manual system, a drug-containing tube 
and a control tube are inoculated with the prepared sample and incubated. From the third day 
both tubes are analysed for fluorescence. The presence of an orange fluorescence until the 14th 
day of incubation, in the antibiotic containing tube at the same time as in the control tube, is 
interpreted as resistance to the drug; otherwise, the strain is considered to be susceptible 
(Palomino et al., 2007). 
Bactec MGIT has 95% - 98% and 99% - 100% sensitivity for detection of resistance of INH and 
RIF respectively when compared to radiometric Bactec 460, as stated in a meta-analysis of 
MGIT comparative studies (Piersimoni et al., 2006) However, liquid systems are prone to 
contamination and therefore require stringent quality assurance. In addition, they are more 
expensive and in the case of the automatic system, require investment in equipment (Pai et al., 
2009).  
Two other commercial and automated methods for DST are the MB/BacT system (Organon 
Technika) and the ESP culture system II (Accumed International, Chicago, IL, USA). Both 
systems rely on expensive equipment and have also been evaluated in several studies. 
9.2.2 Solid culture 
Several solid culture systems for DST are available. The commercial E-test system (AB 
BIODISK, Sweden), based on strips with impregnated gradients of antibiotics for the 
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determination of drug susceptibility, allows the reading of MIC minimal inhibitory concentrations 
directly on agar plates. Sensitivity in comparison with the traditional proportion method is 90% 
(Palomino et al., 2005). 
The thin layered agar method (see chapter 1, section 6.3.2.1) used for detection of MTB, can be 
used for DST. It has a similar time to result as MGIT, 11 days and sensitivity and specificity of 
100% for both RIF and INH compared with the proportion method in agar. It has contamination 
rate of 4.4% (Robledo et al., 2008).  
9.2.3 The microscopic observation drug susceptibility assay  
Recently, new rapid culture-based tests have been described. These include the microscopic 
observation drug susceptibility (MODS) assay, where direct specimen is cultured with and 
without antibiotic in a 24-well plate with liquid selective media where MTB growth can be visually 
observed for characteristic cord formation using an inverted microscope (Reddy et al., 2010, 
Migliori et at., 2008). The test is rapid (mean time to result 7 days) and may be less costly than 
MGIT testing. Sensitivity is 97% and 100% for detection of resistance to INH and RIF 
respectively and 97% for detection of MDR TB. The MODS is significantly cheaper then 
automated culture system, per tube, but labour cost might be higher (Moore et al., 2006).   
But unfortunately, logistics relating to this method are complicated since a skilled technician is 
required, plates must be checked daily until a point of observed growth, methods are labour 
intensive, and biosafety protocols are the same as in the reference laboratory, since live MTB is 
dealt with. In addition, MODS assay requires an inverted microscope for observation of MTB 
growth. Considering the price of the microscope, and the fact that BSL 3 facilities are required, 
this may make MODS difficult to implement in rural environments or developing regions where 
these tests were actually intended to be applied. 
9.2.4 Colorimetric methods 
Several colorimetric methods have been developed for the MTB DST.  They are based on 
reduction of colour indicator added to the culture in a microplate to analyse growth after MTB 
has been exposed to antibiotics (Palomino et al., 2007). Resistance is detected by a change in 
colour of the indicator, which is directly proportional to the number of viable MTB in the medium 
(Palomino et al., 2008). 
Time to result is between 7-14 days. In addition this method does not need sophisticated 
equipment and is therefore less expensive to perform than some other liquid culture techniques 
for DST. But since the microplate needs to be opened, the test requires BSL 3 capacities. It has 
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sensitivity and specificity for detecting RIF resistance ranging from 89% - 100% and 90% - 
100% respectively. Sensitivity and specificity for INH resistance was from 90% - 100% and 88% 
- 100% respectively (Martin et al., 2007). 
9.2.5 Phage-based methods 
Phages are highly specific and can infect a single species. Phage-based tests use the ability of 
an MTB phage to grow inside MTB.  If a reporter gene, like the firefly luciferase gene, is 
incorporated into the genome of the MTB-specific phage, MTB can be detected by gene product 
activity, in this case emitted light (Palomino et al., 2007). 
 A commercially available phage assay, FASTPlaque-TB-MDRi® (Biotec Laboratories Ltd, UK) 
has been developed for RIF DST. This is a phage amplification-based test, and it is intended for 
direct use on sputum specimens. Drug resistance is diagnosed when MTB is detected in 
samples that contain antibiotic. A sensitivity of 97% - 100% and specificity of 84% - 100% was 
reported for detection of RIF resistance (Palomino et al., 2008). 
9.2.6 Nitrate reductase assay 
The nitrate reductase assay (NRA) is based on MTB‟s reductive capacity, and if MTB growth 
occurs, MTB reduces nitrate to nitrite, which is detected by adding a chemical reagent to the 
culture medium. LJ medium is used for the test. The advantage of this method is that a result is 
obtained more rapidly (before growth can be readily observed). The result is measured after 10 
days. An evaluation of this method for three first line drugs: INH, RIF and EMB demonstrated 
accuracy ranging from 96% - 98% (Palomino et al., 2007). 
NRA is less expensive than liquid culture techniques for DST. NRA does not need sophisticated 
equipment, and it can be performed in BSL 2 laboratories in low resource settings (WHO, New 
laboratory diagnostic tools, 2008). 
10 Molecular assays for detection of multidrug resistant tuberculosis 
Conventional methods for DST are slow and expensive. In routine analysis in developing 
regions, definite diagnosis regarding DST using traditional culture based methods can be 
established only after two months (Van Deun et al., 2009). Also, conventional methods are not 
applicable at point-of-care. Therefore, research is heading toward fast and simple options, like 
molecular assays.  
Molecular methods for detecting MDR TB are based on NAAT in conjunction with 
electrophoresis, sequencing or hybridization. The main advantage of molecular testing is time, 
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since there is no need to grow the organism and subculture for DST. So far, several methods 
have been deployed for MDR TB testing: direct sequencing has proved expensive and time 
consuming (Garcia de Viedma, et al., 2003), real-time PCR has proven highly sensitive and 
specific although, it is complicated for routine use, expensive and less applicable in low 
resource settings (Palomino et al., 2009), and hybridization-based line probe assays (LPA) 
were, until recently, the only cost-effective tool for MDR TB testing, with good 
sensitivity/specificity performance (Rossau et al., 1997, Palomino 2005). 
10.1 Line probe assays 
10.1.1 INNO-LiPARif.TB 
INNO-LiPA is an MDR TB detection kit produced by Innogenetics, Belgium. It is based on a 
reverse hybridization assay, referred to as a line probe assay.  
In this assay concentrated specimen is used. The target sequence is within the rpoB gene. 
Nested PCR is used to amplify the sequence and during amplification, product is biotinylated. 
Post-PCR analysis involves hybridization between the product and a set of 10 probes 
immobilised as parallel lines on a strip. According to the hybridization pattern, visible after 
colorimetric reaction, the presence and absence of the mutations can be assessed.  
Each strip contains conjugate control and an MTB control probe, to determine if hybridization 
was effective and if the genome originates from MTB, respectively. The MTB control is also part 
of the rpoB, and it is present in all MTB complex strains. There are five overlapping probes for 
wild-type rpoB and four probes for the most frequently observed mutations. If a mutation is in 
fact present in one of the target regions, a mismatch created will prevent the amplicon from 
hybridization to the probe under stringent conditions. There are also four probes on a strip that 
hybridize with the amplicons carrying specific mutations.   
Interpretation of results is based on a specific scheme of probe appearance. If all probes for wt 
are present, the sample is considered RIF sensitive. If one is missing, even without the mutated 
probe visualisation, the sample is considered RIF resistant (Rossau et al., 1997). 
10.1.2 Hain MTBDRplus 
Hain MTBDRplus (assay will be referred to as Hain for the reminder of thesis) is manufactured 
by Hain Lifescience GmbH, Germany. The assay is the most widely used molecular assay for 
DST. It detects most common mutations related to RIF and INH (low and high level) resistance. 
It is also based on the reverse hybridization assay.   
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The technique may be applied either directly to the concentrated sample or on cultured isolates 
and performance is still excellent for RIF (Pai et al., 2009). A simple procedure is used for DNA 
extraction involving sonication and heating. The sample is amplified using any commercially 
available DNA polymerase kit, with primers and amplification control provided by the 
manufacturer. PCR is performed in the thermocycler according to a protocol for the specific DNA 
polymerase used and the Hain, combined.  
Hybridization is either automated or manual, using strips with immobilised probes. Visualization 
is obtained after a final colorimetric reaction.  
Each strip has amplification and hybridization control. There is also an MTB control, which 
detects all MTB complex strains. There are three locus controls for rpoB, katG and inhA loci. 
There are eight overlapping rpoB wild type probes, followed by four mutation probes, with most 
common mutations within the selected gene.  There is one katG wt probe and two mutation 
probes; and also two inhA wt probes and four mutation probes for the corresponding wt 
segment.  
The result gives evidence of a mutation in any one of three genes, hence RIF and INH 
resistance can be established (Lacoma et al., 2008, Barnard et al., 2008). 
10.1.3 Line probe assays detecting of multidrug resistant tuberculosis performance 
review 
Molecular assays for rapid detection of RIF resistance could significantly reduce the need for 
conventional laboratory infrastructure, though still costly and inadequate for most high-burden 
countries and developing countries. Rapid MDR TB screening tests would impact morbidity, 
mortality and transmission of MDR strains if assays are introduced in screening (WHO, 
Molecular line probe assay, 2008). 
So far two commercial molecular assays, Hain and INNO-LiPA, have been widely used and 
characterised. Performance in detecting RIF resistance had a pooled sensitivity of 97% and 
specificity of 99% for INNO-LiPA and sensitivity of 98% and specificity of 99% for Hain. Pooled 
sensitivity for INH resistance detection was 85% and the pooled specificity 99% (WHO, 
Molecular line probe assay, 2008).  
Both tests have been used widely in resource rich setting since 1999. In the resource limited 
setting both assays have been under evaluation until recently and they have become part of the 
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national TB programme in some countries, like South Africa, since 2006 (WHO, Molecular line 
probe assay, 2008). 
The result of the test is easy to interpret and it is informative for epidemiological study as well, 
since it gives a broad overview of the local mutations involved in drug resistance. Another 
important feature of line probe assays that they are useful for identification of MTB.  
Limitations of the test related to laboratory capabilities. Line probe assays are not suitable for 
point-of-care diagnostic evaluation. They require highly trained staff, BSL3 facilities and 
designated PCR processing areas. The commercial line probe assay is intended for cultured 
isolates and smear positive samples. It is not sufficiently evaluated for smear negative and 
extrapulmonary samples. 
In case of mixed infection, the analysed sample might hinder the actual result, since the test will 
detect a wild type pattern, and a mutated pattern, and it depends on the intensity of wt and a 
mutated probe. It is then up to the operator‟s subjective opinion to decide if the sample has a 
drug resistant strain or not.  
Also, resistance can exist even if a wild type pattern is observed. Some of the possible 
scenarios leading to this result are: 
- sample containing more than one MTB strains can be composed in a way that one of the 
strains contains wt and the mutation is not covered by the mutation probes   
- if amplification was not efficient, because the starting concentration of bacilli was low, 
especially in paediatric patients or extrapulmonary TB, or in case DNA extraction was 
not effective, or PCR inhibitors were present, hybridization might show pale bands, and 
confirmation or resistance is not reliable 
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Commercial line probe assays characteristics 
Characteristic Hain  INNO-Lipa 
 
Drug resistance Rifampicin/Isoniazid (high and low) Rifampicin 
Automated Manual and automated Manual and automated 
No. of samples per run 12 (manual) 48 (automated) 48 (automated) 
Region amplified rpoB, inhA, katG rpoB 
Isolation method Sonication/heat Detergent/heat 
NAAT method PCR Nested PCR 
Detection method Hybridization/strip blot/colorimetric Hybridization/strip blot/colorimetric 
Amplification control Yes No 
Conjugate control Yes Yes 
MTB specific probe Yes Yes 
Carryover prevention No No 
Time 7 h + sample preparation 12 h + sample preparation 
Sample volume 500 500 
Price per test $ $57-120 $45-116 
Table 4 Technical characteristics of Hain and Inno LIPA (Lacoma et al., 2008, Barnard et 
al., 2008) 
LPAs are recommended only for smear positive samples, but not approved for smear negative 
samples. In a South African evaluation, when a small number of smear negative samples were 
analysed on Hain, 80% gave interpretable results for RIF resistance and 74% gave interpretable 
results for INH resistance. Furthermore, 100% sensitivity for resistance detection was observed 
in interpretable samples for both RIF and INH resistance. In the same study performance of 
Hain in detecting resistance in smear-positive samples was excellent, with sensitivity and 
specificity for RIF both 99%, for INH 94% and 100% respectively and MDR 99% and 100% 
respectively.  
Commercial line probe assays characteristics 
Performance in smear positive samples Hain  INNO-LiPA 
 
RIF sensitivity% (range) 98.1 (95.9-99.1) 97 (95-98) 
RIF specificity% (range) 98.7 (97.3-99.4) 99 (98-100) 
INH sensitivity% (range)  84.3 (77-90)  
INH specificity% (range) 99.5 (98-100)  
Table 5 Performance of Hain and INNO LiPA (WHO, Molecular line probe assay, 2008) 
As part of its global laboratory initiative the WHO Strategic and Technical Advisory Group for 
Tuberculosis (STAG) in 2008 recommended the use of LPA for direct detection of resistance to 
RIF and INH in settings where the test can be reliably performed.  
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Performance of Hain 
Specimen RIF sens RIF spec INH sens INH spec Study 
 
Direct smear positive 99% 99% 94% 100% Barnard et al., 2008 
Culture isolate 98% 98% 90% 100% Hillemann et al., 2007 
Clinical strains 92% NA 73% NA Lacoma et al., 2008 
Culture isolate 95% 100% 82% 100% Huang et al., 2009 
Table 6 Performance of Hain in RIF and INH resistance detection, RIF sens (RIF 
sensitivity), RIF spec (RIF specificity), INH sens (INH sensitivity), INH spec (INH 
specificity) 
Hain assay is the used in most reference laboratories as DST on direct samples and culture 
isolates. It was chosen as a comparison test in order to evaluate performance of GeneXpert 
MTB/RIF in detecting RIF resistance, since it detects the same gene and mutations leading to 
resistance to RIF.  
11 Commercial assays for culture speciation 
Until recently, species identification was based on phenotypic characteristics, such as growth 
rate, pigmentation, and colonial morphology. Even though this method is straightforward it is 
very often incorrect and cumbersome. Hence, line probe assays are made into commercial 
assays used to detect species, like GenoType Mycobacterium AS and GenoType 
Mycobacterium CM (Hain Lifescience GmbH, Germany) and INNO-LiPA MYCOBACTERIA. In 
2008 a very simple new test was introduced for confirming MTB grown in culture, named the 
Capilia TB test, developed by FIND and Tauns Co. Japan. 
The test is based on lateral flow technology and allows confirmation of MTBC in 15 minutes. By 
detecting MPB64, with a specific monoclonal antibody using an immunochromatographic assay, 
MTB is readily detected in the culture. 
The assay is based on a double antibody sandwich technique in which an antibody labelled by 
colloidal gold reacts with target antigens to form an antigen-antibody complex. This complex 
migrates across a chromatographic carrier such as filter paper. The complex is captured by a 
second antibody fixed in the middle of a chromatographic carrier. If the target antigens are 
present in the specimen, a colour reaction is caused by the labelled colloidal particles at the site 
where the second antibody is fixed and the specimen is regarded as positive.  
The test procedure is very simple and since TB antigen MPB64 is extracellular protein, there is 
no need for specific sample preparation, if the test is performed from a specimen obtained from 
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liquid culture. Sensitivity and specificity are 99.2% and 100% respectively (Wang et al., 2007, 
Hillemann et al., 2005). 
12 Introducing new diagnostic tests 
Many aspects of TB management need improvement: vaccine, treatment regimens, and 
diagnostic tools for tuberculosis. If those aspects of TB control are improved they may lead to 
reduction of global incidence of TB by 71%. But if there is no improvement in TB control 101.7 
million new TB cases and 17.9 million TB-related deaths are expected between 2015 and 2050 
(Abu-Raddad et al., 2009).By introducing a fast, sensitive, diagnostic test at point-of-care would 
directly impact duration of infectiousness and indirectly reduce incidence in TB. It has been 
calculated that a new NAAT would therefore prevent 24.4 million active TB cases and 4.2 million 
deaths between 2015 and 2050 (Abu-Raddad et al., 2009). 
In order to meet expectations the new diagnostic should assist in many areas of TB care and 
control such as: 
- screening tests for use in health clinics to distinguish active tuberculosis from all other 
conditions that may cause the same symptoms 
- monitoring treatment response, to determine whether there is bacterial resistance to 
specific drugs 
- detection of latent infection in people at greatest risk for progression to active TB 
following exposure 
In terms of global market for TB diagnostics requirements, the new development should 
produce a tool that responds to all the current shortcomings and have an affordable price. At the 
moment the world spends an estimated $1 billion per year on diagnostics for TB (FIND 
Diagnostics for tuberculosis, 2006) 
The performance of a new desired diagnostic test should be compared to available tests.    New 
test should be able to detect TB with at least the same sensitivity as culture and it should be as 
simple as direct smear microscopy and applied at point-of-care. 
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Figure 4 New desired diagnostic test and current diagnostics (Adapted from FIND 
Diagnostics for tuberculosis, 2006) 
A number of commercial diagnostic tests are in the evaluation phase or have been introduced.  
Tests under evaluation include: 
- Breathalyzer screening tests (Rapid Biosensor Systems Ltd and others); could be used 
for screening at point-of-care where patient would cough into a disposable device, which 
is then analyzed for volatile organic compounds specific for MTB  
- TB Patch Test; is an improvement of TST since patch delivers MPT64 an MTB-specific 
antigen, causing irritation in active TB patients after three to four days after application. It 
does not cross-react with BCG vaccination or NTM, and it can be used at health post 
- Vital fluorescent staining of sputum smears; fluorescent dye is used to analyze smears 
and visualizes only living bacteria. It would be potentially be useful to assess response 
to therapy (WHO, New laboratory diagnostic tools, 2008) 
- Loop-mediated isothermal amplification (LAMP) assay (Eiken Chemical Co.); based on 
molecular amplification, but does not require PCR or BSL 3 laboratory, cost effective and 
simple. Isolation does not require centrifugation and amplification but only a simple 
heating block. It is intended for use in low resource laboratory settings (Boehme et al., 
2007) 
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Tests already in use include a test for lipoarabinomannan (LAM) detection in urine. LAM was 
found in urine of TB patients, and this allows a different approach to specimen handling, since 
urine is not infectious. ELISA and dipstick methods have been developed. The test shows poor 
sensitivity in HIV-negative patients and variable (but but generally poor) sensitivity in HIV-
positive patients. Patients with advanced Immunosuppression are more likely to have a positive 
test (Lawn et al, 2009). The test was previously marketed by Chemogen and currently by 
Inverness Medical Innovations, Inc (Mandelson et al., 2007, Boehme et al., 2005) 
13 GeneXpert MTB/RIF 
Cepheid and FIND have developed a fully automated molecular test for TB and MDR TB case 
detection for TB endemic countries. The performance of the test is evaluated in this thesis. 
The GeneXpert platform (referred to as Xpert in the reminder of thesis) has integrated direct 
sputum sample preparation, NAAT and detection in a disposable cartridge. The system is 
completely automated and closed.  
Result is obtained after 1 hour and 45 min. The only manual step is the addition of a bactericidal 
buffer to sputum before transferring it to the cartridge. 
NAAT is based on hemi-nested real time PCR to amplify an MTB sequence involved in RIF 
resistance. Each cartridge contains probes specific to the rpoB gene regions where RIF 
mutations occur. Each probe is labelled with molecular beacons. 
The test is intended for use at point-of-care facilities in high burden countries, since it requires 
only an electricity supply. This is the first molecular assay for TB intended for use at this level.  
In comparison to other molecular and traditional assays, advantages of Xpert are: 
- detection of TB and MDR TB at the same time 
- result is obtained in < 2h 
- may be used in point-of-care facilities (microscopy sites) 
- closed system, inactivated MTB used for analysis 
- limited sample pre-treatment 
- no need for BSL 3 facilities 
- no need for separate PCR preparation, amplification and detection areas 
- no need for technicians skilled in TB detection or molecular biology 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
76 
 
13.1 Description of the test 
The test requires an Xpert platform, and a disposable cartridge. Platforms are available with 
one, four or 16 independent modules, with each module accommodating one cartridge at a time. 
Each module performs a test independently of other modules on the instrument; hence, it is not 
necessary batch samples. This allows the technician to run the test immediately after sputum is 
obtained and a result is ready after 1h and 30min, while the patient is still waiting.  
Sample preparation involves adding a sodium hydroxide based reagent or sample reagent. After 
15min of exposure to the reagent, MTB is inactivated and can be transferred to the cartridge. 
The sample reagent liquefies sputum samples so that they could be tested within the cartridge 
and to decontaminate each sample to reduce possible biohazards. The goal was to achieve a 
minimum 6-log kill of MTB present in the sputum to comply with international decontamination 
standards (Helb et al., 2010). This is the end of hands-on time.  
Sputum 
liquefaction and 
inactivation 
Transfer of 2ml to 
the cartridge after 
15 min
End of hands on 
work: sample is 
automatically 
filtered and washed
Concentration of 
bacilli and 
inhibitors 
removal
Ultrasonic lysis of 
filter captured 
organisms to 
release DNA
DNA molecules are 
mixed with dry PCR 
reagents
Semi-nested real 
time PCR and 
detection in the 
reaction tube
Result
Automated molecular detection of TB and MDR/TB at the 
point of care
 
Figure 5 Xpert assay procedure (adapted from Boehme et al., unpublished work) 
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13.2 GeneXpert MTB/RIF Cartridge 
The cartridge is a disposable unit with necessary reagents for real time PCR including 
lyophilized enzymes, and six labelled probes. Real time PCR is performed on the instrument. 
During the test, the following steps are performed on the cartridge: 
- passes the sample through the filter to discard larger particles, afterwards DNA is 
extracted using sonication 
- moves the sample and reagents into different chambers in the cartridge for sample 
preparation  
- hydrates the reagent beads 
- performs probe checks to ensure that the sample preparation is successful  
- moves the sample and reagent mixture into the reaction tube 
- starts the PCR cycles and real-time detection 
The cartridge holds the samples and reagents needed for the test. Each cartridge consists of 
the following components:  
- processing chambers (hold samples, reagents, processed sample, and waste solutions) 
- one chamber is designated as an air chamber to equilibrate pressures within the 
cartridge 
- valve body (rotates and allows fluid to move to different cartridge chambers and to the 
reaction tube) 
- reaction tube (enables rapid thermal cycling and optical excitation and detection of the 
tube contents) 
Cartridge is a closed-system vessel. Inside the cartridge, the specimen is isolated, PCR 
inhibitors are removed, and specimens are ultrasonically lysed. After the sample is processed, it 
is mixed with PCR reagents and moved into the integrated reaction tube. The reaction tube is 
automatically inserted into the I-CORE module when the cartridge is loaded into the instrument. 
13.3 GeneXpert MTB/RIF module 
Each instrument has 1-16 modules (there is 124 module system being developed), including a 
heating and cooling system, connected to a PC. The same system can be used for different 
tests, using different cartridge, heating/cooling cycles and result analysis: vancomycin resistant 
Enterococcus, Clostridium difficile, methicillin resistant Staphylococcus aureus, enteroviral 
meningitis, group B Streptococcus, FII G20210A and FV Leiden, influenza infection and 
identification of new variant H1N1 influenza (Rossney et al., 2008, Seme et al., 2008) 
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Modules can be replaced in case of troubleshooting without affecting the rest of modules and 
instrument. In addition, the system is designed to perform a self-test before each test starts to 
verify that the system is functioning properly. 
Each instrument module contains the following components that enable automated sample 
processing in the cartridge and filling of the tube with the sample-reagent mixture for PCR: 
- valve drive (rotates the cartridge valve body to address the different cartridge chambers) 
- syringe pump drive (dispenses fluids into the different cartridge chambers) 
- ultrasonic horn (lyses the sample)  
- I-CORE module (performs PCR amplification and detection) 
13.4 I-CORE Module 
The I-CORE (Intelligent Cooling/Heating Optical Reaction) module is the hardware component 
within each instrument module that performs PCR amplification and fluorescence detection. 
When the cartridge is inserted into the module a reaction tube fits into a tiny slot inside I-CORE. 
As the reaction inside the cartridge is running, the sample and reagent mixture are pushed from 
the cartridge into the reaction tube. During the amplification process, the I-CORE heater heats 
up and the fan cools down the reaction tube contents, while optical blocks excite the dye 
molecules and detect the fluorescence emitted. There are six optical blocks calibrated for 
reported dyes.  
13.4.1 Heating and Cooling Mechanisms 
Within the I-CORE, the heater consists of two ceramic plates with high thermal conductivity in 
order to assure equal and fast heat transfer.  
Thermistor is attached directly to each plate to monitor its temperature. A high efficiency fan 
cools the reaction tube during thermocycling, while the instrument firmware controls the 
temperature inside the instrument module. The firmware enables a stringent control system to 
ensure rapid heating of the plates. 
13.4.2 Optical System 
Within the I-CORE, the optical system consists of two blocks: 
- six-colour excitor module (contains high intensity light-emitting diodes (LEDs) to excite 
the reporter dye molecules)  
- six-colour detector module (contains silicon photodetectors and filters to detect the six 
spectral bands) 
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The optical blocks are positioned within the I-CORE in a way that they are in very close 
proximity to the reaction tube, thereby enabling excitation and emission of reaction mixture. By 
using probes labelled with different fluorescent reporter dyes, up to six targets can be detected 
simultaneously in a single reaction tube (Table 7). The emission spectra of fluorescent dyes can 
overlap, and a particular dye could produce signal in more than one channel. To compensate for 
the spectral overlap, the system uses appropriate calibration and data analysis algorithms to 
determine the concentrations of each reporter dye. 
Reporter dyes and their excitation wavelengths  
Reporter dye Excitation nm Emission nm 
 
CF1 375-405 420-480 
FAM 450-495 510-535 
Alexa Fluor 532 500-550 565-590 
Texas Red 555-590 606-650 
Alexa Fluor 647 630-650 665-685 
CF6 630-650 >700 
Table 7 Reporter dyes used for Xpert 
13.5 Results 
Results are obtained after 1h and 30 minutes. They do not need to be interpreted by the 
technician, since the system incorporates an algorithm to automatically determine the presence 
of TB as well as RIF resistance. If none of the reporter dyes (named A, B, C, D, E) are detected 
but internal control (named SPC), the test is negative (Figure 6). If all dyes are detected, test is 
MTB positive (Figure 7). If less than five but more than two dyes are detected, test is RIF 
resistant (Figure 8), since probes complementary to wt did not hybridize properly to the rpoB 
amplicon due to the mutation. This was defined by the presence of greater than a 3.5-cycle 
difference in the cycle threshold values between the earliest and latest rpoB probe signals or if 
one to three rpoB probes did not produce any measurable signal (Helb et al, 2010). Figure 8 
shows RIF resistant case where one of the probes (probe E) was not detected. 
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Figure 6  Xpert negative result 
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Figure 7 Xpert MTB positive result, RIF resistance not detected 
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Figure 8 Xpert MTB positive result, RIF resistance detected 
14 Summary 
There is an urgent need for a rapid, sensitive diagnostic test for TB which can be used at or 
close to the point-of-care. Such a new test could potentially reduce TB incidence by 13% - 42%.   
With the improvement of NAAT techniques in TB detection, sensitivity of tests for TB detection 
has been rising. However, none of the commercially available assays is in a format which could 
be implemented close to point-of-care, but are rather intended for use in centralized, well-
equipped laboratories with highly trained staff. Moreover, the performance of existing 
commercial assays for smear-negative TB is suboptimal. 
The Xpert system, which incorporates integrated sample preparation, DNA extraction and 
detection, is a format which could potentially be applied close to point-of-care. This study aims 
to assess the performance of Xpert for diagnosis of TB in a population with a high prevalence of 
HIV infection (and hence smear-negative TB). 
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II Aims 
The aim of the study is to evaluate the performance and operability of GeneXpert MTB/RIF 
when performed under controlled laboratory conditions for the diagnosis of TB in patients with 
suspected TB. 
Further, the study aims to compare the performance of Xpert in detecting TB and RIF resistance 
when compared with MGIT and LJ culture result as the “gold standard” and when compared 
with two commercially available NAATs, Amplicor and Hain. 
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III Materials and methods 
1 Recruitment and study flow  
Study clinicians and recruitment staff screened the patients to identify TB suspects (see chapter 
3, section 1.2). Patients were asked to participate in the study and informed consent was 
obtained. Thereafter, patients‟ medical history was taken and clinical examination was 
performed.  
HIV testing was advised for all patients with unknown HIV status, but left to the discretion of the 
attending clinician. Chest radiography was performed on all study participants and a CXR digital 
image was stored along with the source documents.  
Patients were instructed how to produce the first spot sputum, and asked to return the next day 
with a morning sputum sample. The second spot sputum was provided on the second visit.  
Sample analysis took place at the NHLS TB laboratory at Groote Schuur Hospital, Cape Town 
and TB laboratory at the IIDMM, Cape Town. Smear and culture analysis was performed at 
NHLS laboratory and molecular tests at IIDMM.  
Sample processing was performed according to study protocol only if all three samples arrived 
at the NHLS laboratory. If there was not a full set of samples, or samples were not of sufficient 
volume (less than 1.5mL), samples were processed for smear and culture according to the 
NHLS protocol but excluded from the study.  
Any remaining pellet was stored at -200C for the duration of the study; at least one positive 
Xpert cartridge was stored at +40C; culture isolates from all positive cultures were stored at -
800C and MGIT and LJ tubes with positive cultures were stored at room temperature. This was 
necessary for further analysis of discrepant cases. 
Drug susceptibility testing was carried out for the first positive culture of each specimen. First-
line drug testing (INH and RIF) was done, and then if proven RIF resistant, second-line drug 
testing followed for ethambutol, ethionamide, ofloxacin and amikacin.   
1.1 Recruitment sites 
The trial site in Cape Town was chosen for its high HIV prevalence among an MTB infected 
population: 70% in the Western Cape and 2.6% MDR cases of all TB cases (MSF report 2009, 
Health Systems Trust. HIV). 
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Recruitment took place at three sites: 
- GF Jooste Hospital - Manenberg, Cape Town 
- Khayelitsha (Site B) Community Health Clinic – Khayelitsha, Cape Town 
- Hannan Crusaid Treatment Centre – Gugulethu, Cape Town 
GF Jooste hospital (GFJ) is located in Manenberg, Cape Town, in the Western Cape Province 
(WCP) of South Africa. GFJ provides secondary treatment and represents a referral facility for 
the antiretroviral clinics located within areas of North Khayelitsha, Nyanga, Gugulethu, Mitchell's 
Plain, Heideveld, Crossroads, Manenberg, Strandfontein and Philippi.  
These areas are populated with the most socially and economically disadvantaged communities 
in the WCP (Kevany, 2005). GFJ hospital serves a population of approximately 1.2 million 
people and HIV prevalence in 2004 in this population was 10% (Meintjes, unpublished data). 
Since GFJ is a referral hospital for many primary health facilities, we expected cases with more 
advanced TB to be recruited at this site.  
Khayelitsha Site B community clinic is situated in the largest informal settlement in the WCP. 
The township is home to at least 500,000 people, over half of whom are unemployed. 
Khayelitsha has one of the highest burdens of both HIV infection and TB in the country and 
globally. In 2007, antenatal HIV prevalence was 30% and the case notification rate for TB was 
1,500 per 100,000 people per year. About a fifth of TB patients die while waiting for a diagnosis 
or after treatment begins. One in six patients who start TB treatment drop out during the course 
of treatment. Treatment success in this environment is as little as 30% while the vast majority of 
drug resistant cases have a poor treatment outcome (MSF report, 2009). 
The Hannan Crusaid Treatment Centre is situated at the Gugulethu Community Health Centre 
in the Nyanga district of Cape Town. Gugulethu has predominantly informal housing, with high 
levels of overcrowding and poverty. In 2005, the Gugulethu/Nyanga district HIV prevalence rate 
was 29.1%, making it the second highest prevalence district in the province (Desmond Tutu HIV 
Foundation, 2010).  
1.2 Inclusion criteria 
Patients were recruited into one of two groups: the case detection group and the MDR risk 
group. 
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Case detection group: 
- Clinically suspected to have TB 
- Persistent, productive cough for ≥ 2 weeks 
- Volunteers to provide three sputum specimens of at least 1.5ml over the course of two 
days 
- Age 18 and above 
- No TB treatment for the past 60 days and not started on TB treatment for >48 hours 
MDR risk group: 
- Re-treatment cases 
- Non-converting pulmonary TB cases 
- Contact of MDR case 
- Clinically suspected or confirmed to (still) have TB 
- Volunteers to provide three sputum specimens of at least 1.5ml over the course of two 
days 
- Age 18 and above 
For the case detection group, TB suspects were eligible for recruitment if they had not started 
TB treatment >48 hours prior to recruitment, and had not been on any TB treatment <60 days 
before recruitment. However, for the MDR risk group, pulmonary TB cases were eligible if they 
were suspected to be treatment failures. If that was the case, duration of treatment did not 
matter even if the treatment was ongoing.  
Patients on TB treatment in the MDR risk group with negative culture results were excluded 
from the study regardless of their smear microscopy result. Since both smear microscopy and 
Xpert assay can detect dead cells, and DNA from dead cells, respectively, inclusion would 
negatively impact assessment of Xpert specificity.  
1.3 Sputum sample collection 
Samples were collected in sterile, screw-capped, leak-proof, wide-mouthed containers. Two 
basic types of sputum specimens were collected: 
- Spot specimens 
- Morning specimens 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
87 
 
Spot specimens were collected at the health facility. If the initial volume of the sample was too 
low, the patient was asked to collect sputum within an hour in the same container. Two spot 
specimens were taken over the period of two days.  
Morning specimens were collected early in the morning of the second visit. Morning samples 
are more likely to contain secretions from the lower airways and hence be of better quality than 
the spot samples.  
Sample collecting procedure:  
- Patient was sitting or standing  
- Patient was instructed to rinse the mouth with water before expressing the sputum 
- Patient was instructed to inhale deeply, cough vigorously, and expectorate the sputum 
into container 
- If the patient did not cough spontaneously, he/she was instructed to take several breaths 
and hold the breath momentarily, thereby inducing the cough 
- If a patient could not produce a sample spontaneously, induced sputum was collected 
using a nebuliser containing saline solution 
- Patient was instructed to hold the sterile container close to the mouth and release the 
specimen without spilling or touching the inside of the container or the lid 
- The lid was firmly screwed on the container 
- Expectoration was performed in an isolated outdoor area 
Labelling the container was done before it was used. Information on the container included two 
labels: one containing patient ID, initials, date of collection and if induction was used; and the 
other one containing study number and method of sampling (spot or morning sample).   
At the NHLS TB laboratory, the sample was visibly examined for: 
- Food particles 
- Blood staining 
- Viscosity 
 At the health facility and also before processing at the NHLS laboratory, the sample was held at 
40 - 80C. All samples analyzed for smear and Xpert were not stored for longer period of time 
than overnight, or for no longer than 48h if sample was obtained at the end of working week. 
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Decontaminated and concentrated pellets form sputum were stored at -200C according to 
manufacturer‟s instructions.  
Samples were carried in the safety transport box the same day. Safety measures were taken 
during sample transport to NHLS and IIDMM. 
1.4 TB diagnosis 
Diagnosis of TB was based on a combination of rapid identification of bacilli using direct 
microscopy combined with culture with species identification and antibiotic sensitivity. The 
following tests were performed on each patient at the initial visit (day1 and day2): 
- Smear microscopy; two specimens of concentrated sputum and one direct smear per 
patient 
- LJ culture; two concentrated  specimens per patient 
- MGIT culture; two concentrated  specimens per patient 
- Capilia; speciation of positive cultures 
- Smear microscopy; identification of acid fast bacilli in positive cultures 
- MGIT SIRE (streptomycin, isoniazid, rifampicin and ethambutol) method; DST for first-
line and second-line drugs on all culture positive specimens 
- NAAT Amplicor; one concentrated  sputum per patient 
- NAAT Hain; one concentrated  sputum per patient 
DST was performed for first-line drugs (INH, RIF, and EMB). If the patient was resolved as MDR 
after first-line DST, the sample was further tested for second-line drugs (PZA, amikacin and 
ofloxacin). In case of discrepant RIF DST results, the test was repeated and an additional 
molecular Hain test was performed on culture isolates. Culture isolates were also sequenced.  
The TB treatment decision was made by the clinic staff, not influenced by results of Xpert, 
Amplicor or Hain. Samples sent for Xpert were two decontaminated and concentrated sputum 
samples, as leftover samples after smear and culture was performed. One direct sputum 
sample was sent for Xpert after direct smear was performed. Samples sent for Amplicor and 
Hain were decontaminated and concentrated samples.  
After two months a number of “cases” and “control” patients were followed up. At two months 
follow up randomly selected smear, culture, Amplicor and Xpert negative patients were also 
invited for the follow up as a comparison group, in the remainder of the thesis those patients are 
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referred to as “control” group. Followed up “cases” were Amplicor and/or Xpert positive but 
culture and smear negative cases.  
At follow up smear, culture and Xpert was repeated (see chapter 3, section 1.6). The patient 
was diagnosed as a TB case if TB was culture confirmed by MGIT and/or LJ (“culture confirmed 
cases” or C+) or if TB was diagnosed by panel of TB clinicians (“clinical TB”) blinded to Xpert 
results and independent from the study. The independent panel of clinicians revised cases and 
CXRs after 2 months of therapy and assigned them to a diagnostic category, either “non-TB” or 
“clinical TB”. This clinical review did not include a systematic scoring of CXRs, but rather relied 
on the overall impression of the panel. In case of dissenting opinions, the diagnosis made by 2/3 
committee members was considered the final diagnosis. For the remainder of this report, 
patients who were diagnosed as TB patients according to panel decision are referred to as 
“clinical TB” patients.  
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Figure 9 TB diagnostic algorithm 
1.5 Sample analysis workflow 
Three samples were obtained from each patient. Each one was labelled and randomised but not 
before all three samples arrived in the laboratory. Thereafter, two randomly selected samples 
(labelled S1 and S2), were decontaminated and concentrated prior to further testing whilst the 
third sample was analysed as direct sputum (labelled S3).  
Sample S1 was decontaminated and concentrated, analysed for smear, culture (solid and 
liquid), speciation, Amplicor and Xpert. If the sample was culture positive, DST was carried out. 
Sample S2 was also decontaminated and concentrated, analysed for smear, culture (solid and 
liquid), speciation, Hain and Xpert. If the sample was culture positive, DST was carried out. 
Final diagnosis 
Smear -positive
Culture-positive
C+S+
Smear-negative
Culture-positive
C+S-
Smear-negative
Culture-negative
NAAT positive or 
matched control
FU after 2 months
Expert panel evaluation
Clinical TB Non-TB
NAAT negative
Non-TB
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
91 
 
Sample S3 was analysed by direct smear and direct Xpert (no sample concentration). The two 
decontaminated and concentrated samples are referred to as “concentrated samples” and the 
third sample as “direct sample” for the remainder of this report. 
 
Figure 10 Sample analysis workflow 
1.6 Follow-up procedure 
Follow-up (FU) clinical and laboratory evaluation was performed on all smear and culture 
negative, but Xpert or Amplicor positive patients referred to as “cases”. FU was conducted two 
months after the initial visit. The same number of randomly selected smear, culture, Amplicor 
and Xpert negative patients were also invited for the follow-up as a comparison group, in the 
remainder of the thesis those patients are referred to as “control” group.  
Patients were not followed up for clinical response to treatment. 
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Figure 11 Follow-up workflow 
At the follow-up visit the patient was re-examined and provided a fourth sputum for further 
laboratory analysis, to determine any remaining suspicion of TB. The fourth sample, labelled S4, 
was decontaminated and concentrated; and then analysed for smear, Xpert, MGIT culture and if 
culture positive, for DST. At the follow-up, a second CXR was taken and a general clinical 
examination was performed. 
1.7 Ethical considerations 
Patients participating in the study benefited from the currently best possible diagnostic analysis 
funded by study sponsors.  
Patients were informed about the study by recruiting personnel and all patients signed informed 
consent in their own native language. Informed consent was provided in Xhosa and English. 
Patients were compensated for travel and time. Patients gave consent for HIV testing or 
consent to have their HIV status revealed to the study clinicians from their medical records.   
Since this was an evaluation trial, no medical decisions were made based on the Xpert result.  
The patient provided only three specimens during the baseline study and a fourth one if follow-
up was required. No sample bank was created.  
Only authorised medical personnel had access to patients‟ personal data. Samples were 
labelled with barcodes and the same barcodes were used throughout the workflow and 
connected to the patient‟s source document and medical files.  
Formal ethical approval for the study was obtained from Research Ethics Committee, with 
reference number REC REF: 012/2007. 
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Culture and smar 
negative , Xpert 
and/or Amplicor 
positive "Cases"
Follow-up visit
Decontaminated
sputum
Smear Culture Xpert
Clinical follow-up
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
93 
 
2 HIV testing 
Patients with unknown HIV status were offered to confirm their HIV status using Determine - 
HIV 1/2 test (Inverness Medical Innovations, Inc.). The test detects antibodies to HIV-1 and HIV-
2 in infected individuals. It is based on immune-chromatographic testing of whole blood. The 
result is visually observed after 15 minutes, up to an hour. Positive tests were confirmed by 
ELISA. 
If the patient had been previously tested for HIV and the result was noted in clinical records, this 
information was used as the HIV result in the study.  
3 Sputum decontamination for culture and microscopy 
Sputum was decontaminated and concentrated using the Kubica method (Kubica et al, 1963). 
NaOH/NALC/Citrate solution is added directly to the sample container in a 1:1 v/v ratio, making 
a final concentration of 1.5% NaOH. The sample was vortexed for 30s and shaken at room 
temperature for 20 minutes to enhance mucolytic activity. The sample was transferred to a 
sterile centrifuge tube and phosphate buffer, and pH 6.8 was added with a final volume of 45ml. 
The sample was centrifuged at 3500g at 100C for 15 minutes. Supernatant was discarded 
according to the laboratory safety regulations and the remaining pellet was resuspended with 
phosphate buffer to 2ml. One drop of the concentrated sample was used for smear microscopy. 
MGIT vials (7ml) and LJ-medium slopes were inoculated with 0.5ml and 0.2ml of the sample 
respectively.  
Sample S1 was used for NAAT Amplicor as well as for Xpert assay. The volume of the sample 
required for Amplicor analysis was 100µl. The volume used for Xpert was at least 0.5ml and up 
to 1ml. The rest of the pellet was stored in case repetition was needed.  
Sample S2 was analysed using Hain and Xpert. Both assays require a minimum 0.5ml pellet. 
The rest of the pellet was stored in case repetition was needed.  
Work was done in a biosafety level (BSL) 3 laboratory. A biosafety cabinet class 2 was used for 
the entire procedure. All containers containing specimens were labelled according to the patient 
study ID number and sample number (1, 2 and 3 for baseline and 4 for follow-up samples). 
Necessary measures were taken to avoid cross-contamination of the samples including: 
processing one sample at a time and recapping each sample after adding buffer, using 
disposable Pasteur pipettes and using fresh buffer each time. Buffer is used within 24 hours 
after all components are combined. Buffer also loses its mucolytic activity on standing.  
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4 Semi-quantitative mycobacterial smear 
The presence of mycobacteria in the sample was determined using auramine staining. The 
sample was fixed to the glass plate and air dried. The sample area was covered with auramine 
phenol mixture for 15min. The slide was washed with distilled water and drained, then 
decolourised with 0.5% acid-alcohol for 3 minutes and rinsed with water. Counterstaining was 
performed using 0.5% potassium permanganate for 30s - 60s. Longer exposure to the 
counterstaining agent leads to fluorescence quenching. The slide was rinsed with water and 
then dried.  
The slide was microscopically examined using a fluorescence microscope and an x40 
noncover-glass objective lens. At least 100 fields were read in a sweeping patter, avoiding 
repeated examination of the same area. 
The smear was made directly from sputum (sample 3) as well as from concentrated sputum 
(samples 1 and 2). In case of direct sputum, areas most likely to contain mycobacteria, i.e., 
necrotic areas and areas that are tinged with blood were selected form sample. 
Semi-quantitative smear interpretation 
Number of AFB Result 
 
0/100 fields negative 
1-9/100 fields number of AFB recorded 
10-99/100 fields + 
1-10/1 field ++ 
>10/1 field +++ 
Table 8 Semi-quantitative mycobacterial smear 
5 MGIT culture 
Commercial MGIT tubes (BD Microbiology Systems, Cockeysville, MD, USA) were used for the 
rapid cultivation of MTB. Each tube was enriched with 0.8ml growth supplement, containing 
oleic acid, albumin, dextrose, and catalase, and an antibiotic mixture of polymyxin B, 
amphotericin B, nalidixic acid, trimethoprim, and azlocillin (PANTA) (Huang et al., 2001). PANTA 
was initially dissolved in 15ml MGIT Growth Supplement. To maintain the concentration of CO2 
in the tube, and lower the risk of contamination, each tube was opened at the time for as short a 
time as possible. Tubes were inoculated with 0.5ml of sample, then recapped and inverted 
several times to mix. Tubes and caps were wiped with mycobactericidal disinfectant. Inoculated 
tubes were left for 30 minutes at room temperature before putting them in the MGIT 960 
instrument. Each tube was scanned and placed into the MGIT 960 drawer into the slot identified 
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by the instrument. MGIT tubes were incubated until the instrument flagged them positive or 
negative. All MGIT tubes were incubated for six weeks before they were considered negative for 
MTB. 
Each MGIT tube was visually inspected for mycbacterial growth on removal from the instrument. 
Typically MTB growth appears granular with slight turbidity and the growth settles on the bottom 
of the tube. Species identification for positive tubes was carried out using Tauns Capilia (see, 
chapter 3, section 7). 
6 LJ culture 
LJ egg slants were inoculated with 0.2ml of resuspended processed sputum sample. Slants 
were laid with medium facing up for 30 minutes to allow bacteria to adhere to the surface. LJ 
tubes were incubated at 370C for up to eight weeks and examined for growth weekly. 
Culture was continuously examined until: 
- colonies were large enough to count 
- contamination was apparent 
- no growth was visible after eight weeks 
In case of visible growth, MTB was confirmed by an AFB smear. Cultures completely overgrown 
by bacterial or fungal contamination within three weeks were discarded and the result recorded 
as contaminated. If contamination occurred during three to eight weeks of incubation, or in case 
of mixed LJ culture, MTB colonies were recultured. Species identification for positive tubes was 
carried out using Auramine smear and Tauns Capilia.  
Reports were reported semi-quantitatively. The number of colonies on the slope were counted 
and reported. 
Semi-quantitative LJ culture interpretation 
Number of AFB colonies Result 
 
0 negative 
0-19 number of AFB colonies recorded 
20-100 + 
101-200 ++ 
201-500 +++ 
>500 ++++ 
Table 9 Semi-quantitative LJ culture 
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7 Species identification 
Species identification was carried out on the first positive tube for each specimen, either MGIT 
or LJ using Tauns Capilia (Capilia TB, Tauns, Numazu, Japan) (Hillemann et al., 2005). 
No sample preparation was required for AFB positive MGIT tubes. Species identification from LJ 
slope was carried out from a bacterial colony picked with a 1mm diameter micro loop. The 
colony was dissolved in 0.2ml Tauns extraction buffer in Eppendorf tube and vortexed.  
The LJ colony suspension or AFB positive MGIT media was applied to the sample slot on the 
Capilia TB specimen placing area. The reading area was observed after 5 minutes for presence 
of red or deep purple bands for control and the test bands. For specimens with negative or 
invalid test after 5 min, the test was read again after 1 hour.  
8 Drug susceptibility testing 
DST was performed in MGIT tubes. Drug-containing tubes were prepared for each culture 
positive specimen according to the following scheme: 
Drug susceptibility testing 
Result Procedure 
 
Positive, non-contaminated MGIT and positive LJ DST performed from MGIT 
Positive, non-contaminated MGIT and negative LJ DST performed from MGIT 
Negative or contaminated MGIT and positive LJ DST performed from LJ 
Positive, contaminated MGIT and negative LJ  MGIT decontaminated, if successful DST  
Negative non-contaminated MGIT and negative LJ No DST 
Negative or contaminated MGIT and negative LJ No DST 
Table 10 DST inoculum source and relevant procedure 
Each specimen was tested for first-line drugs: INH and RIF. Drug susceptibility was determined 
by comparing growth in subcultured MGIT tube with and without drug.  
Growth control tubes were prepared by adding 0.8ml of four primary drugs, SM, 
INH, RIF EMB, a combination known as SIRE supplement, to the drug-containing tube and 
growth control tube. Drug-containing tubes were prepared by adding 0.1ml of the appropriate 
reconstituted drug solution into each of the MGIT tubes. Standard drug concentrations used for 
MGIT are as follows: 
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Drugs used for susceptibility testing 
Drug used for analysis Standard Drug Concentration (µg/ml) 
 
STR 1.0 
INH 0.1 
RIF 1.0 
EMB 5.0 
PZA 100.0 
Table 11 Drug concentration used for DST 
8.1 Preparation of inoculum from MGIT Tube 
The day that the MGIT tube was flagged for positive culture was considered Day 0. The tube 
was kept in the incubator for at least one more day or up to five days before DST. If a tube had 
been left in the incubator for more than five days, it was subcultured in a fresh MGIT tube until it 
turned positive again.  
If processed tube was of Day 1 or Day 2, the tube was vortexed and left undisturbed for five to 
ten minutes for large clumps to settle. Undiluted supernatant was used for inoculation of the 
drug-containing tube and 1:100 dilution was made for growth control tube by adding 0.1ml of 
MGIT supernatant to 10ml sterile saline. The growth control tube and drug-containing tube were 
inoculated with 0.5ml of corresponding diluted and concentrated bacterial suspension.  
If the processed tube was of Day 3-5, the tube was mixed well and left to settle and then diluted 
1:4, by adding 1ml of broth to 4ml of sterile saline. This inoculum corresponds to undiluted 
inoculum of Day1-2 and from this step onward it was processed in the same way as previously 
described.  
8.2 Preparation of inoculum from LJ media 
Colonies from LJ media were used if they were no more than 15 days incubated after the first 
appearance of positive growth. A sterile loop was used to scrape as many colonies as possible 
without removing solid medium and avoiding very young colonies because among them growth 
rate for sensitive and resistant colonies might be different. Growth was transferred into a sterile 
tube containing 4ml of sterile saline and 3-4ml of 3mm glass beads. The tube was vortexed for 
2-3 minutes to break large clumps. After that the tube was left to settle for 20 min. Supernatant 
was transferred to another sterile tube and allowed to settle for another 15 min. Supernatant 
was transferred once again to the new tube and at this stage turbidity should have been greater 
than McFarland 0.5 standard. Turbidity was adjusted to McFarland 0.5 standard by adding 
sterile saline. This suspension was diluted 1:5 by adding 1ml of suspension to 4ml of sterile 
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saline. The growth control tube was inoculated with 0.5 ml of 1:100 dilution of suspension, 
making a final 1:500 diluted culture inoculum. Drug-containing tubes were inoculated with 0.5ml 
of original 1:5 diluted suspension.  
8.3 Incubation and interpretation of results 
Tubes were placed into a BACTEC instrument and incubated for 4-21 days, until the growth 
control reached 400 growth units (GU). At this point GU in the drug containing vial was 
evaluated. If the GU in the RIF tube was 100 or more the result was interpreted as resistant. If 
growth in the drug-containing tube was 100 GU or less than in the control tube reaching 400 
GU, containing 100 times more diluted inoculum, the specimen was considered sensitive.  
9 Hain MTBDRplus assay 
Hain test was performed as additional DST. The test is based on the DNA STRIP technology 
and permits molecular genetic identification of the MTB complex and its resistance to RIF and/or 
INH from pulmonary smear positive direct patient material. Identification of rifampicin resistance 
is enabled by the detection of the mutations in the 81bp core region of the rpoB gene. More than 
96% of the RIF‟s resistant strains have a mutation within the 81bp core region of the rpoB gene 
that encodes the β subunit of DNA-dependent RNA polymerase (Bártfai et al., 2001, Garcia et 
al., 2001). 
For testing high level isoniazid resistance katG gene (coding catalase peroxidase) is examined 
and for testing of low level isoniazid resistance the promoter region of inhA gene (coding NADH 
enoyl ACP reductase) is examined.  
Procedure is divided into three steps: 
- DNA isolation  
- multiplex amplification with biotinylated primers  
- reverse hybridization (chemical denaturation of the amplified products, hybridization of 
the single-stranded, biotin labelled amplicons to membrane-bound probes, stringent 
washing, addition of strepavidin/alkaline phosphatase (AP) conjugate and AP mediated 
staining reaction 
The test procedure was performed in a unilateral direction: the master mix was combined in a 
DNA-free area, before any sample manipulation. Sample labelled 2 was used for this test. 
Samples were processed at level 3 BSC and concentrated after which they were added to the 
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master mix in a designated pre PCR area. The actual test was performed in a designated post 
PCR area.  
9.1 DNA isolation 
Isolation was performed in a BSL3 laboratory. The concentrated sample S2 was used for this 
test. The sample volume of 0.5 mL was incubated for 20 minutes at 950C to destroy viable MTB. 
The sample was then incubated for 15 minutes in an ultrasonic bath and centrifugated at 
maximum speed (Eppendorf 5417C, maximum speed 25000g; 16400rpm) for five minutes. 
Supernatant was used for the test.  
9.2 Amplification 
The master mix was made using Hot Star Taq Polymerase and primers (PNM) designed by Hain 
Lifescience. Master mix was prepared in a DNA-free cabinet. Volume was calculated according 
to the number of samples needed plus one.  
Amplification mix 
Reagent Volume µL 
 
Buffer 10x 5 
PNM 35 
Mg 1 
Q 5x 4 
Taq 0.2 
Total Volume 45.2 
Table 12 Master mix preparation protocol 
The PCR mixture was combined with the sample in a BSC and 5µL of processed sample was 
added to each PCR tube. PCR was performed on Applied Biosystems Thermal Cycler 2720 
according to the amplification profile. 
Amplification profile 
Time Temperature 0C Number of cycles 
 
15 min 95 1 
30 sec 95 10 2 min 58 
25 sec 95 
40 40 sec 53 
40 sec 70 
8 min 70 1 
∞ 4 ∞ 
Table 13 Hain amplification profile 
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The first step in amplification enables Hot Star Taq Polymerase heat activation. Since 
polymerase is inactivated until this step, it is possible to add polymerase to the master mix and 
at the last step add DNA. 
Two amplification steps are introduced to ensure denaturisation and hybridisation of GC-rich 
DNA. The first amplification step is intended for correct primer binding and the second for actual 
amplification.  
9.3 Hybridization and detection 
Hybridization was performed with the GT Blot 48 (Hain Lifescience), which is an automated 
hybridization machine (Protocol available from manufacturer on request, http://www.hain-
lifescience.de/en/). After hybridization and washing, strips were removed and allowed to air dry. 
Strips were analysed according to the manufacturer's instructions: 
If conjugate control (CC) was not detected the test was repeated using PCR product. If 
amplification control (AC) was not detected PCR was repeated using the stored remainder of 
the sample. If MTB complex control (TUB) was not detected and AC and CC were detected, the 
sample was considered TB negative. If the strip was indicated as TB positive but either locus 
control zones for rpoB, inhA or katG was absent or wt and mut probe bands were less intense 
than AC sample, it was considered indeterminate for drug susceptibility but MTB positive.  
TB positive, with at least one rpoB wild type band missing and/or a mutated gene present was 
considered RIF resistant. A TB positive result with at least one katG and/or inhA wt band 
missing and/or mut gene probe present was considered INH resistant. 
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Figure 12 Hain strips reading scheme (adapted from Hain MTBDRplus procedure 
manual) 
10 Cobas Amplicor test 
Amplicor is an automated MTB test designed to detect MTB in a concentrated sample. Sample 
decontamination and isolation are manual steps and PCR and product detection is automated 
and performed on an Amplicor instrument. The sample labelled S1 was processed using 
Amplicor.  
10.1 DNA isolation and reagent preparation  
Workflow in the laboratory was performed in a unidirectional manner. Master mix reagents, 
designed by Roche as part of the Amplicor MTB test kit, were combined according to the 
manufacturer‟s instructions. The master mix was loaded on to PCR tubes at the beginning of the 
procedure. The master mix contained internal control in order to eliminate false negative results 
due to PCR inhibition.  
The sample load per run was 20 samples plus two positive and negative controls. A 
concentrated sputum sample was used for the test and the volume was 0.1 mL. Each sample 
was washed, pelleted using centrifugation, lysed using reagent and incubated at 600C in a dry 
heat block for 45 minutes.  
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Master mix (0.05ml) was added to a set of 12 tubes loaded on a ring and subsequently 0.05ml 
sample template was added and loaded on the instrument.  
10.2 PCR and detection  
PCR reagents were loaded on to the instrument before the run. Each reagent has a different 
expiry date after first usage, so a close monitoring of reagent usage was done as part of the 
routine instrument maintenance.  
Results were expressed as an absolute absorbance value at 660nm and detected as positive or 
negative after comparison with the value of internal control. The run was considered valid if a 
correct result was detected for positive (absorbance >2.0) and negative control (absorbance 
<0.25) of the run. In the case of incorrect absorbance for either positive or negative control, the 
run was considered invalid and it was repeated.   
 If the result was negative and the internal control result was negative, the test was considered 
indeterminate and it was repeated if there was more than 0.1mL of concentrated sample left. If 
the result was positive and the internal control was either positive or negative, the sample was 
considered positive.  
11 GeneXpert MTB/RIF 
11.1 Sample preparation procedure for sputum 1 and 2 (concentrated samples) 
Samples S1 and S2 were concentrated samples analysed on Xpert. No more samples than the 
number of available Xpert modules (up to eight) were processed at a time. Sample volume of 
minimum 0.5mL up to 1 mL was used for Xpert analysis, and the rest of the sample was stored 
at -200C. If samples were not processed on Xpert immediately after collection they were stored 
at 40C for maximum of two days.  
Sample preparation for Xpert took place in a BSL 3 laboratory during the evaluation study, even 
though the proposed use of Xpert is intended as a bench-top procedure.  
Sample reagent was added to the sample container to make up a final volume of 2ml, mixed 
vigorously and placed in the cabinet at room temperature for 15 minutes. During the incubation 
the sample was shaken once again. At the end of 15 minutes, the sample was considered non-
infectious and it was transferred to a cartridge using a disposable Pasteur pipette. Cartridges 
were then loaded onto the Xpert instrument and a result was obtained after 1h30min.  
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11.2 Sample preparation procedure for sputum 3 (direct sputum sample) 
Sample S3 was an untreated sputum sample. Sputum volume was estimated in the leak-proof 
sputum collection cup by comparing with a set of sputum container samples with known 
volumes and sample reagent was added directly to the sputum contained in a 1:2 up to 1:4 v:v 
ratio. The sample was shaken vigorously and left for 15 minutes in the BSC. During incubation it 
was shaken once again. After incubation the sample was transferred to a cartridge and loaded 
onto the Xpert instrument.  
11.3 Amplification 
After loading the cartridge on to the instrument, all further steps were automatic and reactions 
were contained within a closed cartridge system. Firstly, the sample was pressed through a filter 
to remove any impurities or clumps. Then an ultrasonic horn was beaked down the cell and 
DNA released. DNA solution was then transferred between compartments within the cartridge 
and mixed with lyophilized constituents of the master mix. Amplification mix was then exposed 
to the heating/cooling plates and amplification was monitored real-time using a six-colour 
detector module. After the first amplification process, the amplification mix was removed from 
the PCR/detection micro tube and mixed with a nested set of primers. Nested PCR was then 
subsequently performed in the micro tube, and detected in real-time. 
11.4 GeneXpert MTB/RIF results interpretation and evaluation 
All Xpert tests, for which the result was “invalid”, “indeterminate”, “error” or “no result” were 
repeated if there was enough sample (with or without sample reagent) volume left. If result 
message was “invalid” or “error” with respect to MTB detection it meant that run was faulty and 
internal control was not detected. Borderline RIF resistance was described as result message 
“indeterminate” or “no result”. Results after repetition were considered final results. Results MTB 
negative or MTB positive, with either RIF resistance detected or RIF resistance not detected, 
were considered as final Xpert results. The result was as described as semi-quantitative since 
the MTB load was characterised as very low, low, medium and high. 
12 Data analysis 
12.1 Per patient and per sample analysis 
Data analysis based on test results was performed on per patient and per sample.  
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Per sample analysis criteria 
Resolution Description 
Smear positive specimen Positive smear (scanty, 1+,2+,3+) 
Exclusion (smear) Smear positive specimen with both negative or 
contaminated cultures 
Culture positive specimen LJ and/or MGIT positive culture confirmed for 
MTB complex  
Exclusion (cross-contamination)  Single positive LJ culture with <20 colonies or 
a single positive MGIT culture with MTB 
growth ≥28 days per patient  
Exclusion (NTM) Specimens with growth of mycobacteria other 
than MTB complex 
Contaminated culture LJ culture overgrown by fungal or bacterial 
contaminant or flagged positive MGIT culture 
without detection of AFB 
Exclusion contamination Both contaminated cultures for the same 
specimen 
RIF resistant specimen Determined according to MGIT phenotypic RIF 
analysis (see, chapter 3, section 8.3) 
RIF susceptible specimen Determined according to MGIT phenotypic RIF 
analysis (see, chapter 3, section 8.3) 
Xpert MTB positive specimen Any “MTB positive” result was considered 
positive. Any result needed repetition (see 
chapter 3, section 11.4) was considered as 
definite Xpert result after repetition 
Xpert MTB RIF resistant specimen Any “Rif resistance detected” result was 
considered RIF resistant 
Exclusion (RIF resistance) “Rif resistance indeterminate” result 
Xpert MTB invalid If Xpert result was “error”, “invalid” or “no 
result”, and this result remained after repetition 
this sample was excluded from analysis. Rate 
of invalid results was calculated separately.  
Amplicor positive specimen Instrument positive result  
Amplicor indeterminate MTB negative sample and negative internal 
control (see chapter 3 section 10.2) 
Hain MTB positive specimen TB positive result with positive AC and positive 
CC and any result for gene mutations 
Hain MTB RIF resistant specimen TB positive, at least one rpoB control missing 
and/or mutated gene present. 
Hain MTB INH resistant specimen TB positive, katG and/or inhA wt probe missing 
and/or mut gene probe present 
Hain MTB TB indeterminate No visible CC and/or AC band intensity 
stronger than TB probe 
Hain MTB RIF/INH indeterminate Locus control zone for rpoB, inhA or katG 
absent; wt and mut probe bands less intense 
than AC, reported separately 
Table 14 Per sample analysis criteria 
 
Un
ive
rsi
ty 
Of
 C
ap
 To
wn
 
105 
 
Per patient analysis criteria 
Resolution Description 
Smear-positive, Culture-positive case ≥1 1+ positive smear or ≥2 scanty positive of 3 
smears and ≥1 MTB positive culture of 4 
Smear-negative, Culture-positive case 3 negative smears or 1 scanty positive smear 
and ≥1 MTB positive culture of 4 
Patient exclusion on the basis of smear result Smear positive, culture negative patients or 
<3 sputum specimens examined 
Patient exclusion on the basis of culture result Patient with ≥3 contaminated cultures or 
2 NTM cultures 
Culture negative case Smear and culture negative case 
Clinical TB positive case Culture negative case, considered TB positive 
after FU by the expert panel review (see 
chapter 3, section 1.4) 
Clinical TB negative case Culture negative case, considered TB negative 
after FU by the expert panel review (see 
chapter 3, section 1.4) 
Follow-up cases and controls Smear negative culture negative case that is 
Xpert or Amplicor positive and the same 
number of Xpert and Amplicor negative 
controls 
Exclusion after FU Culture negative patient on TB treatment in the 
MDR risk group 
Cases and controls (see chapter 3, section 
1.4) lost to follow up or passed away 
RIF resistant case MGIT RIF resistant case 
RIF sensitive case MGIT RIF sensitive case 
Exclusion from RIF per patient susceptibility 
analysis 
Discrepancy between phenotypic RIF results 
for samples S1 and S2 
INH resistant case MGIT INH resistant case 
INH sensitive case MGIT INH sensitive case 
INH indeterminate case Discrepant results between INH results for 
samples S1 and S2, were not excluded, but 
reported separately 
Xpert MTB positive case ≥1 Xpert “TB positive” case. For S3 separate 
per patient analysis was carried out 
Xpert MTB RIF resistant case 3 Xpert “RIF resistance detected” results. Any 
discrepant result between Xpert results and 
Xpert and culture was further analyzed by 
sequencing Xpert amplicon and culture isolate 
Xpert MTB RIF sensitive case ≥1 Xpert “RIF resistance not detected” 
Exclusion from RIF per patient susceptibility 
analysis 
Discrepant Xpert RIF results confirmed after 
sequencing  
Xpert MTB invalid case 3 results “invalid” or “error” or “no result” are  
analyzed and reported separately 
Amplicor  (see chapter 3 section 10) 
Hain (see chapter 3 section 9) 
Table 15 Per patient analysis criteria 
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12.2 Statistical analysis 
Numerical indicators of test performance were used to compare and analyse diagnostic 
accuracy of tests used in the study. The reference test for TB is the culture result. In this study 
diagnostic accuracy was analysed in respect to culture result and culture and clinical 
examination result.  
Diagnostic test indicators 
Test indicator Formula Description 
 
Sensitivity TP/(TP + FN) Proportion positive test 
results among diseased 
Specificity TN/(TN + FP) Proportion negative test 
results among the disease-
free 
Positive predictive value (PPV) TP/(TP + FP) Proportion of diseased 
among subjects with a 
positive test result 
Negative predictive value (NPV) TN/(TN + FN) Proportion of disease-free 
subjects among subjects with 
a negative test result 
Positive likelihood ratio (LR+) sensitivity/(1 - specificity) Ratio of a positive test result 
among diseased to the same 
result among disease-free 
Negative likelihood ratio (LR-) (1 - sensitivity)/specificity Ratio of a negative test result 
among diseased to the same 
result among disease-free 
Diagnostic odds ratio (DOR) (LR+)/(LR-) Ratio of the odds 
of positivity in diseased to 
the odds of positivity in 
the disease-free 
Table 16 Diagnostic test indicators 
Comparison between a diagnostic test and its reference standard is represented as a 2 x 2 
contingency table. 
Contingency table 
 Reference test 
Disease positive Disease negative 
Test Test positive TP FP Test negative FN TN 
Table 17 Contingency table; TP, FP, FN, and TN denote the number of true positives, 
false positives, false negatives, and true negatives, respectively 
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Sensitivity and specificity give an idea of a test‟s potential to recognise subjects with disease or 
to exclude the condition of interest, respectively. Sensitivity and specificity analysis was 
performed using MS Office 2007 Excel with the data analysis pack. 
PPV and NPV define the probability of disease in subjects with a positive test result or not 
having disease with a negative test, respectively. Predictive values are largely dependent on 
disease prevalence in the examined population. Therefore, predictive values from one study 
could not be compared to the predictive value result obtained in a population with a different 
prevalence of the disease. 
LR+ is the indicator for ruling-in diagnosis. The higher the LR+ the more the test is indicative of 
a disease. Good diagnostic tests have LR+ > 10 and their positive result has a significant 
contribution to the diagnosis. LR- is the indicator for ruling-out the diagnosis. Good diagnostic 
tests have LR- < 0.1. The lower the LR- the more significant contribution of the test is in ruling-
out disease. The confidence interval for LR+ and LR- was calculated using QuesGen Systems, 
Data Management for Clinical Research, Confidence interval - Likelihood Ratio.  
DOR is used for comparison of diagnostic accuracies between two or more diagnostic tests. 
The value of a DOR ranges from zero to infinity, with higher values indicating better 
discriminatory test performance. A result for DOR=1 means that the test does not discriminate 
between patients with the disease and those without disease. Values lower than 1 point to 
improper test interpretation (more negative tests among the diseased) (Calculator for 
confidence intervals of odds ratio in an unmatched case control study). 
The accuracy of each test within a specific group of subjects was compared using a confidence 
interval (CI) at 95%. This means that the probability is 0.95 of the result being within the 
confidence interval. The sensitivity, specificity, PPV and NPV confidence interval was calculated 
using a confidence interval for proportion calculation (Dimension Research, INC. Confidence 
interval for proportion calculator). 
For specificity comparison between NAATs, the McNemar test was performed, in order to 
analyse whether there was a significant difference between two tests. The test is used for a 
sample size larger than 30. A null hypothesis is that two tests are equal and a two tailed result 
was used as final at a confidence level of 95% (Dimension Research, INC. McNemar test 
calculator) 
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In order to analyse if there is a correlation between quantitative Xpert and smear result Fisher‟s 
exact two tailed test was used and p-value was calculated using GraphPad Prism. 
Z – test is used to compare the proportions from two independent groups (early morning and 
spot samples) to determine if they are significantly different from one another. 
13 Minimisation of bias 
Patients presenting with typical symptoms of TB were screened for participating in the study. 
Participants meeting study criteria were included in the study.  
In order to minimise measurement bias, samples were randomised. Since each patient provided 
three samples: two spot samples and one morning sample (generally an early morning sample 
is of the best quality) and since two samples underwent concentration before testing, while the 
other sample was tested directly, it was important to prevent bias in sample allocation.  
Xpert results are generated directly by the software following real-time PCR analysis, and are 
not dependent on an operator‟s potentially subjective evaluation.  
Laboratory technicians performing smear and culture analysis were blinded to the Xpert result. 
In addition, the Xpert instrument was in a separate laboratory from the one where the rest of the 
analysis took place.  
The expert clinical evaluation team did not have access to the results of the three NAATs (Xpert, 
Amplicor and Hain). However, smear, culture and DST result was available to the research team 
performing NAATs.   
Source documents were kept separately from Xpert result documents. The case report form did 
not contain Xpert results and hence could not influence patient diagnostic category assignment. 
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IV Results 
1 Patient characteristics 
The recruitment period of the evaluation study lasted from June 2008 until February 2009. 
During that time 454 TB suspects were recruited. Of these, 364 met the study inclusion criteria, 
and provided three sputum samples. There were 90 patients excluded from the study because 
they failed to provide all three sputum samples, or sample volume was under 1.5ml.  
Patient characteristics 
Age median, range 36, 18-80 
Female gender % 113/333 (33.9%) 
Patients with history of previous TB % 135/328 (41.2%) 
HIV+ patients % 156/200 (78.0%) 
Table 18 Patient characteristics 
Patient demographics are shown in table 18. Patients recruited were mostly male in their 
thirties. Out of all recruited patients 41.2% had a history of previous TB and 78% were HIV 
positive. Distribution may be skewed toward HIV positivity, since patients with known HIV status 
were usually HIV positive. HIV results were only available in 60% of cases. The TB/HIV co-
infection rate, determined after all results were completed, was 76%. This is similar to previous 
data from the same centre: the TB/HIV co-infection rate in the Khayelitsha area in 2006 was 
67% (MSF report, 2007). 
Final diagnostic categories after follow up 
Culture positive, smear positive cases % 96/364 (26.4%) 
Culture positive, smear negative cases % 36/364 (9.9%)  
Clinical TB cases, culture negative, clinically diagnosed as TB  % 12/364 (3.3%)  
Culture negative cases, clinically diagnosed as non-TB % 189/364 (51.9%)  
Cases excluded from further analysis based on pre-stated criteria % 31/364 (8.5%) 
Table 19 Final diagnostic categories 
Patients were distributed among four diagnostic categories as per table 19. There were 8.5% 
(31/364) indeterminate cases after preliminary analysis and those were excluded from further 
analysis and results were not reported (Table 20). Therefore 333 patients met study analysis 
criteria. 
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Criteria for patient exclusion from analysis 
Criteria Number of cases 
 
Lost to follow up 18 
Culture negative MDR TB case on TB treatment 3 
Discrepant phenotypic RIF result 2 
Possible culture cross contamination 3 
NTM 1 
Smear positive culture negative cases 4 
Total 31 
Table 20 Numbers of excluded patients based on different criteria 
Out of 18 patients lost to follow up, 11 patients died during the study period. Three patients in 
the MDR group, who had been on TB treatment at the time of recruitment, were culture negative 
after analysis, and those cases were excluded. Two cases had discrepant RIF susceptibility 
results after phenotypic analysis. Drug sensitivity was repeated and the result was the same.  
After initial culture and NAAT results were obtained, patients with positive NAAT (either Xpert or 
Amplicor), but culture negative were invited to return for follow-up and provided a fourth sputum 
sample. The same number of culture- and NAAT-negative controls, selected from the central 
database as random controls, were invited for a follow-up visit. 
Followed up cases 
All followed up patients 27 
Cases 12  
Initial diagnosis changed to TB after panel review 9/12 (75%)  
Non-TB patients  3/12 (25%) 
Controls 15 
Initial diagnosis changed to TB after panel review  3/15 (20%) 
Non-TB patients 12/15 (80%) 
Table 21 Followed-up patients segregated in two groups: cases that were culture 
negative but Xpert and/or Amplicor positive and randomly selected culture and Xpert 
and Amplicor negative controls 
An expert panel was assembled to examine followed-up cases and to determine whether there 
was a difference in CXR at enrolment and at follow-up, as described in chapter 3, section 1.4. In 
the case group, 75% were diagnosed with TB based on a decision of the expert panel. In the 
control group, 20% of initially symptomatic but culture and NAAT negative patients were 
diagnosed with TB after panel discussion. Nine patients in both case and control groups were 
lost to follow-up. For the remainder of this report, patients in both case and control categories, 
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which were diagnosed as TB patients according to the panel decision, are referred to as “clinical 
TB patients”. There were 12 clinical TB patients; nine cases and three controls. 
 
Figure 13 Diagram of all screened patients and their outcomes 
Patients were recruited at three recruitment centres: Khayelitsha Site B, Gugulethu HIV 
treatment centre and GF Jooste hospital. 
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Patient characteristics in different recruitment sites 
Category Recruitment sites 
K G J All 
 
No of patients 280 21 32 333 
TB positive1 % 124/280 
(44.3%) 
3/21  
(14.3%) 
17/32  
(53.1%) 
144/333 
(43.2%) 
C+S+2 % 80/280  
(28.6%) 
0/21  
(0.0%) 
16/32  
(50.0%) 
96/333  
(28.8%) 
C+S-3 % 33/280  
(11.8%) 
3/21  
(14.3%) 
0/32 
(0.0%) 
36/333  
(10.8%) 
Clinical TB patients4 % 11/280  
(3.9%) 
0/21 
(0.0%) 
1/32 
(3.1%) 
12/333 
(3.6%) 
HIV-positive% 124/163 
(76.1%) 
19/19  
(100%) 
13/18  
(72.2%) 
156/200 
(78.0%) 
Previous TBx5 % 108/275 
(39.3%) 
10/21  
(47.6%) 
17/32 
(53.1%) 
135/328 
(41.2%) 
No of MDR6 2 0 2 4 
No of INH mono7 3 0 1 4 
Table 22 Patient characteristics stratified by recruitment sites K (Khayelitsha Site B) G 
Gugulethu HIV treatment centre) and J (GF Jooste hospital), 1(TB positive cases based 
on culture and clinical diagnosis), 2(culture positive smear positive cases), 3(culture 
positive smear negative cases), 4(patients diagnosis based on clinical examination-
clinical TB), 5(previous history of previous TB), 6(number of MDR cases), 7(number of 
INH mono-resistant cases)   
Most of the patients were recruited in Khayelitsha: 84.1% (280/333) and the general study 
population was representative of this study site. The overall percentage of study participants 
with a TB diagnosis was 43.2% whilst 44.3% of study subjects recruited in Khayelitsha were 
diagnosed with TB 
2 Isoniazid and rifampicin resistance 
Patients were stratified into case detection group (61.9% of patients) and MDR risk group 
(38.1% of patients) as per the predefined criteria, based on their presenting history. RIF and INH 
resistance was based purely on phenotypic testing of two sputum samples. An MDR case was 
defined as resistant to RIF and INH.  
Drug resistance 
RIF resistant/culture positive patients %  4/132 (3.0%) 
INH resistant/culture positive patients %  8/132 (6.1%) 
MDR cases/culture positive patients %  3/132 (2.3%) 
Table 23 Drug resistance 
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Out of all culture positive cases there were 2.3% MDR cases (3 cases) and this figure closely 
resembles an MSF MDR-TB survey result of 2.6% MDR cases among TB cases, conducted in 
March 2009 (MSF report, 2009). 
3 Per patient analysis  
Per patient results are summarised in diagrams below. This analysis focuses on agreement 
between culture, smear and NAAT results. The analysis is primarily based on a comparison 
between commercially available assays (Amplicor and Hain) and Xpert with emphasis on 
performance in culture positive - smear negative cases. Each case had one result for each 
Amplicor and Hain assay and three results for Xpert and was analysed according to the pre-
stated criteria (see chapter 3, section 12.1).  
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Figure 14 Culture positive cases 
NAATSmearCulture
Positive 132
Negative 36
Xpert
Positive 31
Negative  5 
Amplicor
Positive 16
Negative 19
Hain
Positive 13
Negative 20
Positive 96
Xpert
Positive 95
Negative 1
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Negative 8
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Figure 15 Culture negative cases 
In the culture-positive group, TB was detected using smear in 96/132 (72.7%) cases. Xpert 
detected TB in 126/132 (95.5%) cases, Amplicor in 105/130 (80.8%) and Hain in 95/123 
(77.2%) cases.  
Per patient sensitivity analysis might favour Xpert in comparison with alternative NAATs, 
because Xpert was performed on three samples (two concentrated, and one direct sample), 
whereas alternative NAATs were performed on one concentrated sample, each. For the same 
reason specificity might be lower for Xpert.  
Some samples did not have Amplicor and/or Hain testing performed, since sample volume was 
insufficient. This included 25 Hain results (six results missing in the culture positive smear 
positive group, three in culture positive smear negative group and 16 in culture negative group) 
and 4 Amplicor results (one result missing in the both culture positive smear negative and in 
smear positive groups and two in the culture negative group) . The sample volumes for Hain 
and Amplicor tests differ and volume was five times larger for Hain (0.5ml concentrated sample 
for Hain and 0.1 ml concentrated sample for Amplicor) so it was more likely to have a sample of 
insufficient volume to perform the Hain test after the sample had been used for Xpert analysis, 
as performing Xpert was a study priority.  
NAATSmearCulture
Negative 201 Negative 201
Xpert
Positive 12
Negative189
Amplicor
Positive 0
Negative 199
Hain
Positive 2
Negative 183
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Figure 16 Culture and CXR suggestive of TB 
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Figure 17 Diagram non-TB patients 
After follow-up and expert panel evaluation of 27 cases and controls, 12 culture negative cases 
were diagnosed as TB patients based on panel assessment or follow-up culture. Those 12 
clinical TB cases patients with 132 culture positive patients together make 144 TB patients 
recruited during the study. Eleven of the cases were reassigned based on panel assessment, 
whilst 1 of the 12 had a positive TB culture result on the 2-month follow-up sample (this patient 
had a positive Xpert result on an initial sample). Eight out of the 12 (67%) of clinical TB cases 
were HIV positive, one was HIV negative and in three cases HIV status was unknown.   
Xpert detected TB in 75% (9/12) of cases in this group. Of those nine patients, all had a positive 
result on direct sputum (S3). None had a positive result when tested on Amplicor and two were 
positive for MTB complex on Hain.  
3.1 Per patient analysis of performance of NAATs and smear 
Performance of diagnostic tests was analysed, firstly using culture as the reference standard 
and then culture and expert panel assessment combined as the reference standard.  
 
 
 
 
NAATSmear Clinical TB diagnosis
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Per patient performance of methods where culture is the reference test 
Performance Smear Xpert Amplicor Hain 
 
Sensitivity% [CI] 72.7 
[65.1-80.3] 
95.5 
[91.9-99.0] 
80.8  
[74.0-87.5] 
77.2  
[69.8-84.6] 
Specificity% [CI] 100.0 
 
94.0 
[90.8-97.3] 
100.0 98.9  
[97.4-100.0] 
LR+ [CI] 293.1 
[18.4-4,679.5] 
16.0 
[9.2-27.2] 
322.1 
[20.2-5,138.9] 
71.4 
[17.9-284.5] 
LR- [CI] 0.28 
[0.21-0.36] 
0.05  
[0.02-0.11] 
0.19 
[0.14-0.28] 
0.23 
[0.17-0.32] 
DOR [CI] 1,065.5 
[64.7-17,544.1] 
330.8 
[121.0-904.1] 
1,650.8 
[99.5-27,387.0 
310.4 
[72.4-1,331.2] 
PPV% [CI] 100.0 
 
91.3 
[86.8-96.0] 
100.0 97.9 
[95.1-100.0] 
NPV% [CI] 84.8 
[80.2-89.4] 
96.9 
[94.5-99.4] 
88.8 
[84.7-93.0] 
86.7 
[82.2-91.3] 
Table 24 Performance of NAAT and smear where culture is a reference test, in case if 
specificity was 100%, i.e. one of the cells in the 2 x 2 contingency table contains zero, 
0.5 was added to all the values in the table to calculate an approximate LR+, LR- and 
DOR (Haldane et al., 1955) 
Sensitivity of Xpert was higher than other NAATs, resulting in a high NPV. Specificity (and hence 
PPV) of Xpert was lower than smear and other NAATs.  
Per patient performance of methods based on culture and clinical diagnosis 
Performance Smear Xpert Amplicor Hain 
 
Sensitivity% [CI] 66.7 
[59.0-74.4] 
93.8 
[89.8-97.7] 
73.9 
[66.7-81.2] 
72.9 
[65.4-80.5] 
Specificity% [CI] 100.0 
 
98.4 
[96.6-100] 
100.0 
 
100.0 
LR+ [CI] 252.9 
[15.8-4,038.2] 
59.1 
[19.2-181.6] 
277.4 
[17.4-4,426.2] 
256.1 
[16.1-4,086.5] 
LR- [CI] 0.34 
[0.27-0.42] 
0.06 
[0.03-0.12] 
0.26 
[0.20-0.35] 
0.27 
[0.21-0.36] 
DOR 754.1 
[46.0-12,362.1] 
930.0 
[247.1-3,500.0] 
1,055 
[64.1-17,357.0] 
937.6 
[56.9-15,445.4] 
PPV% [CI] 100.0 
 
97.8 
[95.4-100.0] 
100.0 100.0 
NPV% [CI] 79.8 
[74.6-84.9] 
95.4 
[92.9-100.0] 
83.5 
[78.6-88.3] 
82.9 
[77.9-88.0] 
Table 25 Performance of NAAT and smear where diagnosis is based on culture result 
and clinical expert panel diagnosis   
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Including culture negative, clinical TB patients, in the analysis reduced the sensitivity of smear, 
Amplicor and Hain, but increased specificity of Xpert (Table 25). Specificity and hence PPV in 
this analysis was 100% for all tests except Xpert.     
It is of particular interest to analyse the performance of NAAT in the culture-positive, smear-
negative group.  
Per patient performance of methods stratified by culture and smear result 
Test Sensitivity all C+ Sensitivity C+ S+ Sensitivity C+ S- 
 
Xpert% [CI] 
 
95.5 
[91.9-99.0] 
99.0 
[96.9-100.0] 
86.1 
[74.8-97.4] 
Amplicor% [CI] 80.8 
[74.0-87.5] 
93.7 
[88.8-98.6] 
45.7 
[29.2-62.2] 
Hain% [CI] 77.2 
[69.8-84.7] 
91.1 
[85.2-97.0] 
39.4 
[22.7-56.1] 
Table 26 Performance of NAAT stratified by C+ (culture positive), C+S+ (culture positive 
and smear positive) and C+S- (culture positive and smear negative) group 
All tests showed satisfactory performance in the culture and smear positive group (Table 26), 
but in the smear negative group, Xpert demonstrated markedly increased sensitivity, but with a 
wide confidence interval since the sample size was relatively small (36 patients were diagnosed 
as culture-positive, smear-negative). It should also be noted that this is comparison with three 
Xpert results per patient as opposed to one result for Amplicor and Hain.  
3.2 Performance of GeneXpert MTB/RIF on the direct sample 
Xpert and direct smear results from sample S3 are shown in table 27. All Xpert-positive, smear-
positive cases were culture-positive. In the Xpert-positive, smear-negative group (62 cases) 
there was only one non-TB case and nine clinical TB cases whilst the rest were culture-positive 
on samples S1 and S2. One Xpert-negative, smear-positive case was culture-positive and in the 
Xpert negative and smear negative group nine cases were culture-positive and three were 
clinical TB cases.  
Table 27 Correlation between Xpert result and smear result for direct sample S3 
Direct smear analysis 
Smear result for 
direct smear S3 
Xpert result for direct smear S3 
MTB positive  MTB negative  Error 
Positive 69  1 1 
Negative 62  197 3 
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Using Fisher‟s exact two tailed test and excluding error as a result, association between smear 
and Xpert for direct sample was highly significant, with p-value < 0.0001. 
Since there was no culture results for the direct sputum S3, Xpert results for direct sputum S3 
were stratified in groups according to combined culture results from S1 and S2 and overall 
smear results from all three smear results.  
Performance of Xpert on direct sputum 
Test Sensitivity 
C+ 
Sensitivity 
C+ S+ 
Sensitivity 
C+ S- 
Specificity 
C- 
Sensitivity  
Clin+ C+ 
Specificity 
Non-TB 
 
Xpert S3% 
[CI] 
92.4 
[87.8-96.9] 
96.8 
[93.3-100] 
80.6 
[67.7-93.5] 
95.0 
[91.9-98] 
90.9 
[86.2-95.6] 
99.5 
[98.4-100] 
Table 28  Performance of Xpert and smear on direct sputum stratified by C+ (culture 
positive), C+S+ (culture positive and smear positive), C+S- (culture positive and smear 
negative) Clin+C+ (clinical TB and culture positive cases combined), Non-TB (clinically 
and culture negative). 
Four Xpert results for direct sputum were not interpretable, since an error result was observed. 
A single Xpert test performed on direct sputum demonstrated high sensitivity and specificity. 
This is the important finding, since Xpert is intended to be used on direct sputum samples.  
4 Per sample analysis 
In the study 666 culture results were obtained for each solid and liquid culture method, since 
two samples were cultured per patient.  
Culture results in the analysis 
Culture results for samples S1 
and S2 
Liquid culture 
Positive Negative Contaminated 
Solid culture 
Positive 205 0 2 
Negative 18 400 4 
Contaminated 19 17 1 
Table 29  Correlation between solid and liquid culture performance in samples S1 and S2 
(sample 1 and sample 2) 
Contamination rate for liquid culture was 1.1% and for solid culture 5.6% for both samples S1 
and S2. Liquid culture was positive in an additional 18 cases, compared with solid culture, whilst 
there was no sample with a positive solid culture and negative liquid culture. A single liquid 
culture detected 91.7% culture-proven cases and a solid culture 78.4%. 
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Next we compared the performance of Xpert on the two concentrated samples S1 and S2 with 
culture and smear results.  
Xpert performance for concentrated samples S1 and S2 
Culture result per samples S1 and 
S2 
Xpert results for samples S1 and S2 combined 
Negative Positive 
C+S+ 0 173 
C+S- 18 52 
C- 403 13 
 
Sensitivity C+ % [CI] 92.6 [89.3-95.9] 
Sensitivity C+S+ % [CI] 100.0 
Sensitivity C+S- % [CI] 74.3 [64.1-84.5] 
Specificity C- % [CI] 96.9 [95.2-98.6] 
Table 30 Xpert performance for S1 and S2 combined (Xpert result for samples 1 and 2) 
stratified by C+ (culture positive), C+S+ (culture positive and smear positive) and C+S- 
(culture positive and smear negative) group 
Seven concentrated samples out of 666 (1.05%) tested on Xpert were not interpretable. 
Sensitivity in the culture positive group is comparable to sensitivity of a single direct sample S3. 
Interestingly, the combined sensitivity of two Xpert tests on concentrated samples S1 and S2 
(92.6%) was almost identical to that of a single Xpert on direct sputum S3 (92.4%).  
Sample S1 was a concentrated sample tested for culture, smear Xpert and Amplicor. We 
directly compared the performance of Xpert and Amplicor in three diagnostic categories: culture 
and smear positive, culture-positive and smear-negative and culture-negative.   
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Xpert and Amplicor per sample performance on sample S1 
Culture per 
sample S1 
Xpert sample S1 Amplicor sample S1 
Negative Positive Negative Positive 
C+S+ 0 82 1 80 
C+S- 11 28 16 23 
C- 200 8 206 2 
 
Sensitivity C+ %  
[CI] 
90.9 
[85.8-96.0] 
85.8 
[79.6-92.1] 
Sensitivity C+S+ % 
[CI] 
100 
 
98.8 
[96.4-100] 
Sensitivity C+S- % 
[CI] 
71.8 
[57.7-85.9] 
59.9 
[43.5-74.4] 
Specificity %  
[CI] 
96.2 
[93.5-98.8] 
99.0 
[97.7-100] 
Table 31 Xpert and Amplicor performance for sample S1 stratified by C+ (culture 
positive), C+S+ (culture positive and smear positive) and C+S- (culture positive and 
smear negative) ) 
One sample was excluded from the per sample analysis since it was smear positive and culture 
negative, based on study criteria (see chapter 3, section 12.1). Three Xpert results were invalid 
after repetition (3/332). In two cases Amplicor was not performed (2/332) and two Amplicor 
results were indeterminate (2/332).   
Although, there was a trend towards improved sensitivity for Xpert, statistical analysis of culture 
positive patients showed no significant difference in sensitivity between Xpert and Amplicor at 
the 95% confidence level (p-value for 2 tailed test p=0.182). Specificity analysis at 95% 
confidence level showed that Amplicor performed better than Xpert and the difference is 
significant (p-value for 2 tailed test p=0.041).  
Sample S2 was a concentrated sample tested with culture and smear as well as Xpert and 
Hain.  
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Xpert and Hain per sample performance on sample S2 
Culture per 
sample S2 
Xpert sample S2 Hain Sample S2 
Negative Positive Negative Positive 
C+S+ 0 91 4 80 
C+S- 7 24 16 13 
C- 203 5 190 3 
 
Sensitivity C+ % 
[CI] 
94.3 
[90.1-98.4] 
82.3 
[75.3-89.3] 
Sensitivity S+C+ % 
[CI] 
100 
 
95.2 
[90.7-99.8] 
Sensitivity S-C+ % 
[CI] 
77.4 
[62.7-92.1] 
44.8 
[26.7-62.9] 
Specificity % 
[CI] 
97.6 
[95.5-99.7] 
98.5 
[96.7-100] 
Table 32 Xpert and Hain performance for S2 (sample 2) stratified by C+ (culture 
positive), C+S+ (culture positive and smear positive) and C+S- (culture positive and 
smear negative) group 
Two cases (2/333) were excluded, based on study criteria (see chapter 3, section 12.1). One 
was smear positive, culture negative and the other had both contaminated cultures. One Xpert 
result was invalid for sample 2 (1/331). There were 25 results for Hain (25/331) not available, 
since sample volume was insufficient to perform the test. Sensitivity in all culture positive 
samples was 94.3% for Xpert and 82.3% for Hain with a significant difference (p-value for 2 
tailed test p=0.002). Specificity for Xpert was 97.6% and for Hain 98.5%. The McNemar test 
could not be performed to determine significance in difference in specificity, since there were no 
cases that were negative on both Xpert and Hain, but culture positive.  
4.1 Performance of GeneXpert MTB/RIF depending on time of sample taken 
Theoretically, an early morning sample may be of better quality, and should contain more MTB.  
After randomization, only one early morning sample was analyzed as sample S1. Culture was 
not performed on sample S3, and culture results for sample S3 only refer to overall culture 
results for samples S1 and S2, both solid and liquid.  
In order to compare percentage of positive and negative results on the Xpert and liquid culture 
when early morning sample or spot were analyzed only sample S2 should provide valuable 
information, since only in this case Xpert and liquid culture results were available in sufficient 
number for both early morning and smear sample (Table 33).   
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Performance of Xpert and liquid culture on early morning sample and spot sample 
 X negative X positive X NA C negative C positive C contam 
Sample 1 
EM 1/1  
(100%) 
 NA NA  1/1  
(100%) 
 NA  NA 
Spot 211/332 
(63.6%) 
118/332 
(35.3%) 
5/332 
(1.5%) 
209/332 
(63.0%) 
120/332 
(36.1%) 
3/332 (0.9%) 
Sample 2 
EM 122/186 
(65.6%) 
63/186  
(33.9%) 
1/186 (0.5%) 124/186 
(66.7%) 
60/186  
(36.1%) 
2/186 (1.1%) 
Spot 89/147 
(60.5%) 
58/147  
(39.5%) 
 NA 83/147  
(56.5%) 
62/147  
(44.0%) 
 NA 
Sample 3 
EM 81/141 
(57.4%) 
58/141  
(41.1%) 
2/141 (1.4%) 79/141  
(56.0%) 
62/141  
(44.0%) 
 NA 
Spot 117/192 
(60.9%) 
73/192  
(38.0%) 
2/192 (1.0%) 122/192 
(63.5%) 
70/192  
(36.5%) 
 NA 
Table 33 Performance of Xpert and liquid culture on early morning sample and spot 
sample X (Xpert), X NA (Xpert not available), C (culture), C contam (culture 
contaminated), EM (early morning sample), Spot (spot sample)    
Z – test was used to compare the proportions from two independent groups: Xpert and liquid 
culture positive and negative result, to determine if they were significantly different from one 
another.  
Z value for early morning sample at 95% confidence level for positive test results, Xpert and 
liquid culture were 0.22 and for negative test results were 0.11. Z value for spot sample at 95% 
confidence level for positive test results Xpert and liquid culture were 0.356 and for both 
negative test results were 0.592. There was no significant difference in any group.  
The difference between early morning sample and spot sample for Xpert negative and Xpert 
positive results is not significant for one and two tailed test, with Z value of 0.835 and 0.938 
respectively. The difference between early morning sample and spot sample is significant for 
one tailed Z – test for both culture negative and culture positive results with Z value of 1.794 and 
1.751 and not significant for two tailed test.  
5 Performance of NAAT for detection of TB in HIV-infected patients 
Sensitivity and specificity of NAATs were analysed with respect to culture and smear result and 
stratified according to HIV status.  
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NAAT performance according to HIV status 
NAATs C+ C+S+ C+S- C- 
HIV + HIV- HIV+ HIV- HIV+ HIV- HIV+ HIV- 
 
Xpert    
 % [CI] 
95.4   
[90.3-100] 
100 100 100 87.0   
[73.2-100] 
100 (3/3)* 98.8  
[96.5-100] 
96.2   
[88.8-100] 
Amplicor
% [CI] 
80.3   
[70.3-90.3] 
85.7  
[67.4-100] 
92.7  
[84.7-100] 
90.9  
[73.9-100] 
43.5   
[23.2-63.7] 
66.7 (2/3)* 100 100 
Hain 
% [CI] 
75.4   
[64.6-86.2] 
85.7  
[67.4-100] 
94.7  
[87.6-100] 
90.9  
[73.9-100] 
55.0   
[33.2-76.8] 
66.7 (2/3)* 100 100 
Table 34 NAATs performance according to the HIV status and culture and smear result, 
C+ (culture positive), C+S+ (culture positive and smear positive), C+S- (culture positive 
and smear negative) and C- (culture negative) group, (*)case numbers were not high 
enough for CI calculation  
There were 200 patients with known HIV status and 156 were HIV positive. Xpert sensitivity was 
significantly better among HIV-positive patients than Amplicor and Hain, particularly in the 
culture-positive, smear-negative group.  
6 GeneXpert MTB/RIF semi-quantitative analysis 
Xpert software displays results as MTB positive or negative with a semi-quantitative 
determinate, calculated on the basis of the cycle threshold (Ct). Ct is defined as the number of 
cycles required for the fluorescent signal to cross the threshold (exceed background level). Ct 
levels are inversely proportional to the amount of target nucleic acid in the sample (the lower the 
Ct level the greater the amount of target nucleic acid in the sample) (see chapter 1, section 
8.2.2).  
Xpert semi-quantitative results are displayed as: very low, low, medium and high. Smear result 
is quantified according to the number of bacilli visualized on smear and assigned as: scanty, 1+, 
2+ and 3+.  
Semi-quantitative Xpert and smear results 
Smear 
results 
Xpert results for samples S1 S2 and S3 
Negative Very Low Low Medium High 
Negative 619 71 42 13 1 
Scanty 0 9 17 8 2 
1+ 2 9 28 37 13 
2+ 0 3 17 25 10 
3+ 0 0 1 35 29 
Table 35 Semi-quantitative smear result and Xpert result 
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In order to analyse the association, results for smear and Xpert were combined into two groups 
of response “low” and “high”. Very low and low Xpert results were grouped as “low”, while 
medium and high were grouped as “high”. Scanty and +1 smear result were grouped as “low” 
and 2+ and 3+ as “high”.  
Semi-quantitative Xpert and smear contingency table 
Smear  Xpert 
Low High 
Low 63 97 
High 21 99 
Table 36 Contingency table for smear and Xpert quantitative result 
The qualitative value of Xpert and smear results were strongly associated (Fisher‟s exact test 
p<0.0001), however it may be observed from the table 36 that a significant proportion of those 
samples with a “low” smear result had a “high” Xpert result.   
7 GeneXpert MTB/RIF invalid and repeated results 
If Xpert could not determine a result (internal control had high Ct or MTB result was borderline) 
it reported an invalid result. If the reaction was not completed (e.g. due to blockage within the 
cartridge) Xpert reported error. In both cases the test was repeated if there was enough sample 
(≥0.5ml of sample without Xpert sample reagent or 2ml of sample with sample reagent). 
During the study error was reported 25 times. In five cases there was not enough sample to 
repeat the test, in two cases error was reported after repetition, and in 18 cases interpretable 
results were obtained after repetition. Most of the error messages (16/25) were reported for 
direct sample S3.  
An invalid result was reported in five cases. After repetition, four samples had an interpretable 
result and one result out of five was not repeated.  
In two cases Xpert reported RIF result as Rif resistance indeterminate. One result was for 
sample S2 and the other for S3. In both cases samples were culture positive. In one case Xpert 
result for S1 was TB positive RIF sensitive and for S2 MTB negative. In the other case Xpert 
detected RIF sensitivity for samples S1 and S3.  
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8 Detection of rifampicin resistance  
8.1 Per patient rifampicin resistance analysis 
Out of 132 culture positive cases, all were tested for first-line drug resistance. Xpert detects RIF 
resistance and those results were compared with phenotypic RIF resistance results.  
Per patient RIF resistance (Xpert vs. Phenotypic DST) 
RIF DST result for 
S1 and S2 
Xpert per patient result 
RIF resistant RIF sensitive RIF indeterminate 
RIF resistant 4 0 1 
RIF sensitive 0 119 2 
Table 37 Xpert and DST performance for RIF resistance per patient 
Sensitivity of Xpert for RIF was 100% in the phenotypically confirmed RIF resistant group. 
Specificity was also 100%. Six samples were phenotypically RIF sensitive but Xpert TB 
negative.  
There were three cases with discordant Xpert drug sensitivity (these were excluded from the 
above analysis according to predefined criteria), and these were classified as indeterminate 
Xpert results for RIF resistance. One case was phenotypically RIF resistant and Xpert RIF 
resistant in two samples and the third sample (S1) was RIF sensitive. Two phenotypically RIF 
sensitive samples were both sensitive when tested on Xpert for samples S2 and S3 and 
resistant for sample S1.  
Samples with indeterminate Xpert results were sent to New Jersey Medical School, University of 
Medicine and Dentistry of New Jersey, where both culture isolates and amplicons from Xpert 
cartridges were sequenced. Results after sequencing are presented in table 38.  
Discrepant RIF Xpert and phenotypic results 
Case DST Xpert Sequencing 
culture S1 
Sequencing 
culture S2 
Sequencing 
amplicon 
S1 
Sequencing 
amplicon 
S2 
Sequencing 
amplicon 
S3 
 S1 S2 S3  
Case 
1 
RIF 
resistant 
sens res res mut (531 
TTG) and wt 
mut (531 
TTG, 512 
CGC) 
wt mut (512 
CGC) 
mut (531 
TTG, 512 
CGC) and 
wt 
Case 
2 
RIF 
sensitive 
res sens sens mut (533 
CCG) and 
wt 
mut (533 
CCG) and 
wt 
mut (533 
CCG) and 
wt 
mut (533 
CCG) and 
wt 
mut (533 
CCG) and 
wt 
Case 
3 
RIF 
sensitive 
res sens sens wt wt wt   
Table 38 RIF resistance resolution after sequencing for three Xpert RIF indeterminate 
cases, sens (sensitive), res (reisistant), wt (wild type), mut (mutated gene)   
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Cases 1 and 2 were resolved as mixed type infection (both wt and mut genotype found) and 
case 3 was proven to be RIF sensitive after sequencing (false-positive Xpert RIF resistance on 
sample S1).  
The Hain test was also performed in those three cases. In case 1 Hain result was not 
interpretable for RIF resistance since bands were too pale. In case 2 Hain result was negative 
and in case 3 Hain was not performed, since there was not enough decontaminated sample left 
for analysis.  
The Hain test was also compared with standard DST results. Hain was reported as 
indeterminate if RIF resistance was not interpretable, if control bands did not appear or they 
were too pale to reliably read.   
Per patient RIF resistance (Hain vs. Phenotypic DST) 
RIF DST result for S1 
and S2 
Hain result for sample S2 
RIF resistant RIF sensitive RIF indeterminate 
RIF resistant 3 0 0 
RIF sensitive 0 82 10 
Table 39 Hain and DST performance for RIF resistance per patient 
Nine results out of 132 culture positive results were not analysed on Hain since there was not 
enough sample for processing. Two phenotypically RIF resistant cases were negative (no TB 
detected) on Hain and 26 phenotypically RIF sensitive results were negative. Sensitivity and 
specificity for Hain RIF resistance detection are 100% if the negative cases were excluded.  
In the culture-negative group Hain detected TB in two cases. One case was RIF sensitive and 
the other indeterminate (bands were too pale for interpretation). Both cases were clinical TB 
cases. The rest of culture negative cases were also Hain negative and 16 cases were not 
analysed since there was insufficient sample volume.  
8.2 Per sample rifampicin resistance analysis 
Analysis of tests for detection of RIF resistance on a per sample basis was performed for 
sample S1 for Xpert and for sample S2 for Xpert and Hain.  
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RIF resistance per sample S1 
RIF DST result for S1  Xpert result for S1 
RIF resistant RIF sensitive 
RIF resistant 3 1 
RIF sensitive 2 99 
Table 40 Xpert performance for RIF resistance per sample S1 
One case was excluded from analysis since it was smear-positive, culture-negative. There were 
210 culture negative cases for S1. Of these, Xpert was negative in 200 cases, two Xpert results 
were reported as error, one case was RIF resistant and seven were RIF sensitive.  
Xpert sensitivity in the per sample RIF resistance analysis was 75% (3/4) and specificity was 
98% with confidence interval [95.3-100]. In the culture-positive group, eight DST results were 
not available. Xpert result was negative in eight cases and in one case Xpert result was error.  
RIF resistance was analysed per sample S2 for Xpert and Hain. 
RIF resistance per sample S2 
RIF DST result 
for S2 
Xpert result for S2 Hain result for S2 
RIF resistant  RIF sensitive RIF resistant RIF sensitive 
RIF resistant 5 0 3 0 
RIF sensitive 0 106 0 78 
Table 41  Xpert and Hain performance for RIF resistance per sample S2 
Two cases were excluded from per sample analysis, one had both solid and liquid cultures 
contaminated and the other was smear-positive, culture-negative. Three DST results were not 
available, since DST was not performed on those samples, but DST was available for S1, so 
those results were reported in the per patient analysis.  
Sensitivity and specificity for Xpert was 100%. Out of 114 RIF sensitive cases Xpert was 
negative in seven cases, indeterminate in one and sensitive in 106 cases.  
Hain sensitivity and specificity in RIF resistance analysis for S2 was 100%. Out of five 
phenotypically RIF resistant cases, Hain detected RIF resistance in three cases and was 
negative (no TB detected) in two cases. Out of 114 phenotypically RIF sensitive cases, nine 
Hain results were not available, 18 were negative, nine were indeterminate and 78 were RIF 
sensitive.  
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9 Detection of isoniazid resistance 
Hain detects INH resistance as well as RIF resistance. Since the main purpose of this analysis 
is to determine RIF resistance and compare phenotypic and Xpert results, discrepant 
phenotypic INH cases were not excluded from the study, as was the case for RIF resistance. 
DST for INH therefore represents drug susceptibility results for two samples S1 and S2. An 
indeterminate Hain result means that bands for INH resistance were not interpretable but the 
strip was positive for TB. 
INH resistance (Hain vs. Phenotypic DST) 
INH DST result for 
S1 and S2 
Hain result for sample S2 
INH resistant INH sensitive INH indeterminate 
INH resistant 6 0 0 
INH sensitive 2 78 7 
INH discrepant 1 1 0 
Table 42 Performance of Hain test for INH resistance 
Sensitivity of the test for INH resistance was 100% and specificity was 97.5% (95% CI 94.1-
100). Seven results were indeterminate since bands determining INH resistance were pale or 
did not show at all. Nine results were not available since sample volume necessary to perform 
the test was too low (less than 0.5ml of processed sputum). Two phenotypically resistant 
samples were TB negative on Hain. Out of 112 INH sensitive cases based on DST 25 were TB 
negative on Hain.  
Out of 201 culture negative cases there were two positive Hain results. Both culture negative 
cases were clinically diagnosed TB cases based on panel expert decision after FU. One was 
INH indeterminate and the other was INH sensitive.  
The Hain test provides information regarding type of mutation for both RIF and INH. A mutation 
in katG corresponds to high level INH resistance and mutation in inhA corresponds to low INH 
resistance.  
Genes involved in INH resistance 
INH DST result 
for S2 
Hain result for sample S2 
INH R katG INH R inhA INH S INH I 
INH resistant 3 4 0 0 
INH sensitive 0 2 75 6 
Table 43 Hain INH resistance results stratified by DST culture result for S2 INH R katG 
(high resistance established by katG mutation) INH R inhA (low resistance detected by 
inhA mutation), INH S (INH sensitive) as INH sensitive or INH resistant (indeterminate), 
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One case had two culture samples contaminated and was excluded from analysis, and one 
case was culture-negative, smear-positive and was excluded from per sample analysis.  
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V Discussion 
We performed an evaluation study of the performance of Xpert as a novel TB/RIF resistance 
detection system amongst TB suspects with a high rate of HIV co-infection. In 2007, the case 
notification rate for TB in the region was 1,500 per 100,000 per year, which is amongst the 
highest TB incidence rates in the world (WHO report, 2009). The spread of TB through the 
population is influenced by overcrowding, malnutrition and HIV (Jaramillo, 1999).  Presumably 
most TB transmission occurs before the disease is diagnosed, hence a rapid diagnosis method 
and effective treatment would reduce the spread of the disease especially among the most 
vulnerable, the HIV-infected population.  
In the study, patients were recruited during routine visits to the clinic or hospital. At the major 
recruitment site, Khayelitsha, the diagnosis of TB is largely dependent on smear microscopy, 
with CXR and culture only performed if smear is negative and there is a strong clinical suspicion 
of TB.  
Culture-based methods for diagnosing TB were chosen in order to achieve the “gold standard” 
with two MGIT results and two LJ results per patient. The most cited commercially available 
NAAT methods (Amplicor and Hain) were selected in order to compare the performance of Xpert 
with the most frequently used competitor assays.  
Performance of smear microscopy and routine culture: 
Auramine smear performed remarkably well (sensitivity of 72.7% for culture-confirmed cases) in 
this population considering the high HIV prevalence. In field settings where smear microscopy is 
routinely used, performance is often considerably lower (40% - 60%). In HIV-positive patents 
smear sensitivity can be as low as 20% (FIND Diagnostics for tuberculosis, 2006). The high 
sensitivity of smear microscopy during this study may be related to laboratory resources, as 
testing was performed in a well equipped academic TB laboratory, with highly experienced staff 
performing the auramine test. In addition two out of three samples were decontaminated and 
concentrated; since concentration improves the sensitivity of smear microscopy, this may 
explain the high sensitivity of this method.  
The per sample analysis of solid and liquid culture in comparison with pooled culture results 
gives some indication of the relative performance of solid vs. liquid culture. The sensitivity of a 
single liquid culture was 91.7% and of solid culture 78.4% for culture-proven disease. 
Surprisingly, the contamination rate for liquid culture was low (1.1%). The contamination rate for 
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solid culture was higher, 5.6%. Culture contamination rates are usually higher for liquid culture 
than for solid, typically being around 8% and 2% respectively (Paramasivan et al, 2010). The 
low rate of contamination of liquid cultures in this study may be the result of over-vigorous 
decontamination of samples prior to MGIT inoculation. The overall contamination rate of MGIT 
cultures in this laboratory is 8% - it is unclear why this was substantially different in this study. 
False-negative cultures, as a result of over-decontamination, may have resulted in a reduced 
specificity of NAAT tests. 
Performance of NAAT testing: 
The performance of Xpert was impressive, with the highest sensitivity (95.5%) compared with 
Amplicor (80.8%) and Hain (77.2%) amongst culture positive patients. In particular, the 
performance of Xpert in the smear-negative, culture-positive patient group (sensitivity 86.1%) 
was substantially better than that of Amplicor (sensitivity 45.7%) and Hain (sensitivity 39.4%). In 
HIV-infected patients with culture-positive, smear-negative TB the sensitivity of Xpert was 87%, 
Amplicor 43.5% and Hain 55%.  
One needs to bear in mind that this comparison is between 3 Xpert tests and one Amplicor or 
Hain test. Data from previous studies showed a strong correlation between test performance 
and the number of tested specimens for each patient (Piersimoni et al., 2003, Cohen et al., 
1998, Rajalahti et al., 1998). In order to control for this, we performed a per sample analysis, 
which demonstrated increased sensitivity for Xpert (90.9%) compared with Amplicor (85.8%), 
but the difference was not significant at the 95% confidence level (p-value for 2 tailed test 
p=0.182). Similarly, in the per sample analysis, Xpert was more sensitive than Hain (94.3% vs. 
82.3% respectively; p-value for 2 tailed test p=0.002). 
In contrast, Xpert appeared to have the lowest specificity (94.0%) in comparison with smear 
(100%), Amplicor (100%) and Hain (98.9%) in per-patient analysis. One possible reason for 
relatively reduced specificity of Xpert is that there were three Xpert results for each patient and 
only one for Hain and Amplicor. If, however, the relatively enhanced specificity of Amplicor was 
related to sample number, one would expect this difference to disappear on the per sample 
analysis. This was not the case, with specificity of Amplicor (99%) remaining higher than that of 
Xpert (96.2%) on per sample analysis and this was significantly different at the 95% confidence 
level (p-value for 2 tailed test p=0.041). 
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An important issue is whether the Xpert-positive, culture-negative patients had false positive 
Xpert results or false negative culture results. When culture and smear negative but clinically 
diagnosed TB patients were included in the analysis, the sensitivity and NPV of all methods was 
reduced but Xpert performance was less affected (sensitivity reduced from 95.5% to 93.8% and 
NPV from 96.9% to 95.4%) when compared with Amplicor (sensitivity reduced from 80.8% to 
73.9% and NPV from 88.8% to 83.5%) and Hain (sensitivity reduced from 77.2% to 72.9% and 
NPV from 86.7% to 82.9%). In contrast, specificity and hence the PPV value for Xpert improved 
noticeably (specificity from 94.0% to 98.4% and PPV from 91.3% to 97.8%). The implication of 
these results is that, in a high burden setting, such as South Africa, a positive Xpert test is highly 
likely to indicate true TB, whilst a negative test will rule out TB with 95% certainty.  
Since Xpert is intended to be used for unprocessed samples, the most relevant finding is the 
performance of Xpert on direct sputum S3. When the performance of a single Xpert test on 
direct sputum, was analysed, a single Xpert test was almost as sensitive (92.4%) as three Xpert 
tests (95.5%), or two Xpert tests on concentrated sputum (92.6%). Specificity in the non-TB 
group (culture and clinically TB negative patient group) for Xpert on direct sputum was 99.5%. 
These results lead to the conclusion that concentrating sample prior to Xpert does not influence 
performance of the test. The implication is that Xpert can be performed directly on sputum at a 
microscopy level laboratory, without necessity for the BSL3 facilities required for sputum 
concentration. Further, a single Xpert test performed on direct sputum is highly sensitive. 
There was an association between the semi-quantitative Xpert result and the degree of smear 
positivity, suggesting that Xpert may be useful for monitoring response to therapy, although this 
needs further study.  
Performance of NAAT for detection of drug resistance: 
The proportion of MDR cases amongst TB suspects in this area was previously documented to 
be 2.6% (MSF report, 2009). We identified MDR TB in 2.3% of study participants, in line with 
this previous report.  
The sensitivity and specificity of Xpert for detection of RIF resistance on per patient analysis 
was 100% in the phenotypically confirmed RIF resistant group. Three samples were Xpert 
indeterminate due to discordant Xpert results (and hence excluded from the primary analysis). 
After sequencing, two of these were resolved as mixed infections (RIF resistant and sensitive) 
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for both culture and Xpert amplicons, whilst one showed a single false-resistant RIF result on 
Xpert testing. Sensitivity and specificity for Hain RIF resistance were both 100%.  
Due to the small number of RIF resistant cases in this study, the conclusions that may be drawn 
from this data are limited. 
Sensitivity of the Hain test for INH resistance was 100% and specificity was 97.5% in the per 
patient analysis and 100% and 97.4% in the per sample analysis. Again, interpretation is limited 
by small numbers of INH resistant cases. 
Logistic considerations and ease of use 
Amplicor  
The Amplicor test has an automated PCR-detection step, and the result is not operator 
dependent, but it takes considerable logistical organisation in order to achieve cost 
effectiveness in reagent usage.  
The sample used for the Amplicor test must be decontaminated and concentrated. Sample 
preparation for PCR must be performed in a BSL 3 laboratory. Sample preparation involves 
centrifugation in order to obtain a pellet following the sample washing step. This is usually an 
undesirable step, even in a BSL 3 laboratory, due to safety concerns over the process. Besides 
safety, removing supernatant from a pelleted sample requires a lot of skill, since if the pellet is 
aspirated, MTB DNA is lost and the sample could be false negative, so removing supernatant is 
a crucial step in the Amplicor test. The pellet is very light and feathery, often not even visible.  
Reagents required for sample preparation are provided by manufacturer, Roche, and should be 
kept at 4-80C. The sample can be prepared a day in advance, but positive and negative control 
must be prepared just prior to the test, and do not require BSL 3 facilities.  
For each run on the Amplicor instrument, 12 different reagents are used. Some of them are kept 
at room temperature, some at 40 - 80C. Each of them has a different expiration time (16h, 2 
weeks, 28 days or 30 days) and their volumes differ, so each reagent vial is used for a different 
number of samples (32, 75, 100 samples). Also if the test is not run at full capacity, reagents use 
is inefficient.  
Each run takes 6.5h - 7.5h depending on the number of samples, with the maximum number of 
samples being 20, plus positive and negative control. The test could not be performed 
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overnight, since the operator should immediately after the run return unused reagents to the 
storage temperature.  
The instrument is not particularly robust and requires considerable space. It also requires 
weekly maintenance. We encountered instrument malfunction on two occasions, and eventually 
had to replace the instrument.  
Hain 
The Hain test was most time consuming, among NAATs. DNA isolation takes 1h, but samples 
can be prepared in batches. Making batches of DNA samples also enables the researcher to 
more easily follow a uni-directional flow of pre-PCR, especially since DNA isolation requires BSL 
3 facilities, separated from a DNA-free area, which logistically makes pre-PCR sample 
manipulation more complicated. 
PCR is the crucial step for the Hain test. The sample decontamination and DNA isolation 
procedure can influence test outcomes; the concentration of Mg2+ in the master mix and PCR 
amplification profile may make a significant difference to the test‟s sensitivity. 
Hain Lifescience GmbH provides reagents necessary for post-PCR analysis of product, but  
each DNA isolation and PCR is less well standardised, especially with regard to reagents use 
and amplification profile. The major published performance evaluation of this test was carried 
out using HotStarTag polymerase from Qiagen. We elected to use the same polymerase in our 
study.  
Hain Lifescience GmbH has two devices for post-PCR analysis of product, which must be used 
in order to obtain valid results for clinical sample analysis: 
- TwinCubator® for Hybridization 
- GT-Blot 48 for Hybridization 
In our study we used both instruments. The price difference between those instruments is 
considerable in favour of TwinCubator. TwinCubator is a semi-automatic device, essentially an 
over-expensive dry heating block, enabling proper temperature and mixing of products through 
the hybridization step. Hybridization steps require consecutive manual washings and the adding 
of reagents, making the procedure prone to cross-contamination, and offering very little hands-
off time, since each washing step is between 15 and 30 minutes apart, which actually oblige the 
operator to stay next to the instrument, preparing for the next hybridization step.  
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GT-Blot 48 is fully automatic, but only after samples, detection strips and all reagents are loaded 
onto the instrument. Automatic washings and reagent aspiration and addition, make this method 
more favourable considering the threat of cross-contamination. This instrument also gives the 
operator 2.5h hands-off time. But the price and maintenance are considerably higher.  
During the study there were no maintenance problems with either of the instruments, but GT-
Blot 48 can have considerable drawbacks: the hybridization buffer is added after being pre-
warmed at 370 - 450C, and this makes salt crystals dissolve. The buffer is placed in a container 
and a silicon tube is placed into the container, leading to a mobile arm with a syringe. If the 
buffer temperature is not optimal, or the tube is cold due to the environmental temperature, 
buffer salts can clog the tube or the syringe, and those parts need to be replaced. Since the 
manufacturer is based in Germany, it takes a few weeks until the instrument is operational 
again, leading to a huge backlog in sample flow.  
It takes an experienced and accustomed operator to read results. Resulting hybridization strips 
have a wide range of intensities, and result reading and interpretation of results is solely 
operator dependent. Resulting strips fade in time, and they should be kept in a dark place if 
subsequent reading is needed. Strips are also very frail, and should be handled and stored 
accordingly. Storage practically means that they should be glued onto a paper log.  
Xpert 
Xpert was the easiest to use and time efficient. It required 30-45 minutes of sample preparation 
with incubation, depending on the number of samples. When used directly on sputum (not on 
concentrated sediment), the sample preparation step would only involve reagent addition to the 
direct sample and 15 minutes of incubation, before transferring the sample to the disposable 
cartridge. During the study, we followed safety procedures, described by the IIDMM, medical 
microbiology, BSL 3 safety manual, which suggests that all samples containing airborne 
pathogens must be processed in a BSL 3 laboratory, which made sample preparation more 
demanding in terms of time consumption and disposing of infectious material.  
Two Xpert instruments with four modules were placed in a molecular laboratory where routine 
laboratory work involves DNA and RNA manipulation.  
There were no major difficulties while operating the Xpert instrument. Software is easily 
accessible and manageable. Xpert is relatively robust and extraordinarily simple. Training of an 
operator usually takes an hour to get familiar with system. 
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Problems with cartridge loading were encountered after an electrical current fluctuation, even 
though the instrument was connected to an uninterrupted power supply. We had to replace 
three modules during the study. The modules in question gave more error messages than the 
others. On one occasion a cartridge was unable to unload from the instrument. Module 
changing did not interrupt the study flow, since all modules function individually, and even if one 
was not working, others were available and fully functioning.  
Module replacement was a very simple procedure, involving opening the instrument box and 
connecting a new module. 
Since each module within the Xpert instrument operates independently, user can test each 
sputum sample as it arrives in the laboratory instead of saving samples for batch processing. 
This important feature can potentially result in dramatically reduced turnaround times. 
Cost implications 
A direct comparison of Xpert with Amplicor and Hain was not possible, since pricing structures 
for the Xpert test have not yet been released. A preferential pricing agreement is in place for 
Xpert; however the details of this arrangement are not yet available.  
Limitations of this study  
Cases invited for follow-up visits were Xpert and/or Amplicor positive and culture negative, with 
the same number of Xpert and/or Amplicor negative, culture negative controls. In this way, Xpert 
specificity is likely to have been artificially increased, since this gave the opportunity for Xpert-
positive, culture-negative cases to be reviewed and recategorized.  
The drop-out rate during the study, based on the patient‟s inability to provide three sputum 
samples, was 20% (90/454). One of the reasons for this drop-out rate is that routine workup in 
South Africa, according to WHO recommendations, requires two samples for TB testing and this 
was therefore a change to routine clinic practice.  
The HIV result was not available in 45% (164/364) of case study participants, and therefore 
many HIV infected participants are likely to have been missed.  
A very small number of RIF resistant cases was identified during the study, as a result we were 
unable to draw conclusions regarding the performance of Xpert for detection of RIF resistance. 
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Similarly, the number of culture positive, smear negative cases was relatively low, and this 
resulted in wide confidence intervals around the point estimates of performance for this patient 
group.  
Future use of Xpert 
An ongoing study is aiming to compare turnaround time for Xpert, smear, culture and DST result 
and analyze the cost effectiveness of Xpert, implemented at microscopy centre level.  
Moreover since the Xpert instrument is a closed system there is a possibility of implementing it 
at the level of community clinic where tuberculosis is detected, registered, treated, and followed 
up. In this way, there is no need for patient to come back for the result, since result could be 
readily obtained while patient is still at the clinic.   
Whilst this study did not include children and was not specifically designed to address 
performance in HIV-infected patients, since Xpert showed satisfactory sensitivity in smear 
negative samples, it is likely to be useful for diagnosis in these patient populations. Two studies 
including these specific groups are ongoing, and results should be available in the near future.  
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VI Conclusions 
1. The key features of this evaluation of Xpert are a high degree of accuracy for diagnosis 
of TB, rapid time to result and ease of use.  A single Xpert test on direct sputum detected 
90.9% of culture- and clinically-proven TB cases with very high specificity (99.5%).  
2. Xpert is an innovative system that is suitable for testing for both TB diagnosis and drug 
resistance detection at levels of the health system where many seek care. 
3. Xpert has potential value as a replacement for smear microscopy, since it requires very 
basic laboratory infrastructure and was significantly more sensitive than smear 
microscopy.  
4. Since Xpert appears to detect RIF resistance accurately, whilst simultaneously detecting 
the presence of TB, it may be a cost-effective and feasible alternative to smear 
microscopy followed by Hain testing of all smear-positive samples, which is the 
proposed standard algorithm for South Africa, and recommended by the WHO 
5. Cost is likely to be the critical factor determining the widespread uptake of this test. A 
preferential pricing agreement for high burden countries has been negotiated; however 
the details of this remain unclear.  
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